# Top 100 PICO-like extracts for LG149_Polmone_agg2024_cleaned.json

1. [outcome] score 19 ✅ BINGO (PCO)
mic segmentectomy versus lobectomy for clinical stage IA peripheral lung cancer by video assistant thoracoscopic
surgery. J Cancer Res Ther; Sep 2013. 17.Yamashita, S., Tokuishi, K., Anami, K., Moroga, T., Miyawaki, M., Chujo, M.,
Yamamoto, S., Kawahara, K.. Thoracoscopic segmentectomy for T1 classification of non-small cell lung cancer: a single
center experience. Eur J Cardiothorac Surg; Jul 2012. 18.Yamato, Y., Koike, T., Yoshiya, K., Shinohara, H., Toyabe, S..
Results of surgical treatment for small (2 cm or under) adenocarcinomas of the lung. Surg Today; 2008. 19.Tsubokawa, N.,
Tsutani, Y., Miyata, Y., Handa, Y., Misumi, K., Hanaki, H., Hida, E., Okada, M.. Segmentectomy Versus Lobectomy for
Radiologically Pure Solid Clinical T1a-bN0M0 Lung Cancer. World J Surg; Aug 2018. 20.Sugi, K., Kobayashi, S., Sudou, M.,
Sakano, H., Matsuda, E., Okabe, K.. Long-term prognosis of video-assisted limited surgery for early lung cancer. Eur J
Cardiothorac Surg; Feb 2010. 21.Shapiro, M., Weiser, T. S., Wisnivesky, J. P., Chin, C., Arustamyan, M., Swanson, S. J..
Thoracoscopic segmentectomy compares favorably with thoracoscopic lobectomy for patients with small stage I lung cancer.
J Thorac Cardiovasc Surg; Jun 2009. 22.Soukiasian, H. J., Hong, E., McKenna, R. J.,Jr.. Video-assisted thoracoscopic
trisegmentectomy and left upper lobectomy provide equivalent survivals for stage IA and IB lung cancer. J Thorac
Cardiovasc Surg; Sep 2012. 23.Song, C. Y., Sakai, T., Kimura, D., Tsushima, T., Fukuda, I.. Comparison of perioperative
and oncological outcomes between video-assisted segmentectomy and lobectomy for patients with clinical stage IA non-
small cell lung cancer: a propensity score matching study. J Thorac Dis; Aug 2018. 24.Darras, M., Ojanguren, A.,
Forster, C., Zellweger, M., Perentes, J. Y., Krueger, T., Gonzalez, M.. Short-term local control after VATS
segmentectomy and lobectomy for solid NSCLC of less than 2 cm. Thorac Cancer; Feb 2021. 25.De Giacomo, T., Di Stasio,
M., Diso, D., Anile, M., Venuta, F., Furio Coloni, G.. Sub-lobar lung resection of peripheral T1N0M0 NSCLC does not
affect local recurrence rate. Scand J Surg; 2009. 26.Zhao, X., Qian, L., Luo, Q., Huang, J.. Segmentectomy as a safe and
equally effective surgical option under complete video-assisted thoracic surgery for patients of stage I non-small cell
lung cancer. J Cardiothorac Surg; Apr 29 2013. 27.Wang, B. Y., Tu, C. C., Liu, C. Y., Shih, C. S., Liu, C. C.. Single-
incision thoracoscopic lobectomy and segmentectomy with radical lymph node dissection. Ann Thorac Surg; Sep 2013.
28.Echavarria, M. F., Cheng, A. M., Velez-Cubian, F. O., Ng, E. P., Moodie, C. C., Garrett, J. R., Fontaine, J. P.,
Robinson, L. A., Toloza, E. M.. Comparison of pulmonary function tests and perioperative outcomes after robotic-assisted
pulmonary lobectomy vs segmentectomy. Am J Surg; Dec 2016. 29.Schuchert, M.J., Pettiford, B.L., Keeley, S., D'Amato,
T.A., Kilic, A., Close, J., Pennathur, A., Santos, R., Fernando, H.C., Landreneau, J.R., Luketich, J.D., Landreneau,
R.J.. Anatomic segmentectomy in the treatment of stage I non-small cell lung cancer. Ann Thorac Surg 2007. 30.Sienel,
W., Stremmel, C., Kirschbaum, A., Hinterberger, L., Stoelben, E., Hasse, J., Passlick, B.. Frequency of local recurrence
following segmentectomy of stage I

2. [population] score 16 ✅ BINGO (PIO)
re) 9 RR 0.80 16 fewer ⨁◯◯◯ CRITICAL ) (0.73 to per 100 VERY LOW 0.88) (from 21 fewer to 9 fewer) a. Unclear risk of
attrition bias in both studies due to the lack of information b. We decided to downgrade the quality of the evidence by
one level for the risk of bias dimension because in both study crossover to pembrolizumab monotherapy was permitted
among the patients in the chemotherapy combination group who had verified disease progression c. In Keynote-021 trial,
the maintenance treatment consisted of pembrolizumab and optional indefinite pemetrexed d. In KEYNOTE-21 study,
subgroups analysis according to tumour proportion score for PD-L1 were not designed and performed. For this reason we
decided to downgrade the quality of the evidence by one level for indirectness e. KEYNOTE-021 trial was an open-label
trial but efficacy was based on masked, independent, central radiology review f. High risk of performance and detection
bias because KEYNOTE-021 was an open-label trial g. I2=53% h. In KEYNOTE 189 study safety results were showed in the
overall population and not according to PD-L1 tumour proportion score i. We decided to downgrade the quality of the
evidence by one level for imprecision because the 95% CI includes both negligible effect and appreciable benefit or
appreciable harm j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for
the following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43
patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2
physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the
Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9
physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT
alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for
the following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician decision, 2 new anticancer
therapy and 13 clinical progression; k. in KEYNOTE-189 study information for this outcome were showed in the overall
population and not according to PD-L1 tumour proportion score Dovrebbe un trattamento di prima linea a base di platino,
pemetrexed e pembrolizumab, seguito da mantenimento con pemetrexed e pembrolizumab in caso di risposta o stabilità di
malattia dopo 4 cicli di trattamento vs. la chemioterapia essere usato per pazienti affetti da NSCLC a istologia non-
squamosa con espressione di PD-L1 <50% in stadio metastatico senza mutazione attivante l’EGFR o riarrangiamento di ALK e
con buon performance status (0-1)? POPULATION: Pazienti affetti da NSCLC a istologia non-squamosa con espressione di
PD-L1 <50% in stadio metastatico senza mutazione attivante l’EGFR o riarrangiamento di ALK e con buon performance status
(0-1) INTERVENTION: Un trattamento di prima linea a base di platino, pemetrexed e pembrolizumab, seguito da mantenimento
con pemetrexed e pembrolizumab in caso di risposta o stabilità di malattia dopo 4 cicli di trattamento COMPARISON: Alla
chemiot

3. [intervention] score 16 ✅ BINGO (ICO)
ectness imprecision8 (6.1%)15 (0.56%)15 81.18)9 more to 45 more) HIGH 1 pemetrexed 500 mg/m2 2 OS pemetrexed 13,9 mesi
versus 11,1 for placebo. difference = 2,8 months 3 Panel Composition: 6 oncologi medici, 1 radioterapista, 1 chirurgo
toracico. 4 Results based on event-driven analisys (Paz-Ares Lancet Oncol 2012). PFS results were not updated in the
final report (Paz-Ares JCO 2013) 5 The primary outcome declared in  is PFS detected by investigators. Taking into
account the high proportion of indipendent evaluation available 88% and the similar results LINEE GUI obtained we
decided to report the investigator assessed PFS 6 Investigator -> pemetrexed median PFS 4,1 mesi (3,2-4,6), placebo 2,8
(2,6-3,1); Indipendent -> pemetrexed median PFS 3,9 mesi (3- 4,2) , placebo 2,6 ( 2.2-2.9) 7 Assessed by the indipendent
review 8 Wide 95% CI due to low number of events. For this reason we decided to not downgrade quality of evidence for
imprecision 9 Calcolated throught number of events and totals 10 Low questionnaire compliance due to failure by study
site to administer questionnaire. 11 95% confidence interval includes no effect and the upper and lower confidence limit
crosses the minimal important difference (MID= 0.08 U.K population-based index sco 12 Assuming a SD= 1.5 for both arm
(data not provided by authors) 13 95% confidence interval includes no effect and the lower confidence limit crosses the
minimal important difference (MID= 7 VAS) 14 Assuming a SD= 7.24 for both arm (Sds are not reported in the primary
article) and a p-value > 0.05 (the authors reported "Not-Ssignificant" only) 15 we added a further event both in the
intervention and in the control group to permit the calculation of relative and absolute effect IDA ore); both f for
benefit and harm Dovrebbe maintenance therapy with pemetrexed vs placebo essere utiliz POPOLAZIONE: Advanced NSCLC
INTERVENTO: Maintenance therapy with pemetrexed CONFRONTO: Placebo ESITI PRINCIPALI: Overall Survival; Progression free
survival; Objective responce rate; Quality of life -EQ-5D; Qual grade 3-4; Neutropenia grade 3-4 SETTING: PROSPETTIVA:
BACKGROUND: CONFLITTI DI INTERESSE Il problema è una priorità? GIUDIZI RICERCA DELLE PROVE DI EVIDENZA ○ No ○
Probabilmente no ○ Probabilmente si ● Si ○ Varia ○ Non so zzato per adva lity of life -VAS; Sever anced NSCLC re
Toxicity (Non labor CONSIDE ratory); Fatigue grade 3-4; trans ERAZIONI AGGIUNTIVE sfusion; G-CSF ; Anemia Effetti de
Quanto consid GIUDIZI ○ Irrilevanti ○ Piccoli ○ Moderati ● Grandi ○ Variano ○ Non so esider derevoli s rabili sono gli e
effetti des siderabili attesi? RICERCA DELLE PROVE DI EVIDENZA CONS È stata eseguita una ricerca sistematica della
letteratura sulle banche dati PubMed/Medline, Embase e Central (Cochrane Library). La strategia di ricerca ha
identificato 1478 documenti dopo la rimozione dei duplicati. È stato valutato un record in full-text e incluso. Lo
studio PARAMOUNT, è un trial di fase 3 randomizzato in doppio cieco, multicentrico, su pazienti affetti da NSCLC in fase
avanzata (stadio IIIB/IV). Lo studio prevedeva due fasi: una fase non randomizzata (fase di induzione) in cui 939
pazienti non pre-trattati per malattia avanzata sono stati sottoposti a terapia di prima linea con cisplatino/pemetrexed
(cisplatino 75 mg/mq e.v. g.1 e pe

4. [population] score 15 ✅ BINGO (PICO)
ity ention acceptable to key stakeho RICERCA DELLE PROVE DI EVI Nessuna evidenza trovata. y ention feasible to
implement? RICERCA DELLE PROVE DI EVI Nessuna evidenza trovata. IDENZA olders? IDENZA IDENZA NEO OPLASIE E DEL POLMO ONE
L LINEE GUIDA CON CON CON A NSIDERAZI NSIDERAZI NSIDERAZI IONI AGGIUNTIVE IONI AGGIUNTIVE IONI AGGIUNTIVE PROBLEM
DESIRABLE EFFECT UNDESIRABLE EFFE CERTAINTY OF EVIDE VALUES BALANCE OF EFFEC EQUITY ACCEPTABILITY FEASIBILITY No TS
Trivial ECTS Large ENCE Very low Important uncertainty or variability Favors the CTS comparison Reduced No No Probably
no Probably yes Yes Small Moderate Large Moderate Small Trivial Low Moderate High Probably no Possibly important No
important important uncertainty or uncertainty or uncertainty or variability variability variability Does not favor
Probably favors either the Probably favors the comparison intervention or the the intervention comparison Probably
reduced Probably no impact Probably increased Probably no Probably yes Yes Probably no Probably yes Yes Favors th
interventio d Increased Varies Varies Varies he Varies on d Varies Varies Varies Don't know Don't know Don't know No
included studies Don't know Don't know Don't know Don't know Strong recommendation against the Conditional
recommendation against the Conditional recommendation for the Strong recommenda intervention intervention intervention
interventio Recommendation L a segmentectomia rispetto alla lobectomia può essere presa in considerazione per pazienti
affetti da NSCLC in stadio inizia ation for the on ale Author(s): MC Date: September 2019 Question: Durvalumab compared
to placebo/Observation in patients with PD-L1<1 expression, stage III non resectable, responders or with a stable
disease, non small cell lung cancer after concomitant chemoradiotherapy Setting: inpatients Bibliography: Antonia S.J.
"Durvalumab after chemoradiotherapy in stage III Non-Small-Cell Lung Cancer" The New England Journal of Medicine,
September 8, 2017 Antonia S.J. et al. N Engl J Med 2018; 379:2342-50; EMA Assessment report 26 July 2018
EMA/CHMP/548232/2018 Certainty assessment № of patients Effect Certainty Importance № of Study Risk of Other Relative
Absolute Inconsistency Indirectness Imprecision (Q1)Durvalumab placebo/Observation studies design bias considerations
(95% CI) (95% CI) Overall Survival 1 randomised not serious a not serious not serious not serious none 70/212 (33.0%)
45/91 (49.5%) HR 0.53 19 fewer ⨁⨁⨁⨁ CRITICAL trials (0.36 to 0.77) per 100 HIGH (from 28 fewer to 9 fewer) Progression
free survival (follow up: median 14.5 months; assessed with: RECIST 1.1) 1 randomised not serious a not serious not
serious not serious none 84/212 (39.6%) 59/91 (64.8%) HR 0.46 27 fewer ⨁⨁⨁⨁ CRITICAL trials (0.33 to 0.64) per 100 HIGH
(from 36 fewer to 16 fewer) Distant metastasis (assessed with: time to death or distant metastasis (all assessed by
means of blinded independent central review)) 1 randomised not serious a not serious serious b not serious none 72/476
(15.1%) 140/237 (59.1%) HR 0.52 22 fewer ⨁⨁⨁◯ CRITICAL trials (0.39 to 0.69) per 100 MODERATE (from 30 fewer to 13
fewer) NEOPLASI 1 randomised not serious a not serious serious b not serious trials Duration of response (follow up:
median 13.8 months) 1 randomised not serious a not seri

5. [population] score 15 ✅ BINGO (PIO)
posta o stabilità di malattia dopo 4 cicli di trattamento vs. la chemioterapia essere usato per pazienti affetti da
NSCLC a istologia non-squamosa con espressione di PD-L1 <50% in stadio metastatico senza mutazione attivante l’EGFR o
riarrangiamento di ALK e con buon performance status (0-1)? POPULATION: Pazienti affetti da NSCLC a istologia non-
squamosa con espressione di PD-L1 <50% in stadio metastatico senza mutazione attivante l’EGFR o riarrangiamento di ALK e
con buon performance status (0-1) INTERVENTION: Un trattamento di prima linea a base di platino, pemetrexed e
pembrolizumab, seguito da mantenimento con pemetrexed e pembrolizumab in caso di risposta o stabilità di malattia dopo 4
cicli di trattamento COMPARISON: Alla chemioterapia MAIN OUTCOMES: Overall survival; Progression free survival;
Objective response rate; Grade 3-5 any AEs; Discontinuation rate of any treatment component SETTING: PERSPECTIVE:
BACKGROUND: CONFLICT OF INTERESTS: Assenti alla votazione: Dr. Novello, Dr. Facchinetti, Dr. Passaro, Dr. Rossi, Dr.
Trisolini, Dr. Ferrara, Dr. Menis Is the problem a priority? ○ No Inhibitors of programmed death 1 (PD-1) and its ligand
PD-L1 are effective therapies for metastatic non–small-cell ○ Probably no lung cancer (NSCLC) lacking sensitizing EGFR
or ALK mutations. Pembrolizumab (Keytruda, Merck), nivolumab ○ Probably yes (Opdivo, Bristol-Myers Squibb), and
atezolizumab (Tecentriq, Genentech) are approved as second-line therapy. [...] X Yes ○ Varies ○ Don't know Desirable How
substantia JUDGEMENT ○ Trivial ○ Small ○ Moderate X Large ○ Varies ○ Don't know e effec al are the d cts desirable a
LINEE GU Because patients with advanced NSCLC can undergo rapid clinical deterioration during disease progression, less
than one half of patients with advanced NSCLC ever receive second-line therapy.1,2 First-line combination regimens that
include a PD-1 or PD-L1 inhibitor may maximize the chance of response and lead to prolonged survival. Modulation of the
immune response through PD-1 inhibition may be enhanced by the potential immunogenic effects of cytotoxic chemotherapy.
Gandhi L. et al. N Engl J Med 2018;378:2078-92. anticipated effects? RESEARCH EVIDENCE Outcomes Anticipated absolute
effects* (95% CI) Relative № of Certainty of the C effect participants evidence Risk with alla Risk with un trattamento
di prima linea a (95% (studies) (GRADE) chemioterapia base di platino, pemetrexed e CI) pembrolizumab, seguito da
mantenimento con pemetrexed e pembrolizumab in caso di risposta o stabilità di malattia dopo 4 cicli di trattamento
Overall survival Study population HR 0.61 499 ⨁⨁◯◯ (0.45 to (2 RCTs) LOWa,b,c,d 61 per 100 44 per 100 0.83) (35 to 55)
Progression free Study population HR 0.63 499 ⨁⨁⨁◯ survival (0.50 to (2 RCTs) MODERATEa,c,d,e 81 per 100 65 per 100
0.80) (56 to 73) Objective response Study population RR 2.16 499 ⨁⨁⨁◯ rate (1.58 to (2 RCTs) MODERATEa,c,d,e 21 per 100
46 per 100 2.95) (33 to 63) UIDA Comment ADDITIONAL CONSIDERATIONS ts Grade 3-5 any AEs Study population RR 1.06 728
⨁◯◯◯ (0.94 to (2 RCTs) VERY 56 per 100 60 per 100 1.19) LOWa,c,d,f,g,h,i (53 to 67) Discontinuation rate Study
population RR 0.80 739 ⨁◯◯◯ of any treatment (0.73 to (2 RCTs) VERY LOWa,c,d,i,k componentj 78 per 100 62 per 100 0.88)
(57 to 68) a. Unclear ris

6. [intervention] score 15 ✅ BINGO (PICO)
d ○ Varies ○ Don't know Acceptab Is the interve GIUDIZI ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know Is
the interve GIUDIZI ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know be the impact on health equity?
RICERCA DELLE PROVE DI EVI Nessuna evidenza trovata. ed pact ased bility ention acceptable to key stakeho RICERCA DELLE
PROVE DI EVI Nessuna evidenza trovata. y ention feasible to implement? RICERCA DELLE PROVE DI EVI Nessuna evidenza
trovata. IDENZA olders? IDENZA IDENZA NEO OPLASIE E DEL POLMO ONE L LINEE GUIDA CON CON CON A NSIDERAZI NSIDERAZI
NSIDERAZI IONI AGGIUNTIVE IONI AGGIUNTIVE IONI AGGIUNTIVE PROBLEM DESIRABLE EFFECT UNDESIRABLE EFFE CERTAINTY OF EVIDE
VALUES BALANCE OF EFFEC EQUITY ACCEPTABILITY FEASIBILITY No TS Trivial ECTS Large ENCE Very low Important uncertainty or
variability Favors the CTS comparison Reduced No No Probably no Probably yes Yes Small Moderate Large Moderate Small
Trivial Low Moderate High Probably no Possibly important No important important uncertainty or uncertainty or
uncertainty or variability variability variability Does not favor Probably favors either the Probably favors the
comparison intervention or the the intervention comparison Probably reduced Probably no impact Probably increased
Probably no Probably yes Yes Probably no Probably yes Yes Favors th interventio d Increased Varies Varies Varies he
Varies on d Varies Varies Varies Don't know Don't know Don't know No included studies Don't know Don't know Don't know
Don't know Strong recommendation against the Conditional recommendation against the Conditional recommendation for the
Strong recommenda intervention intervention intervention interventio Recommendation L a segmentectomia rispetto alla
lobectomia può essere presa in considerazione per pazienti affetti da NSCLC in stadio inizia ation for the on ale
Author(s): MC Date: September 2019 Question: Durvalumab compared to placebo/Observation in patients with PD-L1<1
expression, stage III non resectable, responders or with a stable disease, non small cell lung cancer after concomitant
chemoradiotherapy Setting: inpatients Bibliography: Antonia S.J. "Durvalumab after chemoradiotherapy in stage III Non-
Small-Cell Lung Cancer" The New England Journal of Medicine, September 8, 2017 Antonia S.J. et al. N Engl J Med 2018;
379:2342-50; EMA Assessment report 26 July 2018 EMA/CHMP/548232/2018 Certainty assessment № of patients Effect Certainty
Importance № of Study Risk of Other Relative Absolute Inconsistency Indirectness Imprecision (Q1)Durvalumab
placebo/Observation studies design bias considerations (95% CI) (95% CI) Overall Survival 1 randomised not serious a not
serious not serious not serious none 70/212 (33.0%) 45/91 (49.5%) HR 0.53 19 fewer ⨁⨁⨁⨁ CRITICAL trials (0.36 to 0.77)
per 100 HIGH (from 28 fewer to 9 fewer) Progression free survival (follow up: median 14.5 months; assessed with: RECIST
1.1) 1 randomised not serious a not serious not serious not serious none 84/212 (39.6%) 59/91 (64.8%) HR 0.46 27 fewer
⨁⨁⨁⨁ CRITICAL trials (0.33 to 0.64) per 100 HIGH (from 36 fewer to 16 fewer) Distant metastasis (assessed with: time to
death or distant metastasis (all assessed by means of blinded independent central review)) 1 randomised not serious a
not serious serious b not serious

7. [intervention] score 15 ✅ BINGO (PIO)
., Reddy, S., Kopp, H. G., Piperdi, B., Li, X., Burke, T., Paz-Ares, L.. Health-Related Quality of Life With
Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-
Cell Lung Cancer. J Clin Oncol; Jan 20 2020. 2. Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A.,
Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., Panwalkar, A., Yang, J. C.,
Gubens, M., Sequist, L. V., Awad, M. M., Fiore, J., Ge, Y., Raftopoulos, H., Gandhi, L.. Carboplatin and pemetrexed with
or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the
open-label KEYNOTE-021 study. Lancet Oncol; Nov 2016. 3. Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto
Parra, H., Mazières, J., Hermes, B., Cicin, I., Medgyasszay, B., Rodríguez-Cid, J., Okamoto, I., Lee, S., Ramlau, R.,
Vladimirov, V., Cheng, Y., Deng, X., Zhang, Y., Bas, T., Piperdi, B., Halmos, B.. A Randomized, Placebo-Controlled Trial
of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of
KEYNOTE-407. J Thorac Oncol; Oct 2020. 4. Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J.,
Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K. H.,
Cheng, Y., Novello, S., Halmos, B., Li, X., Lubiniecki, G. M., Piperdi, B., Kowalski, D. M.. Pembrolizumab plus
Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med; Nov 22 2018. DOMAN Dovrebbe C istologia squ
POPULATION: INTERVENTION: COMPARISON: MAIN OUTCOMES: SETTING: PERSPECTIVE: BACKGROUND: CONFLICT OF INTERESTS: Is the
problem a priority? GIUDIZI ○ No Probably no Probably yes Yes Varies Don't know NDA 34 CBDCA + paclitaxel o nab-
paclitaxel + pembrolizumab vs chemioterapia essere utilizzato per pazienti affetti da NSCLC a uamosa in stadio
metastatico e con buon performance status (0-1) Pazienti affetti da NSCLC a istologia squamosa in stadio metastatico e
con buon performance status (0-1) CBDCA + paclitaxel o nab-paclitaxel + pembrolizumab Chemioterapia Overall survival;
Progression free survival; Response rate (formato da risposte complete + risposte parziali); Qualità della vita ;
Qualità della vita ; Any discontinuation ; Toxic death (morti legate al trattamento) ; Eventi avversi grado 3-4: Anemia;
Eventi avversi grado 3-4: Neutropenia; Eventi avversi grado 3-4: Trombocitopenia; Eventi avversi legati
all'immunoterapia Inpatients E RICERCA DELLE PROVE DI EVIDENZA CONSIDERAZIONI AGGIUNTIVE Desirabl How substant GIUDIZI ○
Trivial Small Moderate Large Varies Don't know le effe tial are the ects e desirabl le anticipated effects? RICERCA
DELLE PROVE DI EVIDENZA La valutazione dell'effetto dell'associazione tra carboplatino + Paclitaxel/Nab-Paclitaxel e
Pembrolizumab in prima linea rispetto alla chemioterapia, seguito da Pembrolizumab di mantenimento con Pembrolizumab in
caso di risposta o stabilità di malattia dopo 4 cicli, nei pazienti affetti da NSCLC a istologia squamosa in stadio
avanzato, con espressione del PDL-1 <50% e con buon performance status (0-1) , è stata eseguita attraverso una ricerca
bibliografica sulle banche dati Medline ed Embase

8. [outcome] score 15 ✅ BINGO (PIO)
azienti Effetto Mancanza di Certo № degli Disegno dello Rischio di Mancanza di Relativo Assoluto riproducibilità
Imprecisione Ulteriori considerazioni LDCT screening no LDCT screening studi studio distorsione generalizzabilità (95%
CI) (95% CI) dei risultati Overdiagnosis - LDCT vs no screening (follow up: intervallo 3 anni a 5 anni; valutato con:
the ratio between the difference of cumulative cancer incidence in the screened population and the cumulative cancer
incidence in the control population, and the screen-detected cancers.) 5 studi serio b serio c non importante non
importante nessuno 14653 14003 - overdiagnosis ⨁⨁◯◯ randomizzati 0.38 maggiore BASSA maggiore a maggiore) False positive
rate - LDCT vs no screening (follow up: intervallo 3 anni a 8.35 anni) 2 studi serio b non importante non importante
serio a nessuno 8635 0 - false positive ⨁⨁◯◯ randomizzati rate 4.53 maggiore BASSA (2.04 inferiore a 11.09 maggiore) CI:
Confidence interval; RR: Risk ratio a. Certainty of evidence was downgraded by one level due to imprecision. Optimal
information size not reached for screening studies. b. Certainty of evidence was downgraded by one level for high risk
of performance and/or detection bias c. Certainty of evidence was downgraded by one level for inconcistency among
studies (I-squared=65%) Importanza e cumulative number of CRITICO IMPORTANTE Nei pazienti fumatori o ex-fumatori che
hanno fumato almeno 15 sigarette al giorno per più di 25 a per più di 30 anni, oppure che hanno smesso meno di 10 anni
prima, lo screening per tumore polmo annuale dovrebbe essere preso in considerazione rispetto al non screening?
POPULATION: Lung cancer INTERVENTION: LDCT screening COMPARISON: No LDCT screening MAIN OUTCOMES: Lung cancer related
mortality; All-cause mortality; Early stage detection; Late stage disease; Resectability rate ; Overdia PERSPECTIVE:
Popolazione CONFLICT OF INTERESTS: Nessun conflitto dichiarato anni oppure almeno 10 sigar onare con la TC torace spira
agnosis; False positive rate rette al giorno ale a bassa dose VALUTAZION Is the problem a prior GIUDIZI ○ No ○ Probably
no ○ Probably yes ● Yes ○ Varies ○ Don't know Desirable effe How substantial are th GIUDIZI ○ Trivial ○ Small ● Moderate
○ Large ○ Varies ○ Don't know NE rity? ects he desira RICERCA DELLE PROVE DI EVIDENZA CONS Lung cancer (LC) screening by
low-dose computed tomography (LDCT) achieved a 20% decrease in LC mortality in the National Lung Screening Trial (NLST),
when compared with chest radiography [1], while European randomized clinical trials (RCT) testing LDCT versus
observation showed no benefit at 5-year, possibly due to small number of participants and short follow-up. The selection
criteria were not homogeneous among RCTs [1– 8], and most European RCTs enrolled younger populations, with lower LC risk
than NLST [2–8]. The majority of RCTs offered annual LDCT rounds for [1]4 years, where the impact of screening duration
and intensity was not evaluable. Pastorino U. et al. Annals of Oncology 0: 1-8, 2019 able anticipated effects? RICERCA
DELLE PROVE DI EVIDENZA CONS Cochrane Database of Systematic Reviews (CENTRAL), Embase, MEDLINE and ClinicalTrial.gov
were searched for eligible studies. A literature search was performed using free text and Mesh terms from inception up
to 1 Se

9. [outcome] score 15 ✅ BINGO (PIO)
mes, B., Cicin, I., Rodriguez-Cid, J., Wilson, J., Kato, T., Ramlau, R., Novello, S., Reddy, S., Kopp, H. G., Piperdi,
B., Li, X., Burke, T., Paz-Ares, L.. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With
or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. J Clin Oncol; Jan 20 2020. 2.
Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D.,
Martins, R. G., Stevenson, J. P., Jalal, S. I., Panwalkar, A., Yang, J. C., Gubens, M., Sequist, L. V., Awad, M. M.,
Fiore, J., Ge, Y., Raftopoulos, H., Gandhi, L.. Carboplatin and pemetrexed with or without pembrolizumab for advanced,
non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol;
Nov 2016. 3. Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., Hermes, B., Cicin, I.,
Medgyasszay, B., Rodríguez-Cid, J., Okamoto, I., Lee, S., Ramlau, R., Vladimirov, V., Cheng, Y., Deng, X., Zhang, Y.,
Bas, T., Piperdi, B., Halmos, B.. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients
With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol; Oct 2020. 4. Paz-Ares,
L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A.,
Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K. H., Cheng, Y., Novello, S., Halmos, B., Li, X.,
Lubiniecki, G. M., Piperdi, B., Kowalski, D. M.. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung
Cancer. N Engl J Med; Nov 22 2018. DOMAN Dovrebbe C istologia squ POPULATION: INTERVENTION: COMPARISON: MAIN OUTCOMES:
SETTING: PERSPECTIVE: BACKGROUND: CONFLICT OF INTERESTS: Is the problem a priority? GIUDIZI ○ No Probably no Probably
yes Yes Varies Don't know NDA 34 CBDCA + paclitaxel o nab-paclitaxel + pembrolizumab vs chemioterapia essere utilizzato
per pazienti affetti da NSCLC a uamosa in stadio metastatico e con buon performance status (0-1) Pazienti affetti da
NSCLC a istologia squamosa in stadio metastatico e con buon performance status (0-1) CBDCA + paclitaxel o nab-paclitaxel
+ pembrolizumab Chemioterapia Overall survival; Progression free survival; Response rate (formato da risposte complete +
risposte parziali); Qualità della vita ; Qualità della vita ; Any discontinuation ; Toxic death (morti legate al
trattamento) ; Eventi avversi grado 3-4: Anemia; Eventi avversi grado 3-4: Neutropenia; Eventi avversi grado 3-4:
Trombocitopenia; Eventi avversi legati all'immunoterapia Inpatients E RICERCA DELLE PROVE DI EVIDENZA CONSIDERAZIONI
AGGIUNTIVE Desirabl How substant GIUDIZI ○ Trivial Small Moderate Large Varies Don't know le effe tial are the ects e
desirabl le anticipated effects? RICERCA DELLE PROVE DI EVIDENZA La valutazione dell'effetto dell'associazione tra
carboplatino + Paclitaxel/Nab-Paclitaxel e Pembrolizumab in prima linea rispetto alla chemioterapia, seguito da
Pembrolizumab di mantenimento con Pembrolizumab in caso di risposta o stabilità di malattia dopo 4 cicli, nei pazienti
affetti da NSCLC a istologia squamosa in stadio avanzato, con espressione del PDL-1 <50% e con buon performance status
(0-1) , è st

10. [outcome] score 15 ✅ BINGO (PIO)
riproducibilità dei risultati|Mancanza di generalizzabilità|Imprecisione|Ulteriori considerazioni|LDCT screening|no LDCT
screening|Relativo (95% CI)|Assoluto (95% CI)| Row 5: ||||||||||| Row 6: Overdiagnosis - LDCT vs no screening (follow
up: intervallo 3 anni a 5 anni; valutato con: the ratio between the difference of cumulative cancer incidence in the
screened population and the cumulative cancer incidence in the control population, and the screen-detected
cancers.)||||||||||| Row 7: ||||||||||| Row 8: 5|studi randomizzati|serio b|serio c|non importante|non
importante|nessuno|14653|14003|-|overdiagnosis 0.38 maggiore (0.14 maggiore a 0.63 maggiore)|⨁⨁◯◯ BASSA Row 9: False
positive rate - LDCT vs no screening (follow up: intervallo 3 anni a 8.35 anni)||||||||||| Row 10: ||||||||||| Row 11:
2|studi randomizzati|serio b|non importante|non importante|serio a|nessuno|8635|0|-|false positive rate 4.53 maggiore
(2.04 inferiore a 11.09 maggiore)|⨁⨁◯◯ BASSA Row 1:  Row 2: Importanza Row 3: cumulative number of Row 4:  Row 5:
CRITICO Row 6:  Row 7:  Row 8: IMPORTANTE Row 1: |Nei pazienti fumatori o ex-fumatori che hanno fumato almeno 15
sigarette al giorno per più di 25 anni oppure almeno 10 sigarette al giorno||| Row 2: |per più di 30 anni, oppure che
hanno smesso meno di 10 anni prima, lo screening per tumore polmonare con la TC torace spirale a bassa dose||| Row 3:
|annuale dovrebbe essere preso in considerazione rispetto al non screening?||| Row 4: |||| Row 5: |POPULATION:||Lung
cancer| Row 6: |||| Row 7: |INTERVENTION:||LDCT screening| Row 8: |||| Row 9: |COMPARISON:||No LDCT screening| Row 10:
|||| Row 11: MAIN OUTCOMES:|||Lung cancer related mortality; All-cause mortality; Early stage detection; Late stage
disease; Resectability rate ; Overdiagnosis; False positive rate| Row 12: |||| Row 13: |SETTING:||| Row 14: |||| Row 15:
|PERSPECTIVE:||Popolazione| Row 16: |||| Row 17: |BACKGROUND:||| Row 18: |||| Row 19: CONFLICT OF INTERESTS:|||Nessun
conflitto dichiarato| Row 20: |||| Row 1: |Nei pazienti fumatori o ex-fumatori che hanno fumato almeno 15 sigarette al
giorno per più di 25 a| Row 2: |per più di 30 anni, oppure che hanno smesso meno di 10 anni prima, lo screening per
tumore polmo| Row 3: |annuale dovrebbe essere preso in considerazione rispetto al non screening?| Row 4: || Row 5:
|POPULATION:| Row 6: || Row 7: |INTERVENTION:| Row 8: || Row 9: |COMPARISON:| Row 10: || Row 11: MAIN OUTCOMES:|| Row
12: || Row 13: |SETTING:| Row 14: || Row 15: |PERSPECTIVE:| Row 16: || Row 17: |BACKGROUND:| Row 18: || Row 19: CONFLICT
OF INTERESTS:|| Row 20: || Row 1: anni oppure almeno 10 sigar Row 2: onare con la TC torace spira Row 3:  Row 4:  Row 1:
rette al giorno| Row 2: ale a bassa dose| Row 3: | Row 4: | Row 1: |||| Row 2: |Problem||| Row 3: |Is the problem a
priority?||| Row 4: |||| Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE| Row 6: ○ No ○
Probably no ○ Probably yes ● Yes ○ Varies ○ Don't know||Lung cancer (LC) screening by low-dose computed tomography
(LDCT) achieved a 20% decrease in LC mortality in the National Lung Screening Trial (NLST), when compared with chest
radiography [1], while European randomized clinical trials (RCT) testing LDCT versus observation showed no benefit at
5-year, possibly due to small number of partic

11. [population] score 14 ✅ BINGO (PCO)
. Comparative study of the anatomic segmentectomy versus lobectomy for clinical stage IA peripheral lung cancer by video
assistant thoracoscopic surgery. J Cancer Res Ther; Sep 2013. 17.Yamashita, S., Tokuishi, K., Anami, K., Moroga, T.,
Miyawaki, M., Chujo, M., Yamamoto, S., Kawahara, K.. Thoracoscopic segmentectomy for T1 classification of non-small cell
lung cancer: a single center experience. Eur J Cardiothorac Surg; Jul 2012. 18.Yamato, Y., Koike, T., Yoshiya, K.,
Shinohara, H., Toyabe, S.. Results of surgical treatment for small (2 cm or under) adenocarcinomas of the lung. Surg
Today; 2008. 19.Tsubokawa, N., Tsutani, Y., Miyata, Y., Handa, Y., Misumi, K., Hanaki, H., Hida, E., Okada, M..
Segmentectomy Versus Lobectomy for Radiologically Pure Solid Clinical T1a-bN0M0 Lung Cancer. World J Surg; Aug 2018.
20.Sugi, K., Kobayashi, S., Sudou, M., Sakano, H., Matsuda, E., Okabe, K.. Long-term prognosis of video-assisted limited
surgery for early lung cancer. Eur J Cardiothorac Surg; Feb 2010. 21.Shapiro, M., Weiser, T. S., Wisnivesky, J. P.,
Chin, C., Arustamyan, M., Swanson, S. J.. Thoracoscopic segmentectomy compares favorably with thoracoscopic lobectomy
for patients with small stage I lung cancer. J Thorac Cardiovasc Surg; Jun 2009. 22.Soukiasian, H. J., Hong, E.,
McKenna, R. J.,Jr.. Video-assisted thoracoscopic trisegmentectomy and left upper lobectomy provide equivalent survivals
for stage IA and IB lung cancer. J Thorac Cardiovasc Surg; Sep 2012. 23.Song, C. Y., Sakai, T., Kimura, D., Tsushima,
T., Fukuda, I.. Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy
for patients with clinical stage IA non-small cell lung cancer: a propensity score matching study. J Thorac Dis; Aug
2018. 24.Darras, M., Ojanguren, A., Forster, C., Zellweger, M., Perentes, J. Y., Krueger, T., Gonzalez, M.. Short-term
local control after VATS segmentectomy and lobectomy for solid NSCLC of less than 2 cm. Thorac Cancer; Feb 2021. 25.De
Giacomo, T., Di Stasio, M., Diso, D., Anile, M., Venuta, F., Furio Coloni, G.. Sub-lobar lung resection of peripheral
T1N0M0 NSCLC does not affect local recurrence rate. Scand J Surg; 2009. 26.Zhao, X., Qian, L., Luo, Q., Huang, J..
Segmentectomy as a safe and equally effective surgical option under complete video-assisted thoracic surgery for
patients of stage I non-small cell lung cancer. J Cardiothorac Surg; Apr 29 2013. 27.Wang, B. Y., Tu, C. C., Liu, C. Y.,
Shih, C. S., Liu, C. C.. Single-incision thoracoscopic lobectomy and segmentectomy with radical lymph node dissection.
Ann Thorac Surg; Sep 2013. 28.Echavarria, M. F., Cheng, A. M., Velez-Cubian, F. O., Ng, E. P., Moodie, C. C., Garrett,
J. R., Fontaine, J. P., Robinson, L. A., Toloza, E. M.. Comparison of pulmonary function tests and perioperative
outcomes after robotic-assisted pulmonary lobectomy vs segmentectomy. Am J Surg; Dec 2016. 29.Schuchert, M.J.,
Pettiford, B.L., Keeley, S., D'Amato, T.A., Kilic, A., Close, J., Pennathur, A., Santos, R., Fernando, H.C., Landreneau,
J.R., Luketich, J.D., Landreneau, R.J.. Anatomic segmentectomy in the treatment of stage I non-small cell lung cancer.
Ann Thorac Surg 2007. 30.Sienel, W., Stremmel, C., Kirschbaum, A., Hinterberger, L., Stoelben, E., Hasse, J., Passlick,
B.. Frequency of l

12. [intervention] score 14 ✅ BINGO (PIO)
owngrade the quality of evidence for attrition bias. b. I2=44% c. Different doses of alectinib (600 mg daily in J-ALEX
trial, 1200 mg daily in Peters et al and Zhou et al. trials). Moreover, in J-ALEX trial the 36% of patients in each arm
had received a previous chemotherapy line d. Lo studio Zhou ha preso in considerazione solo la popolazione asiatica. e.
Nonostante il basso numero di eventi, non abbiamo abbassato la qualità perche l'incidenza della patologia è rara f. Low
sample size, Optimal information size not met 1. Zhou, C., Kim, S. W., Reungwetwattana, T., Zhou, J., Zhang, Y., He, J.,
Yang, J. J., Cheng, Y., Lee, S. H., Bu, L., Xu, T., Yang, L., Wang, C., Liu, T., Morcos, P. N., Lu, Y., Zhang, L..
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung
cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med; May 2019. 2. Nakagawa, K., Hida, T., Nokihara, H.,
Morise, M., Azuma, K., Kim, Y. H., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Kumagai, T., Hotta, K., Watanabe,
S., Goto, K., Satouchi, M., Kozuki, T., Koyama, R., Mitsudomi, T., Yamamoto, N., Asakawa, T., Hayashi, M., Hasegawa, W.,
Tamura, T.. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive
non-small-cell lung cancer. Lung Cancer; Jan 2020. 3. Mok, T., Camidge, D. R., Gadgeel, S. M., Rosell, R., Dziadziuszko,
R., Kim, D. W., Pérol, M., Ou, S. I., Ahn, J. S., Shaw, A. T., Bordogna, W., Smoljanović, V., Hilton, M., Ruf, T., Noé,
J., Peters, S.. Updated overall survival and final progression-free survival data for patients with treatment-naive
advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol; Aug 2020. Dovrebbe alectinib vs
crizotinib essere utilizzato per pazienti affetti da NSCLC in stadio localmente avanzato o meta riarrangiamenti di ALK
POPULATION: Pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con riarrangiamenti di ALK
INTERVENTION: Alectinib COMPARISON: Crizotinib MAIN OUTCOMES: PFS; OS; ORR; Time to CNS progression - Peters s. et al.,
Gadgeel 2018; Time to progression of brain metastasis or death - Hida T. et al; Alanine aminotrasferase in Aspartate
aminotrasferase increase - grade 3-4; Nausea - grade 3-4; Toxic deaths SETTING: Inpatients PERSPECTIVE: BACKGROUND:
CONFLICT OF INTERESTS: Is the problem a priority? GIUDIZI RICERCA DELLE PROVE DI EVIDENZA CONSIDERAZIONI AGGIUNT ○ No ○
Probably no ○ Probably yes ● Yes ○ Varies ○ Don't know A astatico con ncrease- grade 3-4; TIVE Desirabl How substant
GIUDIZI ○ Trivial ○ Small ○ Moderate ● Large ○ Varies ○ Don't know le effe tial are th w ects he desirab ble anticipated
effects? RICERCA DELLE PROVE DI EVIDENZA La valutazione dell'effetto dell'Alectinib in prima linea rispetto al
Crizotinib, nei pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con riarrangiamenti di ALK, è
stata eseguita attraverso una ricerca bibliografica sulle banche dati Medline ed Embase fino a febbraio 2021. Dopo la
rimozione dei duplicati sono stati reperiti 147 records. Sono stati acquisiti 6 records in full-text. Di questi, 1 è
stato escluso perchè pubblicato come abstracts, 1 per disegno di studio. Tre studi sono stati inclusi. Lo studio ALEX ha
arruolato

13. [outcome] score 14 ✅ BINGO (PICO)
y yes ○ Yes ○ Varies ○ Don't know be the impact on health equity? RICERCA DELLE PROVE DI EVI Nessuna evidenza trovata.
ed pact ased bility ention acceptable to key stakeho RICERCA DELLE PROVE DI EVI Nessuna evidenza trovata. y ention
feasible to implement? RICERCA DELLE PROVE DI EVI Nessuna evidenza trovata. IDENZA olders? IDENZA IDENZA NEO OPLASIE E
DEL POLMO ONE L LINEE GUIDA CON CON CON A NSIDERAZI NSIDERAZI NSIDERAZI IONI AGGIUNTIVE IONI AGGIUNTIVE IONI AGGIUNTIVE
PROBLEM DESIRABLE EFFECT UNDESIRABLE EFFE CERTAINTY OF EVIDE VALUES BALANCE OF EFFEC EQUITY ACCEPTABILITY FEASIBILITY No
TS Trivial ECTS Large ENCE Very low Important uncertainty or variability Favors the CTS comparison Reduced No No
Probably no Probably yes Yes Small Moderate Large Moderate Small Trivial Low Moderate High Probably no Possibly
important No important important uncertainty or uncertainty or uncertainty or variability variability variability Does
not favor Probably favors either the Probably favors the comparison intervention or the the intervention comparison
Probably reduced Probably no impact Probably increased Probably no Probably yes Yes Probably no Probably yes Yes Favors
th interventio d Increased Varies Varies Varies he Varies on d Varies Varies Varies Don't know Don't know Don't know No
included studies Don't know Don't know Don't know Don't know Strong recommendation against the Conditional
recommendation against the Conditional recommendation for the Strong recommenda intervention intervention intervention
interventio Recommendation L a segmentectomia rispetto alla lobectomia può essere presa in considerazione per pazienti
affetti da NSCLC in stadio inizia ation for the on ale Author(s): MC Date: September 2019 Question: Durvalumab compared
to placebo/Observation in patients with PD-L1<1 expression, stage III non resectable, responders or with a stable
disease, non small cell lung cancer after concomitant chemoradiotherapy Setting: inpatients Bibliography: Antonia S.J.
"Durvalumab after chemoradiotherapy in stage III Non-Small-Cell Lung Cancer" The New England Journal of Medicine,
September 8, 2017 Antonia S.J. et al. N Engl J Med 2018; 379:2342-50; EMA Assessment report 26 July 2018
EMA/CHMP/548232/2018 Certainty assessment № of patients Effect Certainty Importance № of Study Risk of Other Relative
Absolute Inconsistency Indirectness Imprecision (Q1)Durvalumab placebo/Observation studies design bias considerations
(95% CI) (95% CI) Overall Survival 1 randomised not serious a not serious not serious not serious none 70/212 (33.0%)
45/91 (49.5%) HR 0.53 19 fewer ⨁⨁⨁⨁ CRITICAL trials (0.36 to 0.77) per 100 HIGH (from 28 fewer to 9 fewer) Progression
free survival (follow up: median 14.5 months; assessed with: RECIST 1.1) 1 randomised not serious a not serious not
serious not serious none 84/212 (39.6%) 59/91 (64.8%) HR 0.46 27 fewer ⨁⨁⨁⨁ CRITICAL trials (0.33 to 0.64) per 100 HIGH
(from 36 fewer to 16 fewer) Distant metastasis (assessed with: time to death or distant metastasis (all assessed by
means of blinded independent central review)) 1 randomised not serious a not serious serious b not serious none 72/476
(15.1%) 140/237 (59.1%) HR 0.52 22 fewer ⨁⨁⨁◯ CRITICAL trials (0.39 to 0.69) per 100 MODERATE (from 30 fewer to 13
fewer) NEOPLASI 1 randomised not se

14. [outcome] score 14 ✅ BINGO (PIO)
lattia dopo 4 cicli di trattamento vs. la chemioterapia essere usato per pazienti affetti da NSCLC a istologia non-
squamosa con espressione di PD-L1 <50% in stadio metastatico senza mutazione attivante l’EGFR o riarrangiamento di ALK e
con buon performance status (0-1)? POPULATION: Pazienti affetti da NSCLC a istologia non-squamosa con espressione di
PD-L1 <50% in stadio metastatico senza mutazione attivante l’EGFR o riarrangiamento di ALK e con buon performance status
(0-1) INTERVENTION: Un trattamento di prima linea a base di platino, pemetrexed e pembrolizumab, seguito da mantenimento
con pemetrexed e pembrolizumab in caso di risposta o stabilità di malattia dopo 4 cicli di trattamento COMPARISON: Alla
chemioterapia MAIN OUTCOMES: Overall survival; Progression free survival; Objective response rate; Grade 3-5 any AEs;
Discontinuation rate of any treatment component SETTING: PERSPECTIVE: BACKGROUND: CONFLICT OF INTERESTS: Assenti alla
votazione: Dr. Novello, Dr. Facchinetti, Dr. Passaro, Dr. Rossi, Dr. Trisolini, Dr. Ferrara, Dr. Menis Is the problem a
priority? ○ No Inhibitors of programmed death 1 (PD-1) and its ligand PD-L1 are effective therapies for metastatic
non–small-cell ○ Probably no lung cancer (NSCLC) lacking sensitizing EGFR or ALK mutations. Pembrolizumab (Keytruda,
Merck), nivolumab ○ Probably yes (Opdivo, Bristol-Myers Squibb), and atezolizumab (Tecentriq, Genentech) are approved as
second-line therapy. [...] X Yes ○ Varies ○ Don't know Desirable How substantia JUDGEMENT ○ Trivial ○ Small ○ Moderate X
Large ○ Varies ○ Don't know e effec al are the d cts desirable a LINEE GU Because patients with advanced NSCLC can
undergo rapid clinical deterioration during disease progression, less than one half of patients with advanced NSCLC ever
receive second-line therapy.1,2 First-line combination regimens that include a PD-1 or PD-L1 inhibitor may maximize the
chance of response and lead to prolonged survival. Modulation of the immune response through PD-1 inhibition may be
enhanced by the potential immunogenic effects of cytotoxic chemotherapy. Gandhi L. et al. N Engl J Med 2018;378:2078-92.
anticipated effects? RESEARCH EVIDENCE Outcomes Anticipated absolute effects* (95% CI) Relative № of Certainty of the C
effect participants evidence Risk with alla Risk with un trattamento di prima linea a (95% (studies) (GRADE)
chemioterapia base di platino, pemetrexed e CI) pembrolizumab, seguito da mantenimento con pemetrexed e pembrolizumab in
caso di risposta o stabilità di malattia dopo 4 cicli di trattamento Overall survival Study population HR 0.61 499 ⨁⨁◯◯
(0.45 to (2 RCTs) LOWa,b,c,d 61 per 100 44 per 100 0.83) (35 to 55) Progression free Study population HR 0.63 499 ⨁⨁⨁◯
survival (0.50 to (2 RCTs) MODERATEa,c,d,e 81 per 100 65 per 100 0.80) (56 to 73) Objective response Study population RR
2.16 499 ⨁⨁⨁◯ rate (1.58 to (2 RCTs) MODERATEa,c,d,e 21 per 100 46 per 100 2.95) (33 to 63) UIDA Comment ADDITIONAL
CONSIDERATIONS ts Grade 3-5 any AEs Study population RR 1.06 728 ⨁◯◯◯ (0.94 to (2 RCTs) VERY 56 per 100 60 per 100 1.19)
LOWa,c,d,f,g,h,i (53 to 67) Discontinuation rate Study population RR 0.80 739 ⨁◯◯◯ of any treatment (0.73 to (2 RCTs)
VERY LOWa,c,d,i,k componentj 78 per 100 62 per 100 0.88) (57 to 68) a. Unclear risk of attrition bias

15. [outcome] score 14 ✅ BINGO (ICO)
bly no impact|Probably increase d|Increase d| Row 18: Probably no|Probabl y yes|Yes|| Row 19: |||| Row 20: |||| Row 1:
Row 2:  Row 3:  Row 4:  Row 5:  Row 6:  Row 1: || Row 2: || Row 3: || Row 4: |Don't know| Row 5: |Don't know| Row 6:
|Don't know| Row 7: |No included studies| Row 8: || Row 9: || Row 10: || Row 11: || Row 12: || Row 13: |Don't know| Row
14: |Don't know| Row 15: |Don't know| Row 1: |||||||| Row 2: ||GIUDIZI|||||| Row 3: |||||||| Row 4: |No||Probably
no|Probably yes|Yes||Vari es|Don 't kno w Row 5: FEASIBILITY|||||||| Row 6: |||||||| Row 1: Strong recommendation
against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the
intervention ○| Row 2: |||Strong recommendation Row 3: |||for the intervention Row 4: ||| Row 5: |||● Row 6: ||| Row 1:
Row 2: Recommendation Row 3:  Row 1: |||||||||||| Row 2: Quality assessment|||||||No of patients||Effect||| Row 3:
|||||||||||Quality|Importance Row 4: |||||||||||| Row 5: No of||||||Other|Maintenance therapy||Relative||| Row 6:
|Design|Risk of bias|Inconsistency|Indirectness|Imprecision|||Placebo||Absolute|| Row 7:
studies||||||considerations|with pemetrexed||(95% CI)||| Row 8: |||||||||||| Row 9: Overall Survival (follow-up median
12.5 months; assessed with: not rilevant )|||||||||||| Row 10: 1|randomised trials|no serious risk of bias|no serious
inconsistency|no serious indirectness|no serious imprecision|none|255/359 (71%)|140/180 (77.8%)|HR 0.78 (0.64 to
0.96)2|9 fewer per 100 (from 1 fewer to 16 fewer)|HIGH|CRITICAL3 Row 11: Progression free survival (follow-up median 5
months4; assessed with: indipendent radiologist masked to treatment using RECIST 1.05)|||||||||||| Row 12: 1|randomised
trials|no serious risk of bias|no serious inconsistency|no serious indirectness|no serious imprecision|none|175/359
(48.7%)|62/180 (34.4%)|HR 0.62 (0.49 to 0.79)6|11 fewer per 100 (from 6 fewer to 16 fewer)|HIGH|IMPORTANT3 Row 13:
Objective responce rate (follow-up median 24.3 months; assessed with: overall responce rate (compleate and partial
response) RECIST 1.07)|||||||||||| Row 14: 1|randomised trials|no serious risk of bias|no serious inconsistency|no
serious indirectness|no serious imprecision8|none|9/316 (2.8%)|1/156 (0.64%)|RR 4.44 (0.57 to 34.36)9|2 more per 100
(from 0 fewer to 21 more)|HIGH|NOT IMPORTANT3 Row 15: Quality of life -EQ-5D (measured with: EQ-5D index score - Cycle
6; range of scores: -0,59-1,0; Better indicated by higher values)|||||||||||| Row 16: 1|randomised trials|serious10|no
serious inconsistency|no serious indirectness|serious11|none|98|36|-|SMD 0.04 lower (0.42 lower to 0.34
higher)12|LOW|CRITICAL3 Row 1: ||||||| Row 2: Quality assessment|||||||No of patients Row 3: ||||||| Row 4: No
of||||||Other|Maintenance therapy Row 5: |Design|Risk of bias|Inconsistency|Indirectness|Imprecision|| Row 6:
studies||||||considerations|with pemetrexed Row 7: ||||||| Row 8: Overall Survival (follow-up median 12.5 months;
assessed with: not rilevant )||||||| Row 9: 1|randomised trials|no serious risk of bias|no serious inconsistency|no
serious indirectness|no serious imprecision|none| Row 10: Progression free survival (follow-up median 5 months4;
assessed with: indipendent radiologist masked to treatment using RECIST 1.05||||||| Row 11:

16. [intervention] score 13 ✅ BINGO (PIO)
||LDCT screening| Row 8: |||| Row 9: |COMPARISON:||No LDCT screening| Row 10: |||| Row 11: MAIN OUTCOMES:|||Lung cancer
related mortality; All-cause mortality; Early stage detection; Late stage disease; Resectability rate ; Overdiagnosis;
False positive rate| Row 12: |||| Row 13: |SETTING:||| Row 14: |||| Row 15: |PERSPECTIVE:||Popolazione| Row 16: |||| Row
17: |BACKGROUND:||| Row 18: |||| Row 19: CONFLICT OF INTERESTS:|||Nessun conflitto dichiarato| Row 20: |||| Row 1: |Nei
pazienti fumatori o ex-fumatori che hanno fumato almeno 15 sigarette al giorno per più di 25 a| Row 2: |per più di 30
anni, oppure che hanno smesso meno di 10 anni prima, lo screening per tumore polmo| Row 3: |annuale dovrebbe essere
preso in considerazione rispetto al non screening?| Row 4: || Row 5: |POPULATION:| Row 6: || Row 7: |INTERVENTION:| Row
8: || Row 9: |COMPARISON:| Row 10: || Row 11: MAIN OUTCOMES:|| Row 12: || Row 13: |SETTING:| Row 14: || Row 15:
|PERSPECTIVE:| Row 16: || Row 17: |BACKGROUND:| Row 18: || Row 19: CONFLICT OF INTERESTS:|| Row 20: || Row 1: anni
oppure almeno 10 sigar Row 2: onare con la TC torace spira Row 3:  Row 4:  Row 1: rette al giorno| Row 2: ale a bassa
dose| Row 3: | Row 4: | Row 1: |||| Row 2: |Problem||| Row 3: |Is the problem a priority?||| Row 4: |||| Row 5:
GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE| Row 6: ○ No ○ Probably no ○ Probably yes ● Yes ○
Varies ○ Don't know||Lung cancer (LC) screening by low-dose computed tomography (LDCT) achieved a 20% decrease in LC
mortality in the National Lung Screening Trial (NLST), when compared with chest radiography [1], while European
randomized clinical trials (RCT) testing LDCT versus observation showed no benefit at 5-year, possibly due to small
number of participants and short follow-up. The selection criteria were not homogeneous among RCTs [1– 8], and most
European RCTs enrolled younger populations, with lower LC risk than NLST [2–8]. The majority of RCTs offered annual LDCT
rounds for [1]4 years, where the impact of screening duration and intensity was not evaluable. Pastorino U. et al.
Annals of Oncology 0: 1-8, 2019|| Row 7: |||| Row 8: |Desirable effects||| Row 9: |How substantial are the desirable
anticipated effects?||| Row 10: |||| Row 11: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE| Row 12:
○ Trivial ○ Small ● Moderate ○ Large ○ Varies ○ Don't know||Cochrane Database of Systematic Reviews (CENTRAL), Embase,
MEDLINE and ClinicalTrial.gov were searched for eligible studies. A literature search was performed using free text and
Mesh terms from inception up to 1 September 2021 without language restriction. The database searches retrieved 137
records after duplicate were removed. Sixteen studies were judged as potentially relevant. Two articles were excluded,
because they were not randomized controlled trials; five because did not included either population (n.3) or
intervention (n.2) of interest and three comparing CTLS versus CXR (3, 23, 24, 25). Six randomized controlled trials
comparing LDCT versus NS (6, 8, 10, 11, 13, 14) were excluded as they were already included in the systematic review of
Passiglia 2021 (15). This review was finally included encompassing a total of 31106 participants. In almost all included
trials, baseline characterist

17. [intervention] score 13 ✅ BINGO (PIO)
ri tirosin-chinasici. c. La certezza delle prove è stata abbassata perchè nello studio di Shaw et al. non c'è braccio di
confronto, alcuni pazienti avevano il riarrangiamento di ALK, altri il riarrangiamento di ROS-1. Inoltre i pazienti
hanno ricevuto 1 o più linee di trattamento, sia con chemioterapia che con diversi TKI. 1. Felip, E., Shaw, A. T.,
Bearz, A., Camidge, D. R., Solomon, B. J., Bauman, J. R., Bauer, T. M., Peters, S., Toffalorio, F., Abbattista, A.,
Thurm, H., Peltz, G., Wiltshire, R., Besse, B.. Intracranial and extracranial efficacy of lorlatinib in patients with
ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol; May 2021. 2.
Shaw, A. T., Felip, E., Bauer, T. M., Besse, B., Navarro, A., Postel-Vinay, S., Gainor, J. F., Johnson, M., Dietrich,
J., James, L. P., Clancy, J. S., Chen, J., Martini, J. F., Abbattista, A., Solomon, B. J.. Lorlatinib in non-small-cell
lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1
trial. Lancet Oncol; Dec 2017. Dovrebbe l in progress POPOLAZIONE: INTERVENTO: CONFRONTO: ESITI PRINCIPALI: SETTING:
PROSPETTIVA: BACKGROUND: CONFLITTI DI INTERESSE VALUTA Il problema è una priorit GIUDIZI ○ No ○ Probabilmente no ○
Probabilmente si ● Si ○ Varia ○ Non so LINEE GUID lorlatinib vs chemioterapia essere utilizzato per pazienti affetti da
NSCLC in stadio avanzato con riarrangiam sione a una terapia con alectinib o brigatinib Pazienti affetti da NSCLC in
stadio avanzato con riarrangiamento di ALK in progressione a una terapia con Alectinib o Brigatinib Lorlatinib
Chemioterapia Overall survival; Durata della risposta; Progression free survival; Objective response; Objective response
sul SNC; Adverse effect AST grade 3-4; Effetti sul sis Ipercolesterolemia grado 3-4; Ipertrigliceridemia di grado 3-4;
Aumento di peso Inpatients E Nessun conflitto d'interessi. AZIONE tà? RICERCA DELLE PROVE DI EVIDENZA CONSIDERAZIONI
AGGIUNTIVE Da compilare. DA mento di ALK stema nervoso centrale; Effetti de Quanto consid GIUDIZI ○ Irrilevanti ○
Piccoli ● Moderati ○ Grandi ○ Variano ○ Non so esider derevoli s rabili sono gli e effetti des siderabili attesi?
RICERCA DELLE PROVE DI EVIDENZA CONS E' stata eseguita attraverso una ricerca bibliografica sulle banche dati Medline ed
Embase fino a febbraio 2021. Dopo la rimozione dei duplicati e l'acquisizione dei full text, sono stati inclusi 2 studi.
Lo studio di Shaw et al. è un open-label single arm che ha arruolato 54 pazienti affetti da NSCLC avanzato con
riarrangiamento di ALK e ROS-1, a cui è stato somministrato Lrolatinib a un range di dose tra i 10-200mg die o 35-100mg
BID. Lo studio di Felip et al. è un open-label single arm che ha arruolato 139 pazienti affetti da NSCLC avanzato con
riarrangiamento di ALK e precedentemente trattati con almeno 1 linea di inibitore tirosinchinasico, a cui è stato
somministrato Lorlatinib 100mg die q21. Esiti Impatto № dei Certezza delle partecipanti prove (studi) (GRADE) Overall
survival Nello studio di Felip et al. la (1 studio ⨁◯◯◯ follow up: sopravvivenza mediana è stata di 20.7
osservazionale)1 MOLTO mediana 35.4 mesi (95%IC 16.1-30.3). BASSAa,b mesi Durata della Nello studio di Shaw et al. la
durata (2 studi ⨁◯◯◯ risposta mediana dell

18. [intervention] score 13 ✅ BINGO (PIO)
⨁◯◯◯ CRITICAL ) (0.73 to per 100 VERY LOW 0.88) (from 21 fewer to 9 fewer) a. Unclear risk of attrition bias in both
studies due to the lack of information b. We decided to downgrade the quality of the evidence by one level for the risk
of bias dimension because in both study crossover to pembrolizumab monotherapy was permitted among the patients in the
chemotherapy combination group who had verified disease progression c. In Keynote-021 trial, the maintenance treatment
consisted of pembrolizumab and optional indefinite pemetrexed d. In KEYNOTE-21 study, subgroups analysis according to
tumour proportion score for PD-L1 were not designed and performed. For this reason we decided to downgrade the quality
of the evidence by one level for indirectness e. KEYNOTE-021 trial was an open-label trial but efficacy was based on
masked, independent, central radiology review f. High risk of performance and detection bias because KEYNOTE-021 was an
open-label trial g. I2=53% h. In KEYNOTE 189 study safety results were showed in the overall population and not
according to PD-L1 tumour proportion score i. We decided to downgrade the quality of the evidence by one level for
imprecision because the 95% CI includes both negligible effect and appreciable benefit or appreciable harm j.
KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the following
reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43 patients
discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician
decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab
combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician
decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone arm
for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the
following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician decision, 2 new anticancer therapy
and 13 clinical progression; k. in KEYNOTE-189 study information for this outcome were showed in the overall population
and not according to PD-L1 tumour proportion score Dovrebbe un trattamento di prima linea a base di platino, pemetrexed
e pembrolizumab, seguito da mantenimento con pemetrexed e pembrolizumab in caso di risposta o stabilità di malattia dopo
4 cicli di trattamento vs. la chemioterapia essere usato per pazienti affetti da NSCLC a istologia non-squamosa con
espressione di PD-L1 <50% in stadio metastatico senza mutazione attivante l’EGFR o riarrangiamento di ALK e con buon
performance status (0-1)? POPULATION: Pazienti affetti da NSCLC a istologia non-squamosa con espressione di PD-L1 <50%
in stadio metastatico senza mutazione attivante l’EGFR o riarrangiamento di ALK e con buon performance status (0-1)
INTERVENTION: Un trattamento di prima linea a base di platino, pemetrexed e pembrolizumab, seguito da mantenimento con
pemetrexed e pembrolizumab in caso di risposta o stabilità di malattia dopo 4 cicli di trattamento COMPARISON: Alla
chemioterapia MAIN OUTCOMES: O

19. [intervention] score 13
tract])))))) OR ("grade I"[T "grade II"[Title/Abstract] OR "stage I"[Title/Abstract] OR "stage II"[Title/Abstract]))))
surgery")) AND (((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinic Type]) OR "drug therapy"
[Subheading])) OR ((randomized[Title/Abstract] OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR
randomly[Title/Abstract] trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mes
"Humans"[Mesh]))) espressione del zolizumab dopo oma, Non-Small- g mall-cell lung pt]) OR cer' OR 'non sma apia
postoperat (((((lung ract]) OR lung ung C*[Title/Abstract]) Title/Abstract] OR ))) AND "radical cal Trial" [Publica OR
sh]) AND l PD- o la -Cell all toria R ation NE EOPLASIE DEL POLMONE Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung
tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell
lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'grade ia' OR 'stage ia':de,ti,ab #5 #3 AND
#4 #6 "radical surgery:de,ti,ab #7 #5 AND #6 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta
analysis]/lim OR [controlled clinical trial]/lim OR [randomized controlled trial]/lim) AND [embase]/lim Q9: Nei pazienti
con NSCLC in stadio II-III resecabile una chemioterapia neoadiuvante seguita da chirurgia è raccomandata (rispetto a
sola chirurgia)? (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR "neoadjuvent"[All
Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR ("drug"[All Fields] AND "therapy"[All
Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All Fields] OR "drug therapy"[MeSH Subheading] OR
"chemotherapy"[All Fields]) AND ("resect"[All Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR
"resectates"[All Fields] OR "resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields] OR
"resectional"[All Fields] OR "resectioned"[All Fields] OR "resectioning"[All Fields] OR "resections"[All Fields] OR
"resective"[All Fields] OR "resects"[All Fields]) AND ("lung"[MeSH Terms] OR "lung"[All Fields]) AND ("cancer s"[All
Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR "cancerized"[All
Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR
"cancers"[All Fields])) AND (meta-analysis[Filter] OR randomizedcontrolledtrial[Filter] OR systematicreview[Filter])
Q10: Nei pazienti con NSCLC in stadio IIIA/IIIB non resecabile, o IIIC un trattamento di chemio- radioterapia a dosi
radicali concomitante è raccomandato (rispetto alla sequenziale)? MEDLINE (PubMed) (2019 ad Agosto 2023)
((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp]) OR ((((((((((lung cancer*[Title/Abstract]) OR lung
tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung neoplasm*[Title/Abstract]) OR lung
carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non small cell lung
cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))))))) AND (((grade iii OR stage iii OR advance OR locally advanced
disease)) AND (

20. [intervention] score 13
grade II"[Title/Abstract] OR "stage I"[Title/Abstract] OR "stage II"[Title/Abstract])))) surgery")) AND
(((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinic Type]) OR "drug therapy" [Subheading])) OR
((randomized[Title/Abstract] OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract]
trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mes "Humans"[Mesh]))) espressione del
zolizumab dopo oma, Non-Small- g mall-cell lung pt]) OR cer' OR 'non sma apia postoperat (((((lung ract]) OR lung ung
C*[Title/Abstract]) Title/Abstract] OR ))) AND "radical cal Trial" [Publica OR sh]) AND l PD- o la -Cell all toria R
ation NE EOPLASIE DEL POLMONE Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung
cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'grade ia' OR 'stage ia':de,ti,ab #5 #3 AND #4 #6 "radical surgery:de,ti,ab #7 #5
AND #6 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta analysis]/lim OR [controlled clinical trial]/lim
OR [randomized controlled trial]/lim) AND [embase]/lim Q9: Nei pazienti con NSCLC in stadio II-III resecabile una
chemioterapia neoadiuvante seguita da chirurgia è raccomandata (rispetto a sola chirurgia)? (("neoadjuvant therapy"[MeSH
Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR "neoadjuvant therapy"[All Fields] OR
"neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields]
OR "drug therapy"[MeSH Terms] OR ("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR
"chemotherapies"[All Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All Fields]
OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fields] OR "resected"[All Fields] OR
"resecting"[All Fields] OR "resection"[All Fields] OR "resectional"[All Fields] OR "resectioned"[All Fields] OR
"resectioning"[All Fields] OR "resections"[All Fields] OR "resective"[All Fields] OR "resects"[All Fields]) AND
("lung"[MeSH Terms] OR "lung"[All Fields]) AND ("cancer s"[All Fields] OR "cancerated"[All Fields] OR "canceration"[All
Fields] OR "cancerization"[All Fields] OR "cancerized"[All Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms]
OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR "cancers"[All Fields])) AND (meta-analysis[Filter] OR
randomizedcontrolledtrial[Filter] OR systematicreview[Filter]) Q10: Nei pazienti con NSCLC in stadio IIIA/IIIB non
resecabile, o IIIC un trattamento di chemio- radioterapia a dosi radicali concomitante è raccomandato (rispetto alla
sequenziale)? MEDLINE (PubMed) (2019 ad Agosto 2023) ((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp])
OR ((((((((((lung cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung
neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non
small cell lung cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))))))) AND (((grade iii OR stage iii OR advance OR
locally advanced disease)) AND (inoperable OR surgically unres

21. [intervention] score 13
l cell lung cancer"[Title/Abstract] OR "Non-sm Row 6: carcinoma"[Title/Abstract] OR "Non small cell lung
carcinoma"[Title/Abstract)) OR Row 7: NSCLC[Title/Abstract])))))))))))))))))) AND ("atezolizumab" [Supplementary Concep
Row 8: ((atezolizumab[Title/Abstract] Row 1: (((((((((((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp])
OR (((((( Row 2: cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung tumour*[Title/Abst Row 3:
neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lu Row 4: cancer*[Title/Abstract]) OR
non small cell lung cancer*[Title/Abstract]) OR NSCLC Row 5: AND ((("grade IA"[Title/Abstract] OR "stage
IA"[Title/Abstract])))))) OR ("grade I"[T Row 6: "grade II"[Title/Abstract] OR "stage I"[Title/Abstract] OR "stage
II"[Title/Abstract])))) Row 7: surgery")) AND (((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinic Row
8: Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR Row 9: randomised[Title/Abstract] OR
placebo[Title/Abstract] OR randomly[Title/Abstract] Row 10: trial[Title/Abstract] OR groups OR)))) NOT
((("Animals"[Mesh]) NOT "Animals"[Mes Row 11: "Humans"[Mesh]))) Row 1: (((((lung Row 2: ract]) OR lung Row 3: ung Row 4:
C*[Title/Abstract]) Row 5: itle/Abstract] OR Row 6: ))) AND "radical Row 7: cal Trial" [Publica Row 1: OR Row 2: sh])
AND Row 1: (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR Row 2:
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR Row 3: "neoadjuvent"[All
Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR Row 4: ("drug"[All Fields] AND "therapy"[All
Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All Row 5: Fields] OR "drug therapy"[MeSH Subheading] OR
"chemotherapy"[All Fields]) AND ("resect"[All Row 6: Fields] OR "resectability"[All Fields] OR "resectable"[All Fields]
OR "resectates"[All Fields] OR Row 7: "resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields] OR
"resectional"[All Fields] Row 8: OR "resectioned"[All Fields] OR "resectioning"[All Fields] OR "resections"[All Fields]
OR "resective"[All Row 9: Fields] OR "resects"[All Fields]) AND ("lung"[MeSH Terms] OR "lung"[All Fields]) AND ("cancer
s"[All Row 10: Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR Row
11: "cancerized"[All Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Row 12: Fields] OR
"cancer"[All Fields] OR "cancers"[All Fields])) AND (meta-analysis[Filter] OR Row 13: randomizedcontrolledtrial[Filter]
OR systematicreview[Filter]) Row 1: ((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp]) OR ((((((((((lung
Row 2: cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung Row 3:
neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lung Row 4: cancer*[Title/Abstract]) OR
non small cell lung cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))))))) Row 5: AND (((grade iii OR stage iii OR
advance OR locally advanced disease)) AND (inoperable OR Row 6: surgically unresectable)))) AND
(("Chemoradiotherapy"[Mesh]) OR (("Chemoradiotherapy"[Mesh])

22. [intervention] score 13
act] OR "stage I"[Title/Abstract] OR "stage II"[Title/Abstract])))) surgery")) AND (((((((("Randomized Controlled Trial"
[Publication Type]) OR "Clinic Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR
randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] trial[Title/Abstract] OR groups OR))))
NOT ((("Animals"[Mesh]) NOT "Animals"[Mes "Humans"[Mesh]))) espressione del zolizumab dopo oma, Non-Small- g mall-cell
lung pt]) OR cer' OR 'non sma apia postoperat (((((lung ract]) OR lung ung C*[Title/Abstract]) Title/Abstract] OR )))
AND "radical cal Trial" [Publica OR sh]) AND l PD- o la -Cell all toria R ation NE EOPLASIE DEL POLMONE Embase
(Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung
neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4
'grade ia' OR 'stage ia':de,ti,ab #5 #3 AND #4 #6 "radical surgery:de,ti,ab #7 #5 AND #6 AND ([cochrane review]/lim OR
[systematic review]/lim OR [meta analysis]/lim OR [controlled clinical trial]/lim OR [randomized controlled trial]/lim)
AND [embase]/lim Q9: Nei pazienti con NSCLC in stadio II-III resecabile una chemioterapia neoadiuvante seguita da
chirurgia è raccomandata (rispetto a sola chirurgia)? (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields]
AND "therapy"[All Fields]) OR "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All
Fields] OR "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR ("drug"[All
Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All Fields] OR "drug therapy"[MeSH
Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All Fields] OR "resectability"[All Fields] OR "resectable"[All
Fields] OR "resectates"[All Fields] OR "resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields] OR
"resectional"[All Fields] OR "resectioned"[All Fields] OR "resectioning"[All Fields] OR "resections"[All Fields] OR
"resective"[All Fields] OR "resects"[All Fields]) AND ("lung"[MeSH Terms] OR "lung"[All Fields]) AND ("cancer s"[All
Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR "cancerized"[All
Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR
"cancers"[All Fields])) AND (meta-analysis[Filter] OR randomizedcontrolledtrial[Filter] OR systematicreview[Filter])
Q10: Nei pazienti con NSCLC in stadio IIIA/IIIB non resecabile, o IIIC un trattamento di chemio- radioterapia a dosi
radicali concomitante è raccomandato (rispetto alla sequenziale)? MEDLINE (PubMed) (2019 ad Agosto 2023)
((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp]) OR ((((((((((lung cancer*[Title/Abstract]) OR lung
tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung neoplasm*[Title/Abstract]) OR lung
carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non small cell lung
cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))))))) AND (((grade iii OR stage iii OR advance OR locally advanced
disease)) AND (inoperable OR surgically unresectable)))) AND (("Che

23. [intervention] score 13
t])))))) OR ("grade I"[T "grade II"[Title/Abstract] OR "stage I"[Title/Abstract] OR "stage II"[Title/Abstract]))))
surgery")) AND (((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinic Type]) OR "drug therapy"
[Subheading])) OR ((randomized[Title/Abstract] OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR
randomly[Title/Abstract] trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mes
"Humans"[Mesh]))) espressione del zolizumab dopo oma, Non-Small- g mall-cell lung pt]) OR cer' OR 'non sma apia
postoperat (((((lung ract]) OR lung ung C*[Title/Abstract]) Title/Abstract] OR ))) AND "radical cal Trial" [Publica OR
sh]) AND l PD- o la -Cell all toria R ation NE EOPLASIE DEL POLMONE Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung
tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell
lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'grade ia' OR 'stage ia':de,ti,ab #5 #3 AND
#4 #6 "radical surgery:de,ti,ab #7 #5 AND #6 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta
analysis]/lim OR [controlled clinical trial]/lim OR [randomized controlled trial]/lim) AND [embase]/lim Q9: Nei pazienti
con NSCLC in stadio II-III resecabile una chemioterapia neoadiuvante seguita da chirurgia è raccomandata (rispetto a
sola chirurgia)? (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR "neoadjuvent"[All
Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR ("drug"[All Fields] AND "therapy"[All
Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All Fields] OR "drug therapy"[MeSH Subheading] OR
"chemotherapy"[All Fields]) AND ("resect"[All Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR
"resectates"[All Fields] OR "resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields] OR
"resectional"[All Fields] OR "resectioned"[All Fields] OR "resectioning"[All Fields] OR "resections"[All Fields] OR
"resective"[All Fields] OR "resects"[All Fields]) AND ("lung"[MeSH Terms] OR "lung"[All Fields]) AND ("cancer s"[All
Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR "cancerized"[All
Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR
"cancers"[All Fields])) AND (meta-analysis[Filter] OR randomizedcontrolledtrial[Filter] OR systematicreview[Filter])
Q10: Nei pazienti con NSCLC in stadio IIIA/IIIB non resecabile, o IIIC un trattamento di chemio- radioterapia a dosi
radicali concomitante è raccomandato (rispetto alla sequenziale)? MEDLINE (PubMed) (2019 ad Agosto 2023)
((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp]) OR ((((((((((lung cancer*[Title/Abstract]) OR lung
tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung neoplasm*[Title/Abstract]) OR lung
carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non small cell lung
cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))))))) AND (((grade iii OR stage iii OR advance OR locally advanced
disease)) AND (inoperab

24. [intervention] score 13
t] OR "stage I"[Title/Abstract] OR "stage II"[Title/Abstract])))) surgery")) AND (((((((("Randomized Controlled Trial"
[Publication Type]) OR "Clinic Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR
randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] trial[Title/Abstract] OR groups OR))))
NOT ((("Animals"[Mesh]) NOT "Animals"[Mes "Humans"[Mesh]))) espressione del zolizumab dopo oma, Non-Small- g mall-cell
lung pt]) OR cer' OR 'non sma apia postoperat (((((lung ract]) OR lung ung C*[Title/Abstract]) Title/Abstract] OR )))
AND "radical cal Trial" [Publica OR sh]) AND l PD- o la -Cell all toria R ation NE EOPLASIE DEL POLMONE Embase
(Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung
neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4
'grade ia' OR 'stage ia':de,ti,ab #5 #3 AND #4 #6 "radical surgery:de,ti,ab #7 #5 AND #6 AND ([cochrane review]/lim OR
[systematic review]/lim OR [meta analysis]/lim OR [controlled clinical trial]/lim OR [randomized controlled trial]/lim)
AND [embase]/lim Q9: Nei pazienti con NSCLC in stadio II-III resecabile una chemioterapia neoadiuvante seguita da
chirurgia è raccomandata (rispetto a sola chirurgia)? (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields]
AND "therapy"[All Fields]) OR "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All
Fields] OR "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR ("drug"[All
Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All Fields] OR "drug therapy"[MeSH
Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All Fields] OR "resectability"[All Fields] OR "resectable"[All
Fields] OR "resectates"[All Fields] OR "resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields] OR
"resectional"[All Fields] OR "resectioned"[All Fields] OR "resectioning"[All Fields] OR "resections"[All Fields] OR
"resective"[All Fields] OR "resects"[All Fields]) AND ("lung"[MeSH Terms] OR "lung"[All Fields]) AND ("cancer s"[All
Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR "cancerized"[All
Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR
"cancers"[All Fields])) AND (meta-analysis[Filter] OR randomizedcontrolledtrial[Filter] OR systematicreview[Filter])
Q10: Nei pazienti con NSCLC in stadio IIIA/IIIB non resecabile, o IIIC un trattamento di chemio- radioterapia a dosi
radicali concomitante è raccomandato (rispetto alla sequenziale)? MEDLINE (PubMed) (2019 ad Agosto 2023)
((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp]) OR ((((((((((lung cancer*[Title/Abstract]) OR lung
tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung neoplasm*[Title/Abstract]) OR lung
carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non small cell lung
cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))))))) AND (((grade iii OR stage iii OR advance OR locally advanced
disease)) AND (inoperable OR surgically unresectable)))) AND (("Chemorad

25. [intervention] score 13
lung cancer"[Title/Abstract] OR "Non-sm Row 6: carcinoma"[Title/Abstract] OR "Non small cell lung
carcinoma"[Title/Abstract)) OR Row 7: NSCLC[Title/Abstract])))))))))))))))))) AND ("atezolizumab" [Supplementary Concep
Row 8: ((atezolizumab[Title/Abstract] Row 1: (((((((((((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp])
OR (((((( Row 2: cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung tumour*[Title/Abst Row 3:
neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lu Row 4: cancer*[Title/Abstract]) OR
non small cell lung cancer*[Title/Abstract]) OR NSCLC Row 5: AND ((("grade IA"[Title/Abstract] OR "stage
IA"[Title/Abstract])))))) OR ("grade I"[T Row 6: "grade II"[Title/Abstract] OR "stage I"[Title/Abstract] OR "stage
II"[Title/Abstract])))) Row 7: surgery")) AND (((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinic Row
8: Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR Row 9: randomised[Title/Abstract] OR
placebo[Title/Abstract] OR randomly[Title/Abstract] Row 10: trial[Title/Abstract] OR groups OR)))) NOT
((("Animals"[Mesh]) NOT "Animals"[Mes Row 11: "Humans"[Mesh]))) Row 1: (((((lung Row 2: ract]) OR lung Row 3: ung Row 4:
C*[Title/Abstract]) Row 5: itle/Abstract] OR Row 6: ))) AND "radical Row 7: cal Trial" [Publica Row 1: OR Row 2: sh])
AND Row 1: (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR Row 2:
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR Row 3: "neoadjuvent"[All
Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR Row 4: ("drug"[All Fields] AND "therapy"[All
Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All Row 5: Fields] OR "drug therapy"[MeSH Subheading] OR
"chemotherapy"[All Fields]) AND ("resect"[All Row 6: Fields] OR "resectability"[All Fields] OR "resectable"[All Fields]
OR "resectates"[All Fields] OR Row 7: "resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields] OR
"resectional"[All Fields] Row 8: OR "resectioned"[All Fields] OR "resectioning"[All Fields] OR "resections"[All Fields]
OR "resective"[All Row 9: Fields] OR "resects"[All Fields]) AND ("lung"[MeSH Terms] OR "lung"[All Fields]) AND ("cancer
s"[All Row 10: Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR Row
11: "cancerized"[All Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Row 12: Fields] OR
"cancer"[All Fields] OR "cancers"[All Fields])) AND (meta-analysis[Filter] OR Row 13: randomizedcontrolledtrial[Filter]
OR systematicreview[Filter]) Row 1: ((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp]) OR ((((((((((lung
Row 2: cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung Row 3:
neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lung Row 4: cancer*[Title/Abstract]) OR
non small cell lung cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))))))) Row 5: AND (((grade iii OR stage iii OR
advance OR locally advanced disease)) AND (inoperable OR Row 6: surgically unresectable)))) AND
(("Chemoradiotherapy"[Mesh]) OR (("Chemoradiotherapy"[Mesh]) OR Row

26. [outcome] score 13
llow up: mediana 15.8 mesi) 1 1 studi molto serio b non importante molto serio a molto serio a nessuno Risposta
obiettiva ottenuta da 108/161 pazienti ⨁◯◯◯ CRITICO osservazionali MOLTO BASSA Objective response in pazienti con
malattia encefalica (follow up: mediana 15.8 mesi) 1 1 studi molto serio b non importante molto serio a molto serio a
nessuno La risposta obiettiva ottenuta dal 52.5% dei pazienti con metastasi cerebrali al basale. ⨁◯◯◯ CRITICO
osservazionali MOLTO BASSA Durata della risposta (follow up: mediana 15.8 mesi) Certainty assessment Mancanza di Impatto
Certo № degli Disegno dello Rischio di Mancanza di riproducibilità Imprecisione Ulteriori considerazioni studi studio
distorsione generalizzabilità dei risultati 1 1 studi molto serio b non importante molto serio a molto serio a nessuno
La mediana della durata della risposta è stata 15.7 mesi (IC95% 13.9-28.6) ⨁◯◯◯ osservazionali MOLTO BASSA a. La
certezza delle prove è stata abbassata poichè manca il braccio di confronto. b. La certezza delle prove è stata
abbassata perchè trattasi di una serie di casi. 1. Dziadziuszko, R., Krebs, M. G., De Braud, F., Siena, S., Drilon, A.,
Doebele, R. C., Patel, M. R., Cho, B. C., Liu, S. V., Ahn, M. J., Chiu, C. H., Farago, A. F., Lin, C. C., Karapetis, C.
S., Li, Y. C., Day, B. M., Chen, D., Wilson, T. R., Barlesi, F.. Updated In Efficacy and Safety of Entrectinib in
Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol; Apr 10 2021. Importanza
CRITICO ntegrated Analysis of the Dovrebbe entrectinib vs chemioterapia essere utilizzato per pazienti affe POPOLAZIONE:
Pazienti affetti da NSCLC avanzato con riarrangiamento di ROS1 INTERVENTO: Entrectinib CONFRONTO: Chemioterapia ESITI
PRINCIPALI: Overall survival; Progession free survival; Objective response; Objective response in pazienti c SETTING:
Inpatients PROSPETTIVA: BACKGROUND: CONFLITTI DI Nessun conflitto d'interesse. Il problema è una priorità? GIUDIZI
RICERCA DELLE PROVE DI EVIDENZA ○ No Da compilare. ○ Probabilmente no ○ Probabilmente si ● Si ○ Varia ○ Non so etti da
NSCLC con malattia encefa C avanz alica; Dura zato con riarr ata della risposta CONSIDERAZ LINE rangiam ZIONI AGG EE
GUIDA mento di ROS1 GIUNTIVE Effetti de Quanto consid GIUDIZI ○ Irrilevanti ○ Piccoli ● Moderati ○ Grandi ○ Variano ○
Non so esider derevoli s rabili sono gli e effetti des siderabili attesi? RICERCA DELLE PROVE DI EVIDENZA CONS E' stata
eseguita attraverso una ricerca bibliografica sulle banche dati Medline ed Embase fino a febbraio 2021. Dopo la
rimozione dei duplicati e l'acquisizione dei full text è stato incluso 1 studio. Lo studio di Dziadziuszko et al. (2021)
ha arruolato 161 pazienti affetti da NSCLC avanzato o metastatico con mutazione ROS1, con e senza metastasi cerebrali,
per valutare primariamente la risposta e la sua relativa durata alla terapia con Entrectinib >= 600mg die. Esiti Impatto
№ dei Certezza delle partecipanti prove (studi) (GRADE) Objective response Risposta obiettiva ottenuto da 108/161 (1
studio ⨁◯◯◯ follow up: mediana pazienti osservazionale) MOLTO 15.8 mesi BASSAa,b Progession free La mediana della PFS è
stata di 15.7 (1 studio ⨁◯◯◯ survival mesi (11-21.1), 48/161 pazienti hanno osservazionale) MOLTO follow up: mediana
avuto l'evento. BASSAa,

27. [outcome] score 13
tle/Abstract] OR VATS[Title/Abstract] OR "Thoracic Surgeries, Video-Assisted"[Title/Abstract] OR "Video-assisted
Thoracic Surgery (VATS) Lobectomy"[Title/Abstract] OR "Video-assisted Thoracic Surgery"[Title/Abstract]))) OR ("VATS
segmentectomy"[Title/Abstract] OR segmentectomy[Title/Abstract])))) AND (((((((((("Randomized Controlled
Trial"[Publication Type]) OR "Clinical Trial"[Publication Type]) OR "drug therapy"[Subheading])) OR
((randomized[Title/Abstract] OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] OR
trial[Title/Abstract] OR groups)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND "Humans"[Mesh]))))) AND
("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) Embase (Embase.com) (2019 ad
Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung
tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'grade ia' OR
'stage ia':de,ti,ab #5 #3 AND #4 NE LINEE GU EOPLASIE DEL POLMONE #6 'vats lobectomy' OR vats OR 'thoracic surgeries,
video-assisted' OR 'video surgery (vats) lobectomy' OR 'video-assisted thoracic surgery' OR 'vats segm
segmentectomy:de,ti,ab #7 #5 AND #6 Q3 GRADE: Nei pazienti affetti da NSCLC in stadio iniziale (IA), la segme
raccomandata (rispetto alla lobectomia)? MEDLINE (PubMed) (2019 a Agosto 2023) (("Lung Neoplasms"[Mesh]) OR "Carcinoma,
Non-Small-Cell Lun Neoplasms"[Mesh]) OR "lung cancer"[Title/Abstract] OR "lung neoplasms" tumor"[Title/Abstract] OR
"Non-small-cell lung cancer"[Title/Abstract] OR cancer"[Title/Abstract] OR NSCLC[Title/Abstract]) Embase (Embase.com)
(2019 a Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR
'lung tumor' OR 'non-small-cell lung lung cancer' OR nsclc:ti,ab Q4: Nei pazienti affetti da neoplasia polmonare NSCLC
T1-2N0 inoperab mediche il trattamento stereotassico è raccomandato rispetto alla radio MEDLINE (PubMed) (2019 ad Agosto
2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung Neoplasm (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung t "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[T
NSCLC[Title/Abstract]))))))) AND (("stage T1-2N0"[Title/Abstract] OR "T1-2N0 ((("Radiosurgery"[Mesh])) OR ("stereotactic
radiotherapy"[Title/Abstract])) Records: 8 Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small
cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cell lung cancer' OR
nsclc:ti,ab #3 #1 OR #2 #4 ‘stage T1-2N0’ #5 #3 AND #4 #6 radiosurgery'/exp/mj OR 'stereotactic radiotherapy':ti,ab #7
#5 AND #6 UIDA o-assi mentec entec ng"[M "[Title R "N cance bile pe oterap ms/sur tumor Title/A 0"[Titl g canc isted
thoracic ctomy' OR ctomia anatomica è Mesh]) OR "Lung e/Abstract] OR "lung Non small cell lung er' OR 'non small cell er
controindicazioni pia convenzionale? rgery"[Mesh]) OR "[Title/Abstract] OR Abstract])) OR le/Abstract]))))) AND cer' OR
'non small NE EOPLASIE DEL POLMONE Q5: Nei pazienti con NSCLC radicalmente operato una chemioterapia adiuvante con
combinazioni a base di cisplatino è raccomandata? MEDLINE (PubMed

28. [outcome] score 13
241240"[Title/Abstract] OR NSC241240[Title/Abstract] OR Blastocarb[Title/Abstract])))) OR ((("Paclitaxel"[Mesh]) OR
(Paclitaxel [Title/Abstract] OR Anzatax[Title/Abstract] OR "NSC-125973"[Title/Abstract] OR "NSC 125973"[Title/Abstract]
OR "NSC125973"[Title/Abstract] OR Taxol[Title/Abstract] OR "Taxol A"[Title/Abstract] OR "Bris Taxol"[Title/Abstract] OR
"Paclitaxel, (4 alpha)-Isomer"[Title/Abstract] OR Paxene[Title/Abstract] OR Praxel[Title/Abstract] OR "7-epi-
Taxol"[Title/Abstract] OR "7 epi Taxol"[Title/Abstract] OR Onxol[Title/Abstract] OR nab-paclitaxel[Title/Abstract] OR
nabpaclitaxel[Title/Abstract] OR "nab paclitaxel"[Title/Abstract]))))) AND ((("pembrolizumab" [Supplementary Concept])
OR (pembrolizumab [Title/Abstract] OR "SCH-900475"[Title/Abstract] OR Keytruda[Title/Abstract] OR "MK-
3475"[Title/Abstract] OR lambrolizumab[Title/Abstract]))))) AND (((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-
Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta analy*"[Title] OR
"metaanaly*"[Title] OR "Meta-Analysis"[Title])) OR ("systematic literature review"[Title])) OR ("systematic
review"[Title/Abstract])) OR (((("Randomized Controlled Trial"[Publication Type]) OR "Randomized Controlled Trials as
Topic"[Mesh]) OR ("Clinical Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
randomly[Title/Abstract])))))) NE EOPLASIE DEL POLMONE Embase (Embase.com) (2021 ad Agosto 2023) #1 'lung tumor'/exp OR
'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR
'non small cell lung cancer' OR nsclc:ti,ab #3 'squamous cell lung carcinoma'/exp/mj #4 'squamous cell lung cancer' OR
'squamous cell carcinoma of the lung' OR 'epidermoid carcinoma' OR 'lung squamous cell carcinoma' OR 'metastatic
squamous non-small cell lung cancer' OR 'squamous cell lung carcinoma':ti,ab #5 (#1 OR #2) AND (#3 OR #4) #6
('cisplatin'/exp/mj OR 'carboplatin'/exp/mj OR 'paclitaxel'/exp/mj) OR cisplatin OR 'cis- diamminedichloroplatinum(ii)'
OR 'platinum diamminodichloride' OR 'diamminodichloride, platinum' OR 'cis-platinum' OR 'cis platinum' OR
dichlorodiammineplatinum OR 'cis-diamminedichloroplatinum' OR 'cis diamminedichloroplatinum' OR 'cis-
dichlorodiammineplatinum(ii)' OR 'nsc-119875' OR platino OR platinol OR biocisplatinum OR platidiam OR carboplatin OR
'cis- diammine(cyclobutanedicarboxylato)platinum ii' OR cbdca OR paraplatin OR paraplatine OR platinwas OR ribocarbo OR
carboplat OR neocarbo OR carbosin OR carbotec OR ercar OR 'jm-8' OR 'jm 8' OR jm8 OR nealorin OR 'nsc-241240' OR 'nsc
241240' OR nsc241240 OR blastocarb:ti,ab #7 (pembrolizumab'/exp/mj) OR pembrolizumab OR 'sch-900475' OR keytruda OR
'mk-3475' OR lambrolizumab:ti,ab #8 (#6 OR #7) AND #8 #9 #5 AND #8 AND ([cochrane review]/lim OR [systematic review]/lim
OR [meta analysis]/lim OR [randomized controlled trial]/lim) AND [2019-2021]/py Q39: Nei pazienti affetti da NSCLC ad
istologia adenocarcinoma in stadio localmente avanzato o metastatico, in progressione di malattia dopo una prima linea
di chemioterapia, l’associazione di nintedanib e docetaxel è raccomandata rispetto al docetaxel da solo? MEDLINE
(PubMed) (1966 ad Agosto 2023) ((((((((((((((((((((("Carcinoma, Non-Small-Ce

29. [outcome] score 13
le/Abstract])))) OR ((("Paclitaxel"[Mesh]) OR (Paclitaxel [Title/Abstract] OR NE EOPLASIE DEL POLMONE
Anzatax[Title/Abstract] OR "NSC-125973"[Title/Abstract] OR "NSC 125973"[Title/Abstract] OR "NSC125973"[Title/Abstract]
OR Taxol[Title/Abstract] OR "Taxol A"[Title/Abstract] OR "Bris Taxol"[Title/Abstract] OR "Paclitaxel, (4
alpha)-Isomer"[Title/Abstract] OR Paxene[Title/Abstract] OR Praxel[Title/Abstract] OR "7-epi-Taxol"[Title/Abstract] OR
"7 epi Taxol"[Title/Abstract] OR Onxol[Title/Abstract] OR nab-paclitaxel[Title/Abstract] OR
nabpaclitaxel[Title/Abstract] OR "nab paclitaxel"[Title/Abstract]))))) AND ((("pembrolizumab" [Supplementary Concept])
OR (pembrolizumab [Title/Abstract] OR "SCH-900475"[Title/Abstract] OR Keytruda[Title/Abstract] OR "MK-
3475"[Title/Abstract] OR lambrolizumab[Title/Abstract]))))) AND (((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-
Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta analy*"[Title] OR
"metaanaly*"[Title] OR "Meta-Analysis"[Title])) OR ("systematic literature review"[Title])) OR ("systematic
review"[Title/Abstract])) OR (((("Randomized Controlled Trial"[Publication Type]) OR "Randomized Controlled Trials as
Topic"[Mesh]) OR ("Clinical Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
randomly[Title/Abstract])))))) Embase (Embase.com) (2021 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung
cancer' OR nsclc:ti,ab #3 'squamous cell lung carcinoma'/exp/mj #4 'squamous cell lung cancer' OR 'squamous cell
carcinoma of the lung' OR 'epidermoid carcinoma' OR 'lung squamous cell carcinoma' OR 'metastatic squamous non-small
cell lung cancer' OR 'squamous cell lung carcinoma':ti,ab #5 (#1 OR #2) AND (#3 OR #4) #6 ('cisplatin'/exp/mj OR
'carboplatin'/exp/mj OR 'paclitaxel'/exp/mj) OR cisplatin OR 'cis- diamminedichloroplatinum(ii)' OR 'platinum
diamminodichloride' OR 'diamminodichloride, platinum' OR 'cis-platinum' OR 'cis platinum' OR dichlorodiammineplatinum OR
'cis-diamminedichloroplatinum' OR 'cis diamminedichloroplatinum' OR 'cis-dichlorodiammineplatinum(ii)' OR 'nsc-119875'
OR platino OR platinol OR biocisplatinum OR platidiam OR carboplatin OR 'cis- diammine(cyclobutanedicarboxylato)platinum
ii' OR cbdca OR paraplatin OR paraplatine OR platinwas OR ribocarbo OR carboplat OR neocarbo OR carbosin OR carbotec OR
ercar OR 'jm-8' OR 'jm 8' OR jm8 OR nealorin OR 'nsc-241240' OR 'nsc 241240' OR nsc241240 OR blastocarb:ti,ab #7
(pembrolizumab'/exp/mj) OR pembrolizumab OR 'sch-900475' OR keytruda OR 'mk-3475' OR lambrolizumab:ti,ab #8 (#6 OR #7)
AND #8 #9 #5 AND #8 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta analysis]/lim OR [randomized
controlled trial]/lim) AND [2019-2021]/py Q35: Nei pazienti affetti da NSCLC in stadio avanzato senza mutazioni
attivanti di EGFR o riarrangiamenti di ALK, con espressione di PD-L1 <50% e con buon performance status (0-1), un
trattamento di prima linea a base ipilimumab in associazione a nivolumab e 2 cicli di chemioterapia a base di platino è
raccomandato (rispetto alla chemioterapia)? Q36: Nei pazienti affetti da NSCLC in stadio avanzato senza mutazioni attiv

30. [outcome] score 13
le/Abstract])))) OR ((("Paclitaxel"[Mesh]) OR (Paclitaxel [Title/Abstract] OR Anzatax[Title/Abstract] OR
"NSC-125973"[Title/Abstract] OR "NSC 125973"[Title/Abstract] OR "NSC125973"[Title/Abstract] OR Taxol[Title/Abstract] OR
"Taxol A"[Title/Abstract] OR "Bris Taxol"[Title/Abstract] OR "Paclitaxel, (4 alpha)-Isomer"[Title/Abstract] OR
Paxene[Title/Abstract] OR Praxel[Title/Abstract] OR "7-epi-Taxol"[Title/Abstract] OR "7 epi Taxol"[Title/Abstract] OR
Onxol[Title/Abstract] OR nab-paclitaxel[Title/Abstract] OR nabpaclitaxel[Title/Abstract] OR "nab
paclitaxel"[Title/Abstract]))))) AND ((("pembrolizumab" [Supplementary Concept]) OR (pembrolizumab [Title/Abstract] OR
"SCH-900475"[Title/Abstract] OR Keytruda[Title/Abstract] OR "MK- 3475"[Title/Abstract] OR
lambrolizumab[Title/Abstract]))))) AND (((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-Analysis"[Publication Type])
OR "meta-analysis[Title] OR systematic review"[Title] OR "meta analy*"[Title] OR "metaanaly*"[Title] OR "Meta-
Analysis"[Title])) OR ("systematic literature review"[Title])) OR ("systematic review"[Title/Abstract])) OR
(((("Randomized Controlled Trial"[Publication Type]) OR "Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical
Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
randomly[Title/Abstract])))))) NE EOPLASIE DEL POLMONE Embase (Embase.com) (2021 ad Agosto 2023) #1 'lung tumor'/exp OR
'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR
'non small cell lung cancer' OR nsclc:ti,ab #3 'squamous cell lung carcinoma'/exp/mj #4 'squamous cell lung cancer' OR
'squamous cell carcinoma of the lung' OR 'epidermoid carcinoma' OR 'lung squamous cell carcinoma' OR 'metastatic
squamous non-small cell lung cancer' OR 'squamous cell lung carcinoma':ti,ab #5 (#1 OR #2) AND (#3 OR #4) #6
('cisplatin'/exp/mj OR 'carboplatin'/exp/mj OR 'paclitaxel'/exp/mj) OR cisplatin OR 'cis- diamminedichloroplatinum(ii)'
OR 'platinum diamminodichloride' OR 'diamminodichloride, platinum' OR 'cis-platinum' OR 'cis platinum' OR
dichlorodiammineplatinum OR 'cis-diamminedichloroplatinum' OR 'cis diamminedichloroplatinum' OR 'cis-
dichlorodiammineplatinum(ii)' OR 'nsc-119875' OR platino OR platinol OR biocisplatinum OR platidiam OR carboplatin OR
'cis- diammine(cyclobutanedicarboxylato)platinum ii' OR cbdca OR paraplatin OR paraplatine OR platinwas OR ribocarbo OR
carboplat OR neocarbo OR carbosin OR carbotec OR ercar OR 'jm-8' OR 'jm 8' OR jm8 OR nealorin OR 'nsc-241240' OR 'nsc
241240' OR nsc241240 OR blastocarb:ti,ab #7 (pembrolizumab'/exp/mj) OR pembrolizumab OR 'sch-900475' OR keytruda OR
'mk-3475' OR lambrolizumab:ti,ab #8 (#6 OR #7) AND #8 #9 #5 AND #8 AND ([cochrane review]/lim OR [systematic review]/lim
OR [meta analysis]/lim OR [randomized controlled trial]/lim) AND [2019-2021]/py Q39: Nei pazienti affetti da NSCLC ad
istologia adenocarcinoma in stadio localmente avanzato o metastatico, in progressione di malattia dopo una prima linea
di chemioterapia, l’associazione di nintedanib e docetaxel è raccomandata rispetto al docetaxel da solo? MEDLINE
(PubMed) (1966 ad Agosto 2023) ((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma,
Non-Small-Cell Lung/pathology"[Mes

31. [population] score 12
1.19) (from 3 fewer to 11 more) 9 RR 0.80 16 fewer ⨁◯◯◯ CRITICAL ) (0.73 to per 100 VERY LOW 0.88) (from 21 fewer to 9
fewer) a. Unclear risk of attrition bias in both studies due to the lack of information b. We decided to downgrade the
quality of the evidence by one level for the risk of bias dimension because in both study crossover to pembrolizumab
monotherapy was permitted among the patients in the chemotherapy combination group who had verified disease progression
c. In Keynote-021 trial, the maintenance treatment consisted of pembrolizumab and optional indefinite pemetrexed d. In
KEYNOTE-21 study, subgroups analysis according to tumour proportion score for PD-L1 were not designed and performed. For
this reason we decided to downgrade the quality of the evidence by one level for indirectness e. KEYNOTE-021 trial was
an open-label trial but efficacy was based on masked, independent, central radiology review f. High risk of performance
and detection bias because KEYNOTE-021 was an open-label trial g. I2=53% h. In KEYNOTE 189 study safety results were
showed in the overall population and not according to PD-L1 tumour proportion score i. We decided to downgrade the
quality of the evidence by one level for imprecision because the 95% CI includes both negligible effect and appreciable
benefit or appreciable harm j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination
treatment for the following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded
medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients
withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment
in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients
withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued
treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab
combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician
decision, 2 new anticancer therapy and 13 clinical progression; k. in KEYNOTE-189 study information for this outcome
were showed in the overall population and not according to PD-L1 tumour proportion score Dovrebbe un trattamento di
prima linea a base di platino, pemetrexed e pembrolizumab, seguito da mantenimento con pemetrexed e pembrolizumab in
caso di risposta o stabilità di malattia dopo 4 cicli di trattamento vs. la chemioterapia essere usato per pazienti
affetti da NSCLC a istologia non-squamosa con espressione di PD-L1 <50% in stadio metastatico senza mutazione attivante
l’EGFR o riarrangiamento di ALK e con buon performance status (0-1)? POPULATION: Pazienti affetti da NSCLC a istologia
non-squamosa con espressione di PD-L1 <50% in stadio metastatico senza mutazione attivante l’EGFR o riarrangiamento di
ALK e con buon performance status (0-1) INTERVENTION: Un trattamento di prima linea a base di platino, pemetrexed e
pembrolizumab, seguito da mantenimento con pemetrexed e pembrolizumab in caso di risposta o stabilità di malattia dopo 4
cicli di trattam

32. [intervention] score 12
ract] OR "stage II"[Title/Abstract])))) surgery")) AND (((((((("Randomized Controlled Trial" [Publication Type]) OR
"Clinic Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR randomised[Title/Abstract] OR
placebo[Title/Abstract] OR randomly[Title/Abstract] trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT
"Animals"[Mes "Humans"[Mesh]))) espressione del zolizumab dopo oma, Non-Small- g mall-cell lung pt]) OR cer' OR 'non sma
apia postoperat (((((lung ract]) OR lung ung C*[Title/Abstract]) Title/Abstract] OR ))) AND "radical cal Trial" [Publica
OR sh]) AND l PD- o la -Cell all toria R ation NE EOPLASIE DEL POLMONE Embase (Embase.com) (2019 ad Agosto 2023) #1
'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-
cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'grade ia' OR 'stage ia':de,ti,ab #5 #3
AND #4 #6 "radical surgery:de,ti,ab #7 #5 AND #6 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta
analysis]/lim OR [controlled clinical trial]/lim OR [randomized controlled trial]/lim) AND [embase]/lim Q9: Nei pazienti
con NSCLC in stadio II-III resecabile una chemioterapia neoadiuvante seguita da chirurgia è raccomandata (rispetto a
sola chirurgia)? (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR "neoadjuvent"[All
Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR ("drug"[All Fields] AND "therapy"[All
Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All Fields] OR "drug therapy"[MeSH Subheading] OR
"chemotherapy"[All Fields]) AND ("resect"[All Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR
"resectates"[All Fields] OR "resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields] OR
"resectional"[All Fields] OR "resectioned"[All Fields] OR "resectioning"[All Fields] OR "resections"[All Fields] OR
"resective"[All Fields] OR "resects"[All Fields]) AND ("lung"[MeSH Terms] OR "lung"[All Fields]) AND ("cancer s"[All
Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR "cancerized"[All
Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR
"cancers"[All Fields])) AND (meta-analysis[Filter] OR randomizedcontrolledtrial[Filter] OR systematicreview[Filter])
Q10: Nei pazienti con NSCLC in stadio IIIA/IIIB non resecabile, o IIIC un trattamento di chemio- radioterapia a dosi
radicali concomitante è raccomandato (rispetto alla sequenziale)? MEDLINE (PubMed) (2019 ad Agosto 2023)
((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp]) OR ((((((((((lung cancer*[Title/Abstract]) OR lung
tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung neoplasm*[Title/Abstract]) OR lung
carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non small cell lung
cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))))))) AND (((grade iii OR stage iii OR advance OR locally advanced
disease)) AND (inoperable OR surgically unresectable)))) AND (("Chemoradiotherapy"[Mesh]) OR ((

33. [intervention] score 12
n small cell lung carcinoma"[Title/Abstract)) OR Row 7: NSCLC[Title/Abstract])))))))))))))))))) AND ("atezolizumab"
[Supplementary Concep Row 8: ((atezolizumab[Title/Abstract] Row 1: (((((((((((((((("Carcinoma, Non-Small-Cell
Lung/radiotherapy"[Majr:noexp]) OR (((((( Row 2: cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung
tumour*[Title/Abst Row 3: neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lu Row 4:
cancer*[Title/Abstract]) OR non small cell lung cancer*[Title/Abstract]) OR NSCLC Row 5: AND ((("grade
IA"[Title/Abstract] OR "stage IA"[Title/Abstract])))))) OR ("grade I"[T Row 6: "grade II"[Title/Abstract] OR "stage
I"[Title/Abstract] OR "stage II"[Title/Abstract])))) Row 7: surgery")) AND (((((((("Randomized Controlled Trial"
[Publication Type]) OR "Clinic Row 8: Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR Row 9:
randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] Row 10: trial[Title/Abstract] OR
groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mes Row 11: "Humans"[Mesh]))) Row 1: (((((lung Row 2: ract]) OR lung
Row 3: ung Row 4: C*[Title/Abstract]) Row 5: itle/Abstract] OR Row 6: ))) AND "radical Row 7: cal Trial" [Publica Row 1:
OR Row 2: sh]) AND Row 1: (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields])
OR Row 2: "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR Row 3:
"neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR Row 4: ("drug"[All Fields]
AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All Row 5: Fields] OR "drug therapy"[MeSH
Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All Row 6: Fields] OR "resectability"[All Fields] OR
"resectable"[All Fields] OR "resectates"[All Fields] OR Row 7: "resected"[All Fields] OR "resecting"[All Fields] OR
"resection"[All Fields] OR "resectional"[All Fields] Row 8: OR "resectioned"[All Fields] OR "resectioning"[All Fields]
OR "resections"[All Fields] OR "resective"[All Row 9: Fields] OR "resects"[All Fields]) AND ("lung"[MeSH Terms] OR
"lung"[All Fields]) AND ("cancer s"[All Row 10: Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR
"cancerization"[All Fields] OR Row 11: "cancerized"[All Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR
"neoplasms"[All Row 12: Fields] OR "cancer"[All Fields] OR "cancers"[All Fields])) AND (meta-analysis[Filter] OR Row 13:
randomizedcontrolledtrial[Filter] OR systematicreview[Filter]) Row 1: ((((((("Carcinoma, Non-Small-Cell
Lung/radiotherapy"[Majr:noexp]) OR ((((((((((lung Row 2: cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR
lung tumour*[Title/Abstract]) OR lung Row 3: neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small
cell lung Row 4: cancer*[Title/Abstract]) OR non small cell lung cancer*[Title/Abstract]) OR
NSCLC*[Title/Abstract]))))))) Row 5: AND (((grade iii OR stage iii OR advance OR locally advanced disease)) AND
(inoperable OR Row 6: surgically unresectable)))) AND (("Chemoradiotherapy"[Mesh]) OR (("Chemoradiotherapy"[Mesh]) OR
Row 7: ("chemoradiotherapy"[Title/Abstract] OR "radiochemotherapy"[Title/Abstract]

34. [intervention] score 12
OR "stage II"[Title/Abstract])))) surgery")) AND (((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinic
Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR randomised[Title/Abstract] OR
placebo[Title/Abstract] OR randomly[Title/Abstract] trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT
"Animals"[Mes "Humans"[Mesh]))) espressione del zolizumab dopo oma, Non-Small- g mall-cell lung pt]) OR cer' OR 'non sma
apia postoperat (((((lung ract]) OR lung ung C*[Title/Abstract]) Title/Abstract] OR ))) AND "radical cal Trial" [Publica
OR sh]) AND l PD- o la -Cell all toria R ation NE EOPLASIE DEL POLMONE Embase (Embase.com) (2019 ad Agosto 2023) #1
'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-
cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'grade ia' OR 'stage ia':de,ti,ab #5 #3
AND #4 #6 "radical surgery:de,ti,ab #7 #5 AND #6 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta
analysis]/lim OR [controlled clinical trial]/lim OR [randomized controlled trial]/lim) AND [embase]/lim Q9: Nei pazienti
con NSCLC in stadio II-III resecabile una chemioterapia neoadiuvante seguita da chirurgia è raccomandata (rispetto a
sola chirurgia)? (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR "neoadjuvent"[All
Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR ("drug"[All Fields] AND "therapy"[All
Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All Fields] OR "drug therapy"[MeSH Subheading] OR
"chemotherapy"[All Fields]) AND ("resect"[All Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR
"resectates"[All Fields] OR "resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields] OR
"resectional"[All Fields] OR "resectioned"[All Fields] OR "resectioning"[All Fields] OR "resections"[All Fields] OR
"resective"[All Fields] OR "resects"[All Fields]) AND ("lung"[MeSH Terms] OR "lung"[All Fields]) AND ("cancer s"[All
Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR "cancerized"[All
Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR
"cancers"[All Fields])) AND (meta-analysis[Filter] OR randomizedcontrolledtrial[Filter] OR systematicreview[Filter])
Q10: Nei pazienti con NSCLC in stadio IIIA/IIIB non resecabile, o IIIC un trattamento di chemio- radioterapia a dosi
radicali concomitante è raccomandato (rispetto alla sequenziale)? MEDLINE (PubMed) (2019 ad Agosto 2023)
((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp]) OR ((((((((((lung cancer*[Title/Abstract]) OR lung
tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung neoplasm*[Title/Abstract]) OR lung
carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non small cell lung
cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))))))) AND (((grade iii OR stage iii OR advance OR locally advanced
disease)) AND (inoperable OR surgically unresectable)))) AND (("Chemoradiotherapy"[Mesh]) OR (("Chemora

35. [intervention] score 12
/Abstract] OR "stage II"[Title/Abstract])))) surgery")) AND (((((((("Randomized Controlled Trial" [Publication Type]) OR
"Clinic Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR randomised[Title/Abstract] OR
placebo[Title/Abstract] OR randomly[Title/Abstract] trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT
"Animals"[Mes "Humans"[Mesh]))) espressione del zolizumab dopo oma, Non-Small- g mall-cell lung pt]) OR cer' OR 'non sma
apia postoperat (((((lung ract]) OR lung ung C*[Title/Abstract]) Title/Abstract] OR ))) AND "radical cal Trial" [Publica
OR sh]) AND l PD- o la -Cell all toria R ation NE EOPLASIE DEL POLMONE Embase (Embase.com) (2019 ad Agosto 2023) #1
'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-
cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'grade ia' OR 'stage ia':de,ti,ab #5 #3
AND #4 #6 "radical surgery:de,ti,ab #7 #5 AND #6 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta
analysis]/lim OR [controlled clinical trial]/lim OR [randomized controlled trial]/lim) AND [embase]/lim Q9: Nei pazienti
con NSCLC in stadio II-III resecabile una chemioterapia neoadiuvante seguita da chirurgia è raccomandata (rispetto a
sola chirurgia)? (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR "neoadjuvent"[All
Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR ("drug"[All Fields] AND "therapy"[All
Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All Fields] OR "drug therapy"[MeSH Subheading] OR
"chemotherapy"[All Fields]) AND ("resect"[All Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR
"resectates"[All Fields] OR "resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields] OR
"resectional"[All Fields] OR "resectioned"[All Fields] OR "resectioning"[All Fields] OR "resections"[All Fields] OR
"resective"[All Fields] OR "resects"[All Fields]) AND ("lung"[MeSH Terms] OR "lung"[All Fields]) AND ("cancer s"[All
Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR "cancerized"[All
Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR
"cancers"[All Fields])) AND (meta-analysis[Filter] OR randomizedcontrolledtrial[Filter] OR systematicreview[Filter])
Q10: Nei pazienti con NSCLC in stadio IIIA/IIIB non resecabile, o IIIC un trattamento di chemio- radioterapia a dosi
radicali concomitante è raccomandato (rispetto alla sequenziale)? MEDLINE (PubMed) (2019 ad Agosto 2023)
((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp]) OR ((((((((((lung cancer*[Title/Abstract]) OR lung
tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung neoplasm*[Title/Abstract]) OR lung
carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non small cell lung
cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))))))) AND (((grade iii OR stage iii OR advance OR locally advanced
disease)) AND (inoperable OR surgically unresectable)))) AND (("Chemoradiotherapy"[Mesh]) OR

36. [intervention] score 12
ll cell lung carcinoma"[Title/Abstract)) OR Row 7: NSCLC[Title/Abstract])))))))))))))))))) AND ("atezolizumab"
[Supplementary Concep Row 8: ((atezolizumab[Title/Abstract] Row 1: (((((((((((((((("Carcinoma, Non-Small-Cell
Lung/radiotherapy"[Majr:noexp]) OR (((((( Row 2: cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung
tumour*[Title/Abst Row 3: neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lu Row 4:
cancer*[Title/Abstract]) OR non small cell lung cancer*[Title/Abstract]) OR NSCLC Row 5: AND ((("grade
IA"[Title/Abstract] OR "stage IA"[Title/Abstract])))))) OR ("grade I"[T Row 6: "grade II"[Title/Abstract] OR "stage
I"[Title/Abstract] OR "stage II"[Title/Abstract])))) Row 7: surgery")) AND (((((((("Randomized Controlled Trial"
[Publication Type]) OR "Clinic Row 8: Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR Row 9:
randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] Row 10: trial[Title/Abstract] OR
groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mes Row 11: "Humans"[Mesh]))) Row 1: (((((lung Row 2: ract]) OR lung
Row 3: ung Row 4: C*[Title/Abstract]) Row 5: itle/Abstract] OR Row 6: ))) AND "radical Row 7: cal Trial" [Publica Row 1:
OR Row 2: sh]) AND Row 1: (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields])
OR Row 2: "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR Row 3:
"neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR Row 4: ("drug"[All Fields]
AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All Row 5: Fields] OR "drug therapy"[MeSH
Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All Row 6: Fields] OR "resectability"[All Fields] OR
"resectable"[All Fields] OR "resectates"[All Fields] OR Row 7: "resected"[All Fields] OR "resecting"[All Fields] OR
"resection"[All Fields] OR "resectional"[All Fields] Row 8: OR "resectioned"[All Fields] OR "resectioning"[All Fields]
OR "resections"[All Fields] OR "resective"[All Row 9: Fields] OR "resects"[All Fields]) AND ("lung"[MeSH Terms] OR
"lung"[All Fields]) AND ("cancer s"[All Row 10: Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR
"cancerization"[All Fields] OR Row 11: "cancerized"[All Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR
"neoplasms"[All Row 12: Fields] OR "cancer"[All Fields] OR "cancers"[All Fields])) AND (meta-analysis[Filter] OR Row 13:
randomizedcontrolledtrial[Filter] OR systematicreview[Filter]) Row 1: ((((((("Carcinoma, Non-Small-Cell
Lung/radiotherapy"[Majr:noexp]) OR ((((((((((lung Row 2: cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR
lung tumour*[Title/Abstract]) OR lung Row 3: neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small
cell lung Row 4: cancer*[Title/Abstract]) OR non small cell lung cancer*[Title/Abstract]) OR
NSCLC*[Title/Abstract]))))))) Row 5: AND (((grade iii OR stage iii OR advance OR locally advanced disease)) AND
(inoperable OR Row 6: surgically unresectable)))) AND (("Chemoradiotherapy"[Mesh]) OR (("Chemoradiotherapy"[Mesh]) OR
Row 7: ("chemoradiotherapy"[Title/Abstract] OR "radiochemotherapy"[Title/Abstract] OR "conc

37. [outcome] score 12 ✅ BINGO (ICO)
/m2 2 OS pemetrexed 13,9 mesi versus 11,1 for placebo. difference = 2,8 months 3 Panel Composition: 6 oncologi medici, 1
radioterapista, 1 chirurgo toracico. 4 Results based on event-driven analisys (Paz-Ares Lancet Oncol 2012). PFS results
were not updated in the final report (Paz-Ares JCO 2013) 5 The primary outcome declared in  is PFS detected by
investigators. Taking into account the high proportion of indipendent evaluation available 88% and the similar results
LINEE GUI obtained we decided to report the investigator assessed PFS 6 Investigator -> pemetrexed median PFS 4,1 mesi
(3,2-4,6), placebo 2,8 (2,6-3,1); Indipendent -> pemetrexed median PFS 3,9 mesi (3- 4,2) , placebo 2,6 ( 2.2-2.9) 7
Assessed by the indipendent review 8 Wide 95% CI due to low number of events. For this reason we decided to not
downgrade quality of evidence for imprecision 9 Calcolated throught number of events and totals 10 Low questionnaire
compliance due to failure by study site to administer questionnaire. 11 95% confidence interval includes no effect and
the upper and lower confidence limit crosses the minimal important difference (MID= 0.08 U.K population-based index sco
12 Assuming a SD= 1.5 for both arm (data not provided by authors) 13 95% confidence interval includes no effect and the
lower confidence limit crosses the minimal important difference (MID= 7 VAS) 14 Assuming a SD= 7.24 for both arm (Sds
are not reported in the primary article) and a p-value > 0.05 (the authors reported "Not-Ssignificant" only) 15 we added
a further event both in the intervention and in the control group to permit the calculation of relative and absolute
effect IDA ore); both f for benefit and harm Dovrebbe maintenance therapy with pemetrexed vs placebo essere utiliz
POPOLAZIONE: Advanced NSCLC INTERVENTO: Maintenance therapy with pemetrexed CONFRONTO: Placebo ESITI PRINCIPALI: Overall
Survival; Progression free survival; Objective responce rate; Quality of life -EQ-5D; Qual grade 3-4; Neutropenia grade
3-4 SETTING: PROSPETTIVA: BACKGROUND: CONFLITTI DI INTERESSE Il problema è una priorità? GIUDIZI RICERCA DELLE PROVE DI
EVIDENZA ○ No ○ Probabilmente no ○ Probabilmente si ● Si ○ Varia ○ Non so zzato per adva lity of life -VAS; Sever anced
NSCLC re Toxicity (Non labor CONSIDE ratory); Fatigue grade 3-4; trans ERAZIONI AGGIUNTIVE sfusion; G-CSF ; Anemia
Effetti de Quanto consid GIUDIZI ○ Irrilevanti ○ Piccoli ○ Moderati ● Grandi ○ Variano ○ Non so esider derevoli s rabili
sono gli e effetti des siderabili attesi? RICERCA DELLE PROVE DI EVIDENZA CONS È stata eseguita una ricerca sistematica
della letteratura sulle banche dati PubMed/Medline, Embase e Central (Cochrane Library). La strategia di ricerca ha
identificato 1478 documenti dopo la rimozione dei duplicati. È stato valutato un record in full-text e incluso. Lo
studio PARAMOUNT, è un trial di fase 3 randomizzato in doppio cieco, multicentrico, su pazienti affetti da NSCLC in fase
avanzata (stadio IIIB/IV). Lo studio prevedeva due fasi: una fase non randomizzata (fase di induzione) in cui 939
pazienti non pre-trattati per malattia avanzata sono stati sottoposti a terapia di prima linea con cisplatino/pemetrexed
(cisplatino 75 mg/mq e.v. g.1 e pemetrexed 500 mg/mq e.v. g.1 ogni tre settimane) per 4 cicli ed una successiva fase

38. [outcome] score 12
è stata abbassata per rischio di selection e performance bias considerata la natura osservazionale degli studi.
Complessivamente attraverso la new Ottawa scale, gli studi sono stati giudicati di qualità media. f. Nonostante
l'eterogeneità, la certezza nelle prove non è stata abbassata poichè questa è dovuta alla magnitudo dell'effetto e non
alla sua direzione. g. La certezza nelle prove è stata abbassata per imprecisione, dovuta al basso numero di eventi.
1.Saji, H., Okada, M., Tsuboi, M., Nakajima, R., Suzuki, K., Aokage, K., Aoki, T., Okami, J., Yoshino, I., Ito, H.,
Okumura, N., Yamaguchi, M., Ikeda, N., Wakabayashi, M., Nakamura, K., Fukuda, H., Nakamura, S., Mitsudomi, T., Watanabe,
S. I., Asamura, H.. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer
(JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet; Apr 23
2022. 2.Altorki, N., Wang, X., Kozono, D., Watt, C., Landrenau, R., Wigle, D., Port, J., Jones, D. R., Conti, M.,
Ashrafi, A. S., Liberman, M., Yasufuku, K., Yang, S., Mitchell, J. D., Pass, H., Keenan, R., Bauer, T., Miller, D.,
Kohman, L. J., Stinchcombe, T. E., Vokes, E.. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung
Cancer. N Engl J Med; Feb 9 2023. 3.Qu, X., Wang, K., Zhang, T., Shen, H., Dong, W., Liu, Q., Du, J.. Long-term outcomes
of stage I NSCLC (≤3 cm) patients following segmentectomy are equivalent to lobectomy under analogous extent of lymph
node removal: a PSM based analysis. J Thorac Dis; Nov 2017. 4.Moon, M. H., Moon, Y. K., Moon, S. W.. Segmentectomy
versus lobectomy in early non-small cell lung cancer of 2 cm or less in size: A population-based study. Respirology; Jul
2018. 5.Khullar, O. V., Liu, Y., Gillespie, T., Higgins, K. A., Ramalingam, S., Lipscomb, J., Fernandez, F. G.. Survival
After Sublobar Resection versus Lobectomy for Clinical Stage IA Lung Cancer: An Analysis from the National Cancer Data
Base. J Thorac Oncol; Nov 2015. 6.Dai, C., Shen, J., Ren, Y., Zhong, S., Zheng, H., He, J., Xie, D., Fei, K., Liang, W.,
Jiang, G., Yang, P., Petersen, R. H., Ng, C. S., Liu, C. C., Rocco, G., Brunelli, A., Shen, Y., Chen, C., He, J.. Choice
of Surgical Procedure for Patients With Non-Small-Cell Lung Cancer ≤ 1 cm or &gt; 1 to 2 cm Among Lobectomy,
Segmentectomy, and Wedge Resection: A Population-Based Study. J Clin Oncol; Sep 10 2016. 7.Roman, M., Labbouz, S.,
Valtzoglou, V., Ciesla, A., Hawari, M., Addae-Boateng, E., Thorpe, J. A., Duffy, J. P., Majewski, A.. Lobectomy vs.
segmentectomy. A propensity score matched comparison of outcomes. Eur J Surg Oncol; May 2019. 8.Okada, M., Nishio, W.,
Sakamoto, T., Uchino, K., Yuki, T., Nakagawa, A., Tsubota, N.. Effect of tumor size on prognosis in patients with non-
small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg; Jan 2005.
9.Okada, M., Koike, T., Higashiyama, M., Yamato, Y., Kodama, K., Tsubota, N.. Radical sublobar resection for small-sized
non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg; Oct 2006. 10.Nakamura, H., Taniguchi, Y.,
Miwa, K., Adachi, Y., Fujioka, S., Haruki, T., Takagi, Y., Yurugi, Y.. Comparison of the surgical outcomes of
thoracoscopic lobectomy, segmentectomy, and wedge resecti

39. [outcome] score 12
: A population-based study. Respirology; Jul 2018. 5.Khullar, O. V., Liu, Y., Gillespie, T., Higgins, K. A., Ramalingam,
S., Lipscomb, J., Fernandez, F. G.. Survival After Sublobar Resection versus Lobectomy for Clinical Stage IA Lung
Cancer: An Analysis from the National Cancer Data Base. J Thorac Oncol; Nov 2015. 6.Dai, C., Shen, J., Ren, Y., Zhong,
S., Zheng, H., He, J., Xie, D., Fei, K., Liang, W., Jiang, G., Yang, P., Petersen, R. H., Ng, C. S., Liu, C. C., Rocco,
G., Brunelli, A., Shen, Y., Chen, C., He, J.. Choice of Surgical Procedure for Patients With Non-Small-Cell Lung Cancer
≤ 1 cm or &gt; 1 to 2 cm Among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based Study. J Clin Oncol;
Sep 10 2016. 7.Roman, M., Labbouz, S., Valtzoglou, V., Ciesla, A., Hawari, M., Addae-Boateng, E., Thorpe, J. A., Duffy,
J. P., Majewski, A.. Lobectomy vs. segmentectomy. A propensity score matched comparison of outcomes. Eur J Surg Oncol;
May 2019. 8.Okada, M., Nishio, W., Sakamoto, T., Uchino, K., Yuki, T., Nakagawa, A., Tsubota, N.. Effect of tumor size
on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J
Thorac Cardiovasc Surg; Jan 2005. 9.Okada, M., Koike, T., Higashiyama, M., Yamato, Y., Kodama, K., Tsubota, N.. Radical
sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg; Oct 2006.
10.Nakamura, H., Taniguchi, Y., Miwa, K., Adachi, Y., Fujioka, S., Haruki, T., Takagi, Y., Yurugi, Y.. Comparison of the
surgical outcomes of thoracoscopic lobectomy, segmentectomy, and wedge resection for clinical stage I non-small cell
lung cancer. Thorac Cardiovasc Surg; Apr 11.Landreneau, R. J., Normolle, D. P., Christie, N. A., Awais, O., Wizorek, J.
J., Abbas, G., Pennathur, A., Shende, M., Weksler, B., Luketich, J. D., Schuchert, M. J.. Recurrence and survival
outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small- cell lung cancer: a propensity-
matched analysis. J Clin Oncol; Aug 10 2014. 12.Hwang, Y., Kang, C. H., Kim, H. S., Jeon, J. H., Park, I. K., Kim, Y.
T.. Comparison of thoracoscopic segmentectomy and thoracoscopic lobectomy on the patients with non-small cell lung
cancer: a propensity score matching study. Eur J Cardiothorac Surg; Aug 2015. 13.Dziedzic, R., Zurek, W., Marjanski, T.,
Rudzinski, P., Orlowski, T. M., Sawicka, W., Marczyk, M., Polanska, J., Rzyman, W.. Stage I non-small-cell lung cancer:
long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry. Eur J
Cardiothorac Surg; Aug 1 2017. 14.Whitson, B. A., Groth, S. S., Andrade, R. S., Maddaus, M. A., Habermann, E. B.,
D'Cunha, J.. Survival after lobectomy versus segmentectomy for stage I non-small cell lung cancer: a population-based
analysis. Ann Thorac Surg; Dec 2011. 15.Zhong, C., Fang, W., Mao, T., Yao, F., Chen, W., Hu, D.. Comparison of
thoracoscopic segmentectomy and thoracoscopic lobectomy for small-sized stage IA lung cancer. Ann Thorac Surg; Aug 2012.
16.Zhang, L., Ma, W., Li, Y., Jiang, Y., Ma, G., Wang, G.. Comparative study of the anatomic segmentectomy versus
lobectomy for clinical stage IA peripheral lung cancer by video assistant thoracoscopic surgery. J Cancer Res Ther; Sep
2013. 17.Yamashita, S., Tok

40. [outcome] score 12
of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg; Jan 2005. 9.Okada, M., Koike, T., Higashiyama,
M., Yamato, Y., Kodama, K., Tsubota, N.. Radical sublobar resection for small-sized non-small cell lung cancer: a
multicenter study. J Thorac Cardiovasc Surg; Oct 2006. 10.Nakamura, H., Taniguchi, Y., Miwa, K., Adachi, Y., Fujioka,
S., Haruki, T., Takagi, Y., Yurugi, Y.. Comparison of the surgical outcomes of thoracoscopic lobectomy, segmentectomy,
and wedge resection for clinical stage I non-small cell lung cancer. Thorac Cardiovasc Surg; Apr 11.Landreneau, R. J.,
Normolle, D. P., Christie, N. A., Awais, O., Wizorek, J. J., Abbas, G., Pennathur, A., Shende, M., Weksler, B.,
Luketich, J. D., Schuchert, M. J.. Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for
clinical stage I non-small- cell lung cancer: a propensity-matched analysis. J Clin Oncol; Aug 10 2014. 12.Hwang, Y.,
Kang, C. H., Kim, H. S., Jeon, J. H., Park, I. K., Kim, Y. T.. Comparison of thoracoscopic segmentectomy and
thoracoscopic lobectomy on the patients with non-small cell lung cancer: a propensity score matching study. Eur J
Cardiothorac Surg; Aug 2015. 13.Dziedzic, R., Zurek, W., Marjanski, T., Rudzinski, P., Orlowski, T. M., Sawicka, W.,
Marczyk, M., Polanska, J., Rzyman, W.. Stage I non-small-cell lung cancer: long-term results of lobectomy versus
sublobar resection from the Polish National Lung Cancer Registry. Eur J Cardiothorac Surg; Aug 1 2017. 14.Whitson, B.
A., Groth, S. S., Andrade, R. S., Maddaus, M. A., Habermann, E. B., D'Cunha, J.. Survival after lobectomy versus
segmentectomy for stage I non-small cell lung cancer: a population-based analysis. Ann Thorac Surg; Dec 2011. 15.Zhong,
C., Fang, W., Mao, T., Yao, F., Chen, W., Hu, D.. Comparison of thoracoscopic segmentectomy and thoracoscopic lobectomy
for small-sized stage IA lung cancer. Ann Thorac Surg; Aug 2012. 16.Zhang, L., Ma, W., Li, Y., Jiang, Y., Ma, G., Wang,
G.. Comparative study of the anatomic segmentectomy versus lobectomy for clinical stage IA peripheral lung cancer by
video assistant thoracoscopic surgery. J Cancer Res Ther; Sep 2013. 17.Yamashita, S., Tokuishi, K., Anami, K., Moroga,
T., Miyawaki, M., Chujo, M., Yamamoto, S., Kawahara, K.. Thoracoscopic segmentectomy for T1 classification of non-small
cell lung cancer: a single center experience. Eur J Cardiothorac Surg; Jul 2012. 18.Yamato, Y., Koike, T., Yoshiya, K.,
Shinohara, H., Toyabe, S.. Results of surgical treatment for small (2 cm or under) adenocarcinomas of the lung. Surg
Today; 2008. 19.Tsubokawa, N., Tsutani, Y., Miyata, Y., Handa, Y., Misumi, K., Hanaki, H., Hida, E., Okada, M..
Segmentectomy Versus Lobectomy for Radiologically Pure Solid Clinical T1a-bN0M0 Lung Cancer. World J Surg; Aug 2018.
20.Sugi, K., Kobayashi, S., Sudou, M., Sakano, H., Matsuda, E., Okabe, K.. Long-term prognosis of video-assisted limited
surgery for early lung cancer. Eur J Cardiothorac Surg; Feb 2010. 21.Shapiro, M., Weiser, T. S., Wisnivesky, J. P.,
Chin, C., Arustamyan, M., Swanson, S. J.. Thoracoscopic segmentectomy compares favorably with thoracoscopic lobectomy
for patients with small stage I lung cancer. J Thorac Cardiovasc Surg; Jun 2009. 22.Soukiasian, H. J., Hong, E.,
McKenna, R. J.,Jr.. Video-assisted thoracoscopic tri

41. [outcome] score 12 ✅ BINGO (ICO)
n Probab ly reduce d PLASIE DEL POLMO Moderate Probabl y no importa nt uncerta inty or variabili ty Does not favor
either the interve ntion or the compar ison Probably no impact ONE JUDG GEMENT High No important uncertainty or
variability Probabl y favors the interve ntion Probabl y increas ed Favor interventi Incre ased L rs the ion Va rie s Va
rie s A No included studies D o n' t k n o w D o n' t k n o w ACCEPTAB ILITY FEASIBILIT Y TYPE OF REC Strong
recommendation against the intervention NEOPL Probab No ly no Probab No ly no COMMENDATION Conditional recommendation
against the intervention LASIE DEL POLMONE JUDG Probabl y yes Probabl y yes Conditional recommendation for the
intervention GEMENT Yes Yes Strong recommendati for the intervention X Va rie s Va rie s ion n A D o n' t k n o w D o n'
t k n o w Nei pazienti affetti da NSCLC a istologia non-squamosa con espressione di PD-L1 <50% in stadio metastatico
senza mutazione attivante l’EGFR o riarrangiamento di ALK e con buon performance status (0-1) un trattamento di prima
linea a base di platino, pemetrexed e pembrolizumab, seguito da mantenimento con pemetrexed e pembrolizumab dovrebbe
essere preso in considerazione come prima opzione in caso di risposta o stabilità di malattia dopo 4 cicli di
trattamento rispetto alla chemioterapia. Autore/i: ACT Domanda: Dovrebbe un trattamento a base di carboplatino,
paclitaxel o nabpaclitaxel, e pembrolizumab, seguito da mantenimento con pembrolizumab in caso di risposta o stabilità
di m istologia squamosa in stadio metastatico e con buon performance status (0-1) Setting: inpatients Bibliografia: 1,2
Certainty assessment № di pazienti CBDCA + Mancanza di № degli Disegno dello Rischio di Mancanza di Paclitaxel o Nab-
riproducibilità Imprecisione Ulteriori considerazioni chemioterapia studi studio distorsione generalizzabilità
Paclitaxel + dei risultati Pembrolizumab Overall survival 2 2,3 studi serio a non importante serio b non importante
nessuno 181/338 (53.6%) 211/344 (61.3%) randomizzati 2 2,3 studi serio a non importante serio b non importante nessuno
240/338 (71.0%) 285/344 (82.8%) randomizzati Response rate (formato da risposte complete + risposte parziali) 2 2,3
studi serio a non importante serio b non importante nessuno 207/338 (61.2%) 126/344 (36.6%) randomizzati Qualità della
vita (follow up: 9 settimane; valutato con: EORTC Quality of Life Questionnaire- Core 30 (global health status/quality
of life score); Scala da: 0 a 100) 1 1 studi molto serio c non importante serio b non importante nessuno 187 199
randomizzati Qualità della vita (follow up: 18 settimane; valutato con: EORTC Quality of Life Questionnaire- Core 30
(global health status/quality of life score); Scala da: 0 a 100) malattia dopo 4 cicli di trattamento rispetto a
chemioterapia in pazien Effetto Certo Relativo Assoluto (95% CI) (95% CI) HR 0.72 12 meno per ⨁⨁◯◯ (0.59 a 0.88) 100 (da
18 meno a BASSA 5 meno) HR 0.57 19 meno per ⨁⨁◯◯ (0.47 a 0.68) 100 (da 27 meno a BASSA 13 meno) RR 1.66 24 più per ⨁⨁◯◯
(1.41 a 1.96) 100 (da 15 più a BASSA 35 più) - MD 3.9 ⨁◯◯◯ maggiore (0.1 maggiore MOLTO BASSA a 7.7 maggiore) nti
affetti da NSCLC a Importanza CRITICO IMPORTANTE CRITICO CRITICO NEOPLASIE Certainty assessment Mancanza di № degli
Disegno dello Rischio di Mancanza di riproducibilità

42. [outcome] score 12
petto alla radio MEDLINE (PubMed) (2019 ad Agosto 2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung
Neoplasm (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung t "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[T NSCLC[Title/Abstract]))))))) AND (("stage
T1-2N0"[Title/Abstract] OR "T1-2N0 ((("Radiosurgery"[Mesh])) OR ("stereotactic radiotherapy"[Title/Abstract])) Records:
8 Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR
'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 ‘stage T1-2N0’
#5 #3 AND #4 #6 radiosurgery'/exp/mj OR 'stereotactic radiotherapy':ti,ab #7 #5 AND #6 UIDA o-assi mentec entec ng"[M
"[Title R "N cance bile pe oterap ms/sur tumor Title/A 0"[Titl g canc isted thoracic ctomy' OR ctomia anatomica è Mesh])
OR "Lung e/Abstract] OR "lung Non small cell lung er' OR 'non small cell er controindicazioni pia convenzionale?
rgery"[Mesh]) OR "[Title/Abstract] OR Abstract])) OR le/Abstract]))))) AND cer' OR 'non small NE EOPLASIE DEL POLMONE
Q5: Nei pazienti con NSCLC radicalmente operato una chemioterapia adiuvante con combinazioni a base di cisplatino è
raccomandata? MEDLINE (PubMed) (2019 ad Agosto 2023) (((("Carcinoma, Non-Small-Cell Lung"[Majr]) OR (((((((((lung
cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung
neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non
small cell lung cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]) AND radical surgery AND ("Cisplatin"[Mesh] OR
cisplatin[Title/Abstract] Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung
cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'adjuvant chemotherapy'/exp/mj #5 #3 AND #4 Q6: Nei pazienti con NSCLC
radicalmente operato in stadio IB-IIIA e mutazioni attivanti classiche del gene EGFR, una terapia adiuvante con
osimertinib è raccomandata? MEDLINE (PubMed) (1946 ad Agosto 2023) (((((((( "Carcinoma, Non-Small-Cell Lung/drug
therapy"[Mesh] OR "Carcinoma, Non-Small-Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung
tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract]
OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "Non small cell lung carcinoma"[Title/Abstract)) OR
NSCLC[Title/Abstract]))))))))))))))) AND ((((((((((("grade III" OR "stage III" OR advanced OR "advanced disease")))))))
OR (metastas*[Title/Abstract]))) AND (("osimertinib" [Supplementary Concept]) OR (Tagrisso[Title/Abstract] OR
AZD9291[Title/Abstract])))) AND (((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-Analysis" [Publication Type]) OR
("meta- analysis[Title] OR systematic review"[Title] OR "meta analy*"[Title] OR "metaanaly*"[Title] OR "Meta-
Analysis"[Title])) OR ("systematic literature review"[Title])) OR ("systematic review"[Title/Abstract])) O

43. [outcome] score 12
"meta analy*"[Title] OR "metaanaly*"[Title] OR "Meta-Analysis"[Title])) OR ("systematic literature review"[Title])) OR
("systematic review"[Title/Abstract])) OR (((("Randomized Controlled Trial"[Publication Type]) OR "Randomized Controlled
Trials as Topic"[Mesh]) OR ("Clinical Trial" [Publication Type])) OR (randomized[Title/Abstract] OR
randomised[Title/Abstract] OR randomly[Title/Abstract])))))))) Embase (Embase.com) (2021 ad Agosto 2023) #1 'lung
tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell
lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 'grade iii' OR 'stage iii' OR advanced OR 'advanced
disease' NEAR/7 (egfr OR 'egfr mutated') #4 (#1 OR #2) AND #3 #5 'osimertinib'/exp #6 'osimertinib':ti,ab #7 #5 OR #6 #8
#4 AND #7 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta analysis]/lim OR [randomized controlled
trial]/lim OR 'controlled clinical trial'/de) Q15: Nei pazienti affetti da NSCLC in stadio localmente avanzato o
metastatico, con mutazioni non comuni di EGFR (eccetto le inserzioni dell’esone 20), un trattamento di prima linea con
inibitore tirosino-chinasico di EGFR afatinib o osimertinib è raccomandato (rispetto alla chemioterapia)? MEDLINE
(PubMed) (1966 a dicembre 2023) (((("Carcinoma, Non-Small-Cell Lung"[Majr]) AND "EGFR, uncommon"[Majr])) OR
(((((((((lung cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung
neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non
small cell lung cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]) AND EGFR, uncommon*[Title/Abstract])) Embase
(Embase.com) (1974 a dicembre 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung
neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4
'egfr uncommon':ti,ab #5 #3 AND #4 NE EOPLASIE DEL POLMONE Q16: Nei pazienti affetti da NSCLC metastatico, con
inserzioni dell’esone 20 del gene EGFR, in progressione dopo precedente trattamento chemioterapico a base di platino, un
trattamento con amivantamab è raccomandato (rispetto alla chemioterapia)? MEDLINE (PubMed) (2021 ad Agosto 2023)
((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell Lung/pathology"[Mesh] )) OR
( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR
"lung neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non
small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "Non small cell lung
carcinoma"[Title/Abstract)) OR NSCLC[Title/Abstract]))))))))))))))) AND (((((((((((("grade III" OR "stage III" OR
advanced OR "advanced disease"))))))) OR (metastas*[Title/Abstract]))))) AND AND (("amivantamab " [Supplementary
Concept]) OR amivantamab [Title/Abstract])))) AND (((((((((((("Meta- Analysis as Topic"[Mesh]) OR "Meta-
Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta analy*"[Title] OR
"metaanaly*"[Title] OR "Meta-Analysis"[Title])) OR ("systematic literature review"[Title

44. [outcome] score 12
al" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
randomly[Title/Abstract])))))))) Embase (Embase.com) (2021 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung
cancer' OR nsclc:ti,ab #3 'grade iii' OR 'stage iii' OR advanced OR 'advanced disease' NEAR/7 (egfr OR 'egfr mutated')
#4 (#1 OR #2) AND #3 #5 'osimertinib'/exp #6 'osimertinib':ti,ab #7 #5 OR #6 #8 #4 AND #7 AND ([cochrane review]/lim OR
[systematic review]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim OR 'controlled clinical trial'/de)
Q15: Nei pazienti affetti da NSCLC in stadio localmente avanzato o metastatico, con mutazioni non comuni di EGFR
(eccetto le inserzioni dell’esone 20), un trattamento di prima linea con inibitore tirosino-chinasico di EGFR afatinib o
osimertinib è raccomandato (rispetto alla chemioterapia)? MEDLINE (PubMed) (1966 a dicembre 2023) (((("Carcinoma, Non-
Small-Cell Lung"[Majr]) AND "EGFR, uncommon"[Majr])) OR (((((((((lung cancer*[Title/Abstract]) OR lung
tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung neoplasm*[Title/Abstract]) OR lung
carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non small cell lung
cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]) AND EGFR, uncommon*[Title/Abstract])) Embase (Embase.com) (1974 a
dicembre 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung
tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'egfr
uncommon':ti,ab #5 #3 AND #4 NE EOPLASIE DEL POLMONE Q16: Nei pazienti affetti da NSCLC metastatico, con inserzioni
dell’esone 20 del gene EGFR, in progressione dopo precedente trattamento chemioterapico a base di platino, un
trattamento con amivantamab è raccomandato (rispetto alla chemioterapia)? MEDLINE (PubMed) (2021 ad Agosto 2023)
((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell Lung/pathology"[Mesh] )) OR
( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR
"lung neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non
small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "Non small cell lung
carcinoma"[Title/Abstract)) OR NSCLC[Title/Abstract]))))))))))))))) AND (((((((((((("grade III" OR "stage III" OR
advanced OR "advanced disease"))))))) OR (metastas*[Title/Abstract]))))) AND AND (("amivantamab " [Supplementary
Concept]) OR amivantamab [Title/Abstract])))) AND (((((((((((("Meta- Analysis as Topic"[Mesh]) OR "Meta-
Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta analy*"[Title] OR
"metaanaly*"[Title] OR "Meta-Analysis"[Title])) OR ("systematic literature review"[Title])) OR ("systematic
review"[Title/Abstract])) OR (((("Randomized Controlled Trial"[Publication Type]) OR "Randomized Controlled Trials as
Topic"[Mesh]) OR ("Clinical Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
randomly[Title/Abstract]

45. [outcome] score 12 ✅ BINGO (PIO)
: ||||| Row 5: № degli studi|Disegno dello studio|Rischio di distorsione|Mancanza di riproducibilità dei
risultati|Mancanza di generalizzabilità|Imprecisione Row 6: ||||| Row 7: 11|studi randomizzati|serioc|non importante|non
importante|seriob Row 8: Loco-regional progression||||| Row 9: ||||| Row 10: 11|studi randomizzati|seriod|non
importante|non importante|seriob Row 11: Polmoniti (follow up: mediana 23.6 mesi)||||| Row 12: ||||| Row 13: 11|studi
randomizzati|seriod|non importante|non importante|seriob Row 14: Tossicità grado 3-5||||| Row 15: ||||| Row 16:
24,5|studi randomizzati|serioc|non importante|non importante|seriob Row 1: ||||| Row 2: |№ di pazienti||Effetto||Certo
Row 3: ||||| Row 4: Ulteriori considerazioni|un trattamento loco-regionale + terapia sistemica|sola terapia
sistemica|Relativo (95% CI)|Assoluto (95% CI)| Row 5: ||||| Row 6: |1/68 (1.5%)|1/65 (1.5%)|RR 0.95 (0.06 a 14.97)|0
meno per 100 (da 1 meno a 21 più)| Row 1:  Row 2:  Row 1: 6/68 (8.8%)|29/65 (44.6%)|RR 0.20 (0.09 a 0.44)|36 meno per
100 (da 41 meno a 25 meno) Row 1: 27/65 (41.5%)|17/65 (26.2%)|RR 1.59 (0.96 a 2.61)|15 più per 100 (da 1 meno a 42 più)
Row 1: 8/39 (20.5%)|6/39 (15.4%)|RR 1.36 (0.52 a 3.51)|6 più per 100 (da 7 meno a 39 più) Row 1: | Row 2: |Importanza
Row 3: | Row 4: |CRITICO Row 5: | Row 6: | Row 7: |IMPORTANTE Row 8: | Row 9: | Row 10: |IMPORTANTE Row 11: | Row 12: |
Row 13: |IMPORTANTE Row 1: |Dovrebbe un trattamento locoregionale + terapia sistemica vs sola terapia sistemica essere
utilizzato per pazienti affetti da NSCLC||| Row 2: |in stadio avanzato oligometastatico||| Row 3: |||| Row 4:
|POPULATION:||Pazienti affetti da NSCLC in stadio avanzato oligometastatico| Row 5: |||| Row 6: |INTERVENTION:||Un
trattamento locoregionale + terapia sistemica| Row 7: |||| Row 8: |||Sola terapia sistemica| Row 9: |COMPARISON:||| Row
10: |||| Row 11: |MAIN OUTCOMES:||Overall survival; Progression-free survival; Quality of life; ORR; Discontinuation of
any treatment component; Loco-regional progression; Polmoniti; Tossicità grado 3-5| Row 12: |||| Row 13:
|SETTING:||Inpatients| Row 14: |||| Row 15: |PERSPECTIVE:||| Row 16: |||| Row 17: |BACKGROUND:||| Row 18: |||| Row 19:
|CONFLICT OF||| Row 20: |INTERESTS:||| Row 21: |||| Row 1: |||| Row 2: |Problem||| Row 3: |Is the problem a priority?|||
Row 4: |||| Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE| Row 6: ○ No ○ Probably no ○
Probably yes ● Yes ○ Varies ○ Don't know|||| Row 7: |||| Row 8: |Desirable Effects||| Row 9: |How substantial are the
desirable anticipated effects?||| Row 10: |||| Row 11: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI
AGGIUNTIVE| Row 12: ○ Trivial ○ Small ○ Moderate ● Large ○ Varies ○ Don't know||E' stata eseguita una ricerca
bibliografica sulle banche dati Medline ed Embase fino a luglio 2022. Dopo la rimozione dei duplicati sono stati
reperiti 121 records. Sono stati acquisiti 7 records in full-text, di cui 3 esclusi per disegno di studio. Sono stati
inclusi 4 studi: Lo studio di Gomez et al. ha incluso 49 pazienti affetti da NSCLC metastatico (fino a 3 lesioni),
randomizzandoli a trattamento sistemico e locoregionale rispetto a solo trattamento sistemico/osservazione. Lo studio di
Iyengar et al. ha incluso 29 pazienti affetti da NSCLC oligometastat

46. [outcome] score 12
a. These were three open-label studies. Only the PFS outcome was assessed by an independent central review. The
objective responses were assessed by an independent central review only in Hida et al trial. No information about the
loss to follow-up in Nakagawa et al. and in Zhou et al. studies. For this reason we decide to downgrade the quality of
evidence for attrition bias. b. I2=44% c. Different doses of alectinib (600 mg daily in J-ALEX trial, 1200 mg daily in
Peters et al and Zhou et al. trials). Moreover, in J-ALEX trial the 36% of patients in each arm had received a previous
chemotherapy line d. Lo studio Zhou ha preso in considerazione solo la popolazione asiatica. e. Nonostante il basso
numero di eventi, non abbiamo abbassato la qualità perche l'incidenza della patologia è rara f. Low sample size, Optimal
information size not met 1. Zhou, C., Kim, S. W., Reungwetwattana, T., Zhou, J., Zhang, Y., He, J., Yang, J. J., Cheng,
Y., Lee, S. H., Bu, L., Xu, T., Yang, L., Wang, C., Liu, T., Morcos, P. N., Lu, Y., Zhang, L.. Alectinib versus
crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a
randomised phase 3 study. Lancet Respir Med; May 2019. 2. Nakagawa, K., Hida, T., Nokihara, H., Morise, M., Azuma, K.,
Kim, Y. H., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Kumagai, T., Hotta, K., Watanabe, S., Goto, K., Satouchi,
M., Kozuki, T., Koyama, R., Mitsudomi, T., Yamamoto, N., Asakawa, T., Hayashi, M., Hasegawa, W., Tamura, T.. Final
progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell
lung cancer. Lung Cancer; Jan 2020. 3. Mok, T., Camidge, D. R., Gadgeel, S. M., Rosell, R., Dziadziuszko, R., Kim, D.
W., Pérol, M., Ou, S. I., Ahn, J. S., Shaw, A. T., Bordogna, W., Smoljanović, V., Hilton, M., Ruf, T., Noé, J., Peters,
S.. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-
positive non-small-cell lung cancer in the ALEX study. Ann Oncol; Aug 2020. Dovrebbe alectinib vs crizotinib essere
utilizzato per pazienti affetti da NSCLC in stadio localmente avanzato o meta riarrangiamenti di ALK POPULATION:
Pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con riarrangiamenti di ALK INTERVENTION: Alectinib
COMPARISON: Crizotinib MAIN OUTCOMES: PFS; OS; ORR; Time to CNS progression - Peters s. et al., Gadgeel 2018; Time to
progression of brain metastasis or death - Hida T. et al; Alanine aminotrasferase in Aspartate aminotrasferase increase
- grade 3-4; Nausea - grade 3-4; Toxic deaths SETTING: Inpatients PERSPECTIVE: BACKGROUND: CONFLICT OF INTERESTS: Is the
problem a priority? GIUDIZI RICERCA DELLE PROVE DI EVIDENZA CONSIDERAZIONI AGGIUNT ○ No ○ Probably no ○ Probably yes ●
Yes ○ Varies ○ Don't know A astatico con ncrease- grade 3-4; TIVE Desirabl How substant GIUDIZI ○ Trivial ○ Small ○
Moderate ● Large ○ Varies ○ Don't know le effe tial are th w ects he desirab ble anticipated effects? RICERCA DELLE
PROVE DI EVIDENZA La valutazione dell'effetto dell'Alectinib in prima linea rispetto al Crizotinib, nei pazienti affetti
da NSCLC in stadio localmente avanzato o metastatico con riarrangiamenti di ALK, è stata eseguita attraverso una ricerca
bibl

47. [outcome] score 12
/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] OR trial[Title/Abstract] OR groups)))) NOT
((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND "Humans"[Mesh]))))) AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) AND
("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small
cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small
cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'grade ia' OR 'stage ia':de,ti,ab #5 #3 AND #4 NE LINEE GU EOPLASIE DEL
POLMONE #6 'vats lobectomy' OR vats OR 'thoracic surgeries, video-assisted' OR 'video surgery (vats) lobectomy' OR
'video-assisted thoracic surgery' OR 'vats segm segmentectomy:de,ti,ab #7 #5 AND #6 Q3 GRADE: Nei pazienti affetti da
NSCLC in stadio iniziale (IA), la segme raccomandata (rispetto alla lobectomia)? MEDLINE (PubMed) (2019 a Agosto 2023)
(("Lung Neoplasms"[Mesh]) OR "Carcinoma, Non-Small-Cell Lun Neoplasms"[Mesh]) OR "lung cancer"[Title/Abstract] OR "lung
neoplasms" tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR cancer"[Title/Abstract] OR
NSCLC[Title/Abstract]) Embase (Embase.com) (2019 a Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp
#2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung lung cancer' OR nsclc:ti,ab Q4: Nei
pazienti affetti da neoplasia polmonare NSCLC T1-2N0 inoperab mediche il trattamento stereotassico è raccomandato
rispetto alla radio MEDLINE (PubMed) (2019 ad Agosto 2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR
"Lung Neoplasm (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung t "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[T NSCLC[Title/Abstract]))))))) AND (("stage
T1-2N0"[Title/Abstract] OR "T1-2N0 ((("Radiosurgery"[Mesh])) OR ("stereotactic radiotherapy"[Title/Abstract])) Records:
8 Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR
'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 ‘stage T1-2N0’
#5 #3 AND #4 #6 radiosurgery'/exp/mj OR 'stereotactic radiotherapy':ti,ab #7 #5 AND #6 UIDA o-assi mentec entec ng"[M
"[Title R "N cance bile pe oterap ms/sur tumor Title/A 0"[Titl g canc isted thoracic ctomy' OR ctomia anatomica è Mesh])
OR "Lung e/Abstract] OR "lung Non small cell lung er' OR 'non small cell er controindicazioni pia convenzionale?
rgery"[Mesh]) OR "[Title/Abstract] OR Abstract])) OR le/Abstract]))))) AND cer' OR 'non small NE EOPLASIE DEL POLMONE
Q5: Nei pazienti con NSCLC radicalmente operato una chemioterapia adiuvante con combinazioni a base di cisplatino è
raccomandata? MEDLINE (PubMed) (2019 ad Agosto 2023) (((("Carcinoma, Non-Small-Cell Lung"[Majr]) OR (((((((((lung
cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung
neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non
small cell lung cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]) AND radical surgery AND ("Cisplatin"[Mesh] OR
cisplatin[Title/Abstract] Embase (Embase.com) (2019 ad Agosto 2023) #1 'lu

48. [outcome] score 12
g tumor"[Title/Abstract] OR "Non- small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract])) OR NSCLC[Title/Abstract]))))))))))) AND (("Cigarette Smoking"[Mesh]) OR ("Cigarette
Smoking"[Title/Abstract] OR smoking[Title/Abstract])))) AND ((((("Tomography, Spiral Computed"[Mesh]) OR ("Spiral
Computer-Assisted Tomography"[Title/Abstract] OR "Tomography Spiral Computer-Assisted"[Title/Abstract] OR "CT Scan*
Spiral"[Title/Abstract] OR "Spiral CT Scan*"[Title/Abstract] OR "Helical CT"[Title/Abstract] OR "spiral
CT"[Title/Abstract] OR "CT Helical"[Title/Abstract] OR "Helical CTs"[Title/Abstract] OR "Spiral Computed
Tomography"[Title/Abstract] OR "CT Spiral"[Title/Abstract] OR "CTs Spiral"[Title/Abstract] OR "Spiral
CTs"[Title/Abstract] OR "Tomography, Helical Computed"[Title/Abstract] OR "CAT Scan*, Spiral"[Title/Abstract] OR "Spiral
CAT Scan*"[Title/Abstract] OR "Helical Computed Tomography"[Title/Abstract] OR "Helical Computed Tomography
CT"[Title/Abstract] OR "low-dose helical computed tomography (CT)"[Title/Abstract]))))))) Q2: Nei pazienti con NSCLC in
stadio clinico I la lobectomia dovrebbe essere eseguita con approccio mini-invasivo (VATS o robotico) o toracotomico?
MEDLINE (PubMed) (2019 ad Agosto 2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung
Neoplasms/surgery"[Mesh]) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung
tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract]))
OR NSCLC[Title/Abstract]))))))) AND (("grade IA"[Title/Abstract] OR "stage IA"[Title/Abstract])))) AND (((("Thoracic
Surgery, Video-Assisted"[Mesh]) OR ("VATS Lobectomy"[Title/Abstract] OR VATS[Title/Abstract] OR "Thoracic Surgeries,
Video-Assisted"[Title/Abstract] OR "Video-assisted Thoracic Surgery (VATS) Lobectomy"[Title/Abstract] OR "Video-assisted
Thoracic Surgery"[Title/Abstract]))) OR ("VATS segmentectomy"[Title/Abstract] OR segmentectomy[Title/Abstract])))) AND
(((((((((("Randomized Controlled Trial"[Publication Type]) OR "Clinical Trial"[Publication Type]) OR "drug
therapy"[Subheading])) OR ((randomized[Title/Abstract] OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR
randomly[Title/Abstract] OR trial[Title/Abstract] OR groups)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND
"Humans"[Mesh]))))) AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) Embase
(Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung
neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4
'grade ia' OR 'stage ia':de,ti,ab #5 #3 AND #4 NE LINEE GU EOPLASIE DEL POLMONE #6 'vats lobectomy' OR vats OR 'thoracic
surgeries, video-assisted' OR 'video surgery (vats) lobectomy' OR 'video-assisted thoracic surgery' OR 'vats segm
segmentectomy:de,ti,ab #7 #5 AND #6 Q3 GRADE: Nei pazienti affetti da NSCLC in stadio iniziale (IA), la segme
raccomandata (rispetto alla lobectomia)? MEDLINE (PubMed) (2019 a Agosto 2023) (("Lung Neoplasms"[Mesh]) OR "Carcinoma,
Non-Small-Cell Lun Neoplasms"[Mesh]) OR "lung cancer"[Title/Abstract] OR "lung neoplasms" tumor"[Title/Abstract] OR
"Non-small-cell l

49. [outcome] score 12
g tumor"[Title/Abstract] OR "Non- small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract])) OR NSCLC[Title/Abstract]))))))))))) AND (("Cigarette Smoking"[Mesh]) OR ("Cigarette
Smoking"[Title/Abstract] OR smoking[Title/Abstract])))) AND ((((("Tomography, Spiral Computed"[Mesh]) OR ("Spiral
Computer-Assisted Tomography"[Title/Abstract] OR "Tomography Spiral Computer-Assisted"[Title/Abstract] OR "CT Scan*
Spiral"[Title/Abstract] OR "Spiral CT Scan*"[Title/Abstract] OR "Helical CT"[Title/Abstract] OR "spiral
CT"[Title/Abstract] OR "CT Helical"[Title/Abstract] OR "Helical CTs"[Title/Abstract] OR "Spiral Computed
Tomography"[Title/Abstract] OR "CT Spiral"[Title/Abstract] OR "CTs Spiral"[Title/Abstract] OR "Spiral
CTs"[Title/Abstract] OR "Tomography, Helical Computed"[Title/Abstract] OR "CAT Scan*, Spiral"[Title/Abstract] OR "Spiral
CAT Scan*"[Title/Abstract] OR "Helical Computed Tomography"[Title/Abstract] OR "Helical Computed Tomography
CT"[Title/Abstract] OR "low-dose helical computed tomography (CT)"[Title/Abstract]))))))) Q2: Nei pazienti con NSCLC in
stadio clinico I la lobectomia dovrebbe essere eseguita con approccio mini-invasivo (VATS o robotico) o toracotomico?
MEDLINE (PubMed) (2019 ad Agosto 2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung
Neoplasms/surgery"[Mesh]) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung
tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract]))
OR NSCLC[Title/Abstract]))))))) AND (("grade IA"[Title/Abstract] OR "stage IA"[Title/Abstract])))) AND (((("Thoracic
Surgery, Video-Assisted"[Mesh]) OR ("VATS Lobectomy"[Title/Abstract] OR VATS[Title/Abstract] OR "Thoracic Surgeries,
Video-Assisted"[Title/Abstract] OR "Video-assisted Thoracic Surgery (VATS) Lobectomy"[Title/Abstract] OR "Video-assisted
Thoracic Surgery"[Title/Abstract]))) OR ("VATS segmentectomy"[Title/Abstract] OR segmentectomy[Title/Abstract])))) AND
(((((((((("Randomized Controlled Trial"[Publication Type]) OR "Clinical Trial"[Publication Type]) OR "drug
therapy"[Subheading])) OR ((randomized[Title/Abstract] OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR
randomly[Title/Abstract] OR trial[Title/Abstract] OR groups)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND
"Humans"[Mesh]))))) AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) Embase
(Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung
neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4
'grade ia' OR 'stage ia':de,ti,ab #5 #3 AND #4 NE LINEE GU EOPLASIE DEL POLMONE #6 'vats lobectomy' OR vats OR 'thoracic
surgeries, video-assisted' OR 'video surgery (vats) lobectomy' OR 'video-assisted thoracic surgery' OR 'vats segm
segmentectomy:de,ti,ab #7 #5 AND #6 Q3 GRADE: Nei pazienti affetti da NSCLC in stadio iniziale (IA), la segme
raccomandata (rispetto alla lobectomia)? MEDLINE (PubMed) (2019 a Agosto 2023) (("Lung Neoplasms"[Mesh]) OR "Carcinoma,
Non-Small-Cell Lun Neoplasms"[Mesh]) OR "lung cancer"[Title/Abstract] OR "lung neoplasms" tumor"[Title/Abstract] OR
"Non-small-cell l

50. [population] score 11 ✅ BINGO (PCO)
fibrosis”. QUESITO 12: N chemio-radioter consolidamento POPOLAZIONE: INTERVENTO: CONFRONTO: ESITI PRINCIPALI: SETTING:
BACKGROUND: Il problema è una priorità? GIUDIZI ○ No ○ Probabilmente no Nei pazienti affetti da NSCLC in stadio III non
resecabile, in risposta o stabilità di malattia dopo trattamento rapico a dosi radicali e con espressione di PD-L1 sulle
cellule tumorali superiore o uguale a 1%, una terapia di o con durvalumab è raccomandata rispetto all’osservazione?
Pazienti affetti da NSCLC in stadio III non resecabile, in risposta o stabilità di malattia dopo trattamento chemio-
radioterapico a dosi radicali e con espressione del PD-L1 sulle cellule tumorali superiore o uguale a 1% Durvalumab
Osservazione Sopravvivenza globale; sopravvivenza libera da malattia; metastasi a distanza; controllo locale di
malattia; tasso di risposte obiettive; durata delle risposte; qualità di vita; eventi avversi di grado 3-4; polmoniti di
grado 3-4; morti correlate al trattamento Ambulatoriali Lo studio randomizzato di fase 3 PACIFIC ha confrontato una
terapia di consolidamento con durvalumab della durata di 12 mesi rispetto a sola osservazione, nei pazienti affetti da
NSCLC in stadio III non resecabile, in risposta o stabilità di malattia dopo trattamento chemio-radioterapico a dosi
radicali. E RICERCA DELLE PROVE CONSIDERAZIONI AGGIUNTIVE ○ Probabilme X Si ○ Varia ○ Non so Effetti d Quanto consid
GIUDIZI ○ Irrilevanti ○ Piccoli ○ Moderati X Grandi ○ Variano ○ Non so ente si deside derevoli s erabi sono gli ef NEO
ili ffetti desiderabili attesi? RICERCA DELLE PROVE Outcomes Anticipated absol Risk with placebo/Observat Overall Study
population Survival 49 per 100 Progression Study population free survival 65 per 100 assessed with: RECIST 1.1 follow
up: median 14.5 months Distant Study population metastasis assessed 59 per 100 with: time to death or OPLASIE DEL lute
effects* (95% Risk with tion (Q1)Durval 30 per 100 (22 to 41) 38 per 100 (29 to 49) 37 per 100 (29 to 46) L POLMONE %
CI) Relative № of effect particip (95% (studies lumab CI) HR 0.53 303 (0.36 to (1 RCT) HR 0.46 303 (0.33 to (1 RCT) HR
0.52 713 (0.39 to (1 RCT) Certainty pants the eviden s) (GRADE) ) HIGHa ) HIGHa ) MODERA of C nce ATEa,b Comments CONS s
SIDERAZIONI AGGIUNTIVE NEO distant metastasis (all assessed by means of blinded independent central review) Local -
control - not reported Objective Study population response 18 per 100 Duration of Study population response follow up:
35 per 100c median 13.8 months Quality of - life - not reportedd Grade 3-4 Study population pneumonia assessed 4 per 100
with: NCI- CTCAE follow up: median 14.5 months OPLASIE DEL n 30 per 100 (22 to 41) n 17 per 100 (9 to 31)c -e n 4 per
100 (2 to 10) L POLMONE RR 1.68 656 (1.22 to (1 RCT) HR 0.43 160 (0.22 to (1 RCT) -e - RR 1.15 709 (0.53 to (1 RCT) )
MODE )c MODE -a,b ) LOWa ERATE ERATE a,b,f Ea,b Ea,b L LINE EE GUIDA NEO Grade 3-4 Study population pneumonitis or
radiation 3 per 100 pneumonitis assessed with: NCI- CTCAE follow up: median 14.5 monthsg Grade 3-4 Study population
anemia assessed 3 per 100 with: NCI- CTCAE follow up: median 14.5 months Grade 3-4 Study population adverse events 26
per 100 assessed with: NCI- CTCAE follow up: median 14.5 months Treatment Study population related death 1 per 100
OPLASIE

51. [population] score 11 ✅ BINGO (PIO)
rs Squibb), and atezolizumab (Tecentriq, Genentech) are approved as second-line therapy. [...] X Yes ○ Varies ○ Don't
know Desirable How substantia JUDGEMENT ○ Trivial ○ Small ○ Moderate X Large ○ Varies ○ Don't know e effec al are the d
cts desirable a LINEE GU Because patients with advanced NSCLC can undergo rapid clinical deterioration during disease
progression, less than one half of patients with advanced NSCLC ever receive second-line therapy.1,2 First-line
combination regimens that include a PD-1 or PD-L1 inhibitor may maximize the chance of response and lead to prolonged
survival. Modulation of the immune response through PD-1 inhibition may be enhanced by the potential immunogenic effects
of cytotoxic chemotherapy. Gandhi L. et al. N Engl J Med 2018;378:2078-92. anticipated effects? RESEARCH EVIDENCE
Outcomes Anticipated absolute effects* (95% CI) Relative № of Certainty of the C effect participants evidence Risk with
alla Risk with un trattamento di prima linea a (95% (studies) (GRADE) chemioterapia base di platino, pemetrexed e CI)
pembrolizumab, seguito da mantenimento con pemetrexed e pembrolizumab in caso di risposta o stabilità di malattia dopo 4
cicli di trattamento Overall survival Study population HR 0.61 499 ⨁⨁◯◯ (0.45 to (2 RCTs) LOWa,b,c,d 61 per 100 44 per
100 0.83) (35 to 55) Progression free Study population HR 0.63 499 ⨁⨁⨁◯ survival (0.50 to (2 RCTs) MODERATEa,c,d,e 81
per 100 65 per 100 0.80) (56 to 73) Objective response Study population RR 2.16 499 ⨁⨁⨁◯ rate (1.58 to (2 RCTs)
MODERATEa,c,d,e 21 per 100 46 per 100 2.95) (33 to 63) UIDA Comment ADDITIONAL CONSIDERATIONS ts Grade 3-5 any AEs Study
population RR 1.06 728 ⨁◯◯◯ (0.94 to (2 RCTs) VERY 56 per 100 60 per 100 1.19) LOWa,c,d,f,g,h,i (53 to 67)
Discontinuation rate Study population RR 0.80 739 ⨁◯◯◯ of any treatment (0.73 to (2 RCTs) VERY LOWa,c,d,i,k componentj
78 per 100 62 per 100 0.88) (57 to 68) a. Unclear risk of attrition bias in both studies due to the lack of information
b. We decided to downgrade the quality of the evidence by one level for the risk of bias dimension because in both study
crossover to pembrolizumab monotherapy was permitted among the patients in the chemotherapy combination group who had
verified disease progression c. In Keynote-021 trial, the maintenance treatment consisted of pembrolizumab and optional
indefinite pemetrexed d. In KEYNOTE-21 study, subgroups analysis according to tumour proportion score for PD-L1 were not
designed and performed. For this reason we decided to downgrade the quality of the evidence by one level for
indirectness dimension e. KEYNOTE-021 trial was an open-label trial but efficacy was based on masked, independent,
central radiology review f. We decided to downgrade the quality of the evidence by one level for imprecision because the
95% CI includes both negligible effect and appreciable benefit or appreciable harm g. I2=53% h. In KEYNOTE 189 study
safety results were showed in the overall population and not according to PD-L1 tumour proportion score i. High risk of
performance and detection bias because KEYNOTE-021 was an open-label trial j. KEYNOTE-021 study: 31 patients
discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 17 PD, 6 AEs, 4 patients
withdrawal, 3 physician d

52. [population] score 11 ✅ BINGO (PIO)
nzato o metastatico in progressione dopo una prima linea di chemioterapia, INTERVENTO: Nivolumab, pembrolizumab,
atezolizumab CONFRONTO: Chemioterapia ESITI PRINCIPALI: Sopravvivenza libera da progressione; sopravvivenza globale;
tasso di risposte obiettive; tossicità di grado superiore o uguale a 3; Tasso di Interruzione del trattamento correlato
ad eventi avversi SETTING: Ambulatoriale BACKGROUND: Studi randomizzati di fase 3 hanno confrontato un trattamento
immunoterapico a base di nivolumab o pembrolizumab o atezolizumab versus chemioterapia a base di docetaxel nei pazienti
affetti NSCLC metastatico in progressione a chemioterapia. Il problema è una priorità? ○ No ○ Probabilmente no ○
Probabilmente si ○ Varia ○ Non so Effetti de Quanto conside GIUDIZI ○ Irrilevanti ○ Piccoli ○ Moderati X Grandi ○
Variano ○ Non so esider erevoli son rabili no gli effet tti desiderabili attesi? RICERCA DELLE PROVE Outcomes
Anticipated absolute effects* (95% CI) Relative № of Certainty effect participants evidence Risk with II line Risk with
Q10: (95% (studies) (GRADE chemotherapy immunotherapy with CI) nivolumab, pembrolizumab or atezolizumab Overall Survival
Study population HR 0.71 3024 ⨁⨁⨁⨁ (0.65 to (5 RCTs) HIGHa 76 per 100 64 per 100 0.77) (61 to 67) Progression free Study
population HR 0.85 2737 ⨁⨁⨁◯ survival (0.79 to (4 RCTs) MODERA 83 per 100 78 per 100 0.92) (76 to 81) Overall response
Study population RR 1.93 3024 ⨁⨁◯◯ rate (1.12 to (5 RCTs) LOWa,b,c 9 per 100 17 per 100 1.73) (10 to 16) Treatment-
related Study population RR 0.32 3014 ⨁⨁⨁◯ AE (grade 3 or 4) (0.28 to (5 RCTs) MODERA 47 per 100 15 per 100 0.36) (13 to
17) Study population y of the E) ATEa,b ATEa,b,d LI Commen INEE G CON nts GUIDA NSIDERAZI IONI AGGIUNTIVE
Discontinuation 17 per 100 8 per 100 RR 0.47 3014 ⨁⨁⨁◯ (6 to 10) (0.38 to rate (5 RCTs) MODERATEa,b Allocation
concealment was not clear in two studies (OAK and POPLAR studies) High risk of performance and detection bias, all
studies were open label Although heterogeneity across study was found (I2=82%), we decided not to downgrade for
inconsistency, because heterogeneity is related to magnitude and not to direction of effects Overall survival
progression free survival NEO Objective response rate treatment related AEs OPLAS SIE DEL POLMON NE Discontinu NEO
uation rate OPLAS SIE DEL POLMON NE Effetti ind Quanto conside GIUDIZI ○ Grandi ○ Moderati ○ Piccoli X Irrilevanti ○
Variano ○ Non so deside erevoli son erabili no gli effet tti indesiderabili attesi? RICERCA DELLE PROVE Outcomes
Anticipated absolute effects* (95% CI) Relative № of Certainty effect participants evidence Risk with II line Risk with
Q10: (95% (studies) (GRADE chemotherapy immunotherapy with CI) nivolumab, pembrolizumab or atezolizumab Overall Survival
Study population HR 0.71 3024 ⨁⨁⨁⨁ (0.65 to (5 RCTs) HIGHa 76 per 100 64 per 100 0.77) (61 to 67) Progression free Study
population HR 0.85 2737 ⨁⨁⨁◯ survival (0.79 to (4 RCTs) MODERA 83 per 100 78 per 100 0.92) (76 to 81) Overall response
Study population RR 1.93 3024 ⨁⨁◯◯ rate (1.12 to (5 RCTs) LOWa,b,c 9 per 100 17 per 100 1.73) (10 to 16) Treatment-
related Study population RR 0.32 3014 ⨁⨁⨁◯ AE (grade 3 or 4) (0.28 to (5 RCTs) MODERA 47 per 100 15 per 100 0.36) (13 to
17) Discontinuation Study population RR 0.47 3014 ⨁⨁⨁◯

53. [population] score 11 ✅ BINGO (PCO)
||||| Row 6: ||placebo/Observation|||(Q1)Durvalumab||||| Row 7: |||||||||| Row 8: Overall Survival|||||||HR 0.53 (0.36
to 0.77)|303 (1 RCT)|⨁⨁⨁⨁ HIGHa| Row 9: ||Study population|||||||| Row 10: |||||||||| Row 11: |||||||||| Row 12: |49 per
100||||30 per 100||||| Row 13: |||||(22 to 41)||||| Row 14: |||||||||| Row 15: Progression free survival assessed with:
RECIST 1.1 follow up: median 14.5 months|||||||HR 0.46 (0.33 to 0.64)|303 (1 RCT)|⨁⨁⨁⨁ HIGHa| Row 16: ||Study
population|||||||| Row 17: |||||||||| Row 18: |||||||||| Row 19: |65 per 100|||38 per 100 (29 to 49)|||||| Row 20:
|||||||||| Row 21: Distant metastasis assessed with: time to death or|||||||HR 0.52 (0.39 to 0.69)|713 (1 RCT)|⨁⨁⨁◯
MODERATEa,b| Row 22: ||Study population|||||||| Row 23: |||||||||| Row 24: |||||||||| Row 25: |59 per 100|||37 per 100
(29 to 46)|||||| Row 26: |||||||||| Row 1: Relative Row 2: effect Row 3: (95% Row 4: CI) Row 1: № of Row 2: participants
Row 3: (studies) Row 1: Certainty of Row 2: the evidence Row 3: (GRADE) Row 1: 38 per 100 Row 2: (29 to 49) Row 1: 37
per 100 Row 2: (29 to 46) Row 1: | Row 2: |Effetti d Row 3: |Quanto consid Row 4: | Row 1:  Row 2: deside Row 3:
derevoli s Row 4:  Row 1:  Row 2: erabi Row 3: sono gli ef Row 4:  Row 1: | Row 2: ili| Row 3: ffetti desiderabili
attesi?| Row 4: | Row 1: || Row 2: Outcomes||Anticipated absol Row 3: || Row 4: || Row 5: ||Risk with Row 6:
||placebo/Observat Row 7: || Row 8: Overall Survival|| Row 9: ||Study population Row 10: || Row 11: || Row 12: |49 per
100|49 per 100 Row 13: || Row 14: Progression free survival assessed with: RECIST 1.1 follow up: median 14.5 months||
Row 15: ||Study population Row 16: || Row 17: || Row 18: |65 per 100|65 per 100 Row 19: || Row 20: Distant metastasis
assessed with: time to death or|| Row 21: ||Study population Row 22: || Row 23: || Row 24: |59 per 100|59 per 100 Row
25: || Row 1:  Row 2:  Row 3:  Row 4:  Row 1: ||| Row 2: lute effects* (95%||| Row 3: ||| Row 4: ||| Row 5: |||Risk with
Row 6: tion|||(Q1)Durval Row 7: ||| Row 8: ||| Row 9: ||| Row 10: ||| Row 11: ||| Row 12: |||30 per 100 Row 13: |||(22
to 41) Row 14: ||| Row 15: ||| Row 16: ||| Row 17: ||| Row 18: ||| Row 19: ||38 per 100 (29 to 49)|38 per 100 Row 20:
|||(29 to 49) Row 21: ||| Row 22: ||| Row 23: ||| Row 24: ||| Row 25: ||| Row 26: ||37 per 100 (29 to 46)|37 per 100 Row
27: |||(29 to 46) Row 28: ||| Row 1: |||| Row 2: % CI)||Relative effect (95% CI)|№ of particip (studies|№ of Row 3:
||||particip Row 4: |||| Row 5: ||||(studies Row 6: lumab|||| Row 7: |||| Row 8: ||HR 0.53 (0.36 to 0.77)|| Row 9: ||||
Row 10: |||| Row 11: |||| Row 12: |||| Row 13: |||| Row 14: |||| Row 15: ||HR 0.46 (0.33 to 0.64)|| Row 16: |||| Row 17:
|||| Row 18: |||| Row 19: |||| Row 20: |||| Row 21: |||| Row 22: ||HR 0.52 (0.39 to 0.69)|| Row 23: |||| Row 24: ||||
Row 25: |||| Row 26: |||| Row 27: |||| Row 28: |||| Row 1: || Row 2: |Certainty the eviden (GRADE)|Certainty Row 3:
pants||the eviden Row 4: s)||(GRADE) Row 1: || Row 2: of|C|C Row 3: nce|| Row 4: || Row 1:  Row 2: Comments Row 3:  Row
1: | Row 2: | Row 3: | Row 4: | Row 1:  Row 2: s Row 1: |distant metastasis (all assessed by means of blinded
independent central review) Local - - - - - control - not reported Objective Study population RR 1.68 656 ⨁⨁⨁◯ response
(1.22 to (1 RCT) MO

54. [population] score 11
ità di malattia dopo 4 cicli di trattamento Effect Relative Absolute Certainty Importance apia (95% CI) (95% CI) 4 RR
1.06 3 more ⨁◯◯◯ CRITICAL ) (0.94 to per 100 VERY LOW 1.19) (from 3 fewer to 11 more) 9 RR 0.80 16 fewer ⨁◯◯◯ CRITICAL )
(0.73 to per 100 VERY LOW 0.88) (from 21 fewer to 9 fewer) a. Unclear risk of attrition bias in both studies due to the
lack of information b. We decided to downgrade the quality of the evidence by one level for the risk of bias dimension
because in both study crossover to pembrolizumab monotherapy was permitted among the patients in the chemotherapy
combination group who had verified disease progression c. In Keynote-021 trial, the maintenance treatment consisted of
pembrolizumab and optional indefinite pemetrexed d. In KEYNOTE-21 study, subgroups analysis according to tumour
proportion score for PD-L1 were not designed and performed. For this reason we decided to downgrade the quality of the
evidence by one level for indirectness e. KEYNOTE-021 trial was an open-label trial but efficacy was based on masked,
independent, central radiology review f. High risk of performance and detection bias because KEYNOTE-021 was an open-
label trial g. I2=53% h. In KEYNOTE 189 study safety results were showed in the overall population and not according to
PD-L1 tumour proportion score i. We decided to downgrade the quality of the evidence by one level for imprecision
because the 95% CI includes both negligible effect and appreciable benefit or appreciable harm j. KEYNOTE-021 study: 31
patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 17 PD, 6 AEs, 4
patients withdrawal, 3 physician decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT
alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician decision, 1 use of excluded
medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the
following reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy
and 11 clinical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268
patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic
PD, 21 AEs, 8 patients withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression; k. in
KEYNOTE-189 study information for this outcome were showed in the overall population and not according to PD-L1 tumour
proportion score Dovrebbe un trattamento di prima linea a base di platino, pemetrexed e pembrolizumab, seguito da
mantenimento con pemetrexed e pembrolizumab in caso di risposta o stabilità di malattia dopo 4 cicli di trattamento vs.
la chemioterapia essere usato per pazienti affetti da NSCLC a istologia non-squamosa con espressione di PD-L1 <50% in
stadio metastatico senza mutazione attivante l’EGFR o riarrangiamento di ALK e con buon performance status (0-1)?
POPULATION: Pazienti affetti da NSCLC a istologia non-squamosa con espressione di PD-L1 <50% in stadio metastatico senza
mutazione attivante l’EGFR o riarrangiamento di ALK e con buon performance status (0-1) INTERVENTION: Un trattamento di
prima lin

55. [population] score 11 ✅ BINGO (PICO)
serious b,c very serious d serious e not serious none 748/1859 644/5536 HR 0.62 4 fewer ⨁◯◯◯ CRITICAL studies a (40.2%)
f (11.6%) f (0.59 to 0.66) per 100 VERY LOW (from 5 fewer to 4 fewer) 5 observational serious h serious i serious e not
serious none 0/261 (0.0%) 0/406 (0.0%) HR 0.76 -- per 100 ⨁◯◯◯ CRITICAL studies g (0.65 to 0.89) (from -- to VERY LOW 1
randomised not serious k not serious not serious not serious none Authors stated that "The rate of compliance with the
quality-of-life ⨁⨁⨁⨁ CRITICAL trials j assessment was 93.7% at baseline but decreased to 46.3% at 9 HIGH months. From
baseline to month 9, there was no statistically or clinically significant difference in global health status between the
study groups (P = 0.10)" Impared Cognitive Function (neurologica damage) - not reported - - - - - - - - - - - - CRITICAL
Any grade 3-5 AEs - not reported - - - - - - - - - - - - CRITICAL 2 observational not serious not serious not serious
serious m none 52/386 (13.5%) 16/570 (2.8%) RR 4.92 110 more ⨁◯◯◯ IMPORTANT studies l (2.86 to 8.44) per 1.000 VERY LOW
(from 52 more to 209 more) CI: Confidence interval; HR: Hazard Ratio; RR: Risk ratio a. There was 9 RCT and 12
observational studies b. In 13 out of 21 studies, the number of events were not showed c. The quality of the
observational included studies was assessed according to the Newcastle-Ottawa scale. Studies was considerate as moderate
or high quality, the reasons for downgrade the quality were selection and outcome bias. The quality of the included RCTs
was assessed according to the Cochrane Handbook 5.1. Studies had, in general, a low risk of bias d. I2=84% e. Patients
included in the Prophylactic Cranial irradiation overview collaborative group had achieved a complete response after
induction treatment. In Rule at al. all patients were 70 years or older. Salama et al presented a secondary analysis of
the CALGB 30504 study, included patients received placebo or sunitinib f. This is not the total number of events, Ge
2018 et al. did not show the number of events but only the overall number of patients g. There was 2 RCT and 3
observational studies h. The number of events were not showed in all included studies i. I2=64% j. Slotman et al 2007 k.
Unclear risk of bias due to the lack of information l. There were 1 RCT and 1 observational study m. Low number of
events QUESITO 45: Nei pazienti affetti da SCLC con malattia estesa e in risposta dopo chemioterapia, l’irradiazione
profilattica dell’encefalo (PCI) è raccomandata? POPOLAZIONE: INTERVENTO: CONFRONTO: ESITI PRINCIPALI: SETTING:
BACKGROUND: VALUTA Il problema è una priorità GIUDIZI ○ No ○ Probabilmente no ○ Probabilmente si X Si ○ Varia ○ Non so
Pazienti affetti da SCLC con malattia estesa e in risposta dopo chemioterapia Irradiazione profilattica dell’encefalo
(PCI) Osservazione Sopravvivenza libera da progressione; sopravvivenza globale; sopravvivenza libera da progres
tossicità di grado superiore o uguale a 3; Fatigue e Letargia di ogni grado. Ambulatoriale Molteplici studi hanno
valutato efficacia e tollerabilità dell’irradiazione profilattica dell’encefa chemioterapico. AZIONE RICERCA DELLE PROVE
ssione encefalica; qu alo (PCI) nei pazienti ualità di vita; Compromissione neurocognitiva (danno neurologico); i
affetti da SCLC con m

56. [intervention] score 11
("Randomized Controlled Trial" [Publication Type]) OR "Clinic Type]) OR "drug therapy" [Subheading])) OR
((randomized[Title/Abstract] OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract]
trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mes "Humans"[Mesh]))) espressione del
zolizumab dopo oma, Non-Small- g mall-cell lung pt]) OR cer' OR 'non sma apia postoperat (((((lung ract]) OR lung ung
C*[Title/Abstract]) Title/Abstract] OR ))) AND "radical cal Trial" [Publica OR sh]) AND l PD- o la -Cell all toria R
ation NE EOPLASIE DEL POLMONE Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung
cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'grade ia' OR 'stage ia':de,ti,ab #5 #3 AND #4 #6 "radical surgery:de,ti,ab #7 #5
AND #6 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta analysis]/lim OR [controlled clinical trial]/lim
OR [randomized controlled trial]/lim) AND [embase]/lim Q9: Nei pazienti con NSCLC in stadio II-III resecabile una
chemioterapia neoadiuvante seguita da chirurgia è raccomandata (rispetto a sola chirurgia)? (("neoadjuvant therapy"[MeSH
Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR "neoadjuvant therapy"[All Fields] OR
"neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields]
OR "drug therapy"[MeSH Terms] OR ("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR
"chemotherapies"[All Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All Fields]
OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fields] OR "resected"[All Fields] OR
"resecting"[All Fields] OR "resection"[All Fields] OR "resectional"[All Fields] OR "resectioned"[All Fields] OR
"resectioning"[All Fields] OR "resections"[All Fields] OR "resective"[All Fields] OR "resects"[All Fields]) AND
("lung"[MeSH Terms] OR "lung"[All Fields]) AND ("cancer s"[All Fields] OR "cancerated"[All Fields] OR "canceration"[All
Fields] OR "cancerization"[All Fields] OR "cancerized"[All Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms]
OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR "cancers"[All Fields])) AND (meta-analysis[Filter] OR
randomizedcontrolledtrial[Filter] OR systematicreview[Filter]) Q10: Nei pazienti con NSCLC in stadio IIIA/IIIB non
resecabile, o IIIC un trattamento di chemio- radioterapia a dosi radicali concomitante è raccomandato (rispetto alla
sequenziale)? MEDLINE (PubMed) (2019 ad Agosto 2023) ((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp])
OR ((((((((((lung cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung
neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non
small cell lung cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))))))) AND (((grade iii OR stage iii OR advance OR
locally advanced disease)) AND (inoperable OR surgically unresectable)))) AND (("Chemoradiotherapy"[Mesh]) OR
(("Chemoradiotherapy"[Mesh]) OR ("chemoradiotherapy"[Title/Abstr

57. [intervention] score 11
domized Controlled Trial" [Publication Type]) OR "Clinic Type]) OR "drug therapy" [Subheading])) OR
((randomized[Title/Abstract] OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract]
trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mes "Humans"[Mesh]))) espressione del
zolizumab dopo oma, Non-Small- g mall-cell lung pt]) OR cer' OR 'non sma apia postoperat (((((lung ract]) OR lung ung
C*[Title/Abstract]) Title/Abstract] OR ))) AND "radical cal Trial" [Publica OR sh]) AND l PD- o la -Cell all toria R
ation NE EOPLASIE DEL POLMONE Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung
cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'grade ia' OR 'stage ia':de,ti,ab #5 #3 AND #4 #6 "radical surgery:de,ti,ab #7 #5
AND #6 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta analysis]/lim OR [controlled clinical trial]/lim
OR [randomized controlled trial]/lim) AND [embase]/lim Q9: Nei pazienti con NSCLC in stadio II-III resecabile una
chemioterapia neoadiuvante seguita da chirurgia è raccomandata (rispetto a sola chirurgia)? (("neoadjuvant therapy"[MeSH
Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR "neoadjuvant therapy"[All Fields] OR
"neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields]
OR "drug therapy"[MeSH Terms] OR ("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR
"chemotherapies"[All Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All Fields]
OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fields] OR "resected"[All Fields] OR
"resecting"[All Fields] OR "resection"[All Fields] OR "resectional"[All Fields] OR "resectioned"[All Fields] OR
"resectioning"[All Fields] OR "resections"[All Fields] OR "resective"[All Fields] OR "resects"[All Fields]) AND
("lung"[MeSH Terms] OR "lung"[All Fields]) AND ("cancer s"[All Fields] OR "cancerated"[All Fields] OR "canceration"[All
Fields] OR "cancerization"[All Fields] OR "cancerized"[All Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms]
OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR "cancers"[All Fields])) AND (meta-analysis[Filter] OR
randomizedcontrolledtrial[Filter] OR systematicreview[Filter]) Q10: Nei pazienti con NSCLC in stadio IIIA/IIIB non
resecabile, o IIIC un trattamento di chemio- radioterapia a dosi radicali concomitante è raccomandato (rispetto alla
sequenziale)? MEDLINE (PubMed) (2019 ad Agosto 2023) ((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp])
OR ((((((((((lung cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung
neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non
small cell lung cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))))))) AND (((grade iii OR stage iii OR advance OR
locally advanced disease)) AND (inoperable OR surgically unresectable)))) AND (("Chemoradiotherapy"[Mesh]) OR
(("Chemoradiotherapy"[Mesh]) OR ("chemoradiotherapy"[Title/Abstract] OR

58. [comparator] score 11 ✅ BINGO (ICO)
%)15 (0.56%)15 81.18)9 more to 45 more) HIGH 1 pemetrexed 500 mg/m2 2 OS pemetrexed 13,9 mesi versus 11,1 for placebo.
difference = 2,8 months 3 Panel Composition: 6 oncologi medici, 1 radioterapista, 1 chirurgo toracico. 4 Results based
on event-driven analisys (Paz-Ares Lancet Oncol 2012). PFS results were not updated in the final report (Paz-Ares JCO
2013) 5 The primary outcome declared in  is PFS detected by investigators. Taking into account the high proportion of
indipendent evaluation available 88% and the similar results LINEE GUI obtained we decided to report the investigator
assessed PFS 6 Investigator -> pemetrexed median PFS 4,1 mesi (3,2-4,6), placebo 2,8 (2,6-3,1); Indipendent ->
pemetrexed median PFS 3,9 mesi (3- 4,2) , placebo 2,6 ( 2.2-2.9) 7 Assessed by the indipendent review 8 Wide 95% CI due
to low number of events. For this reason we decided to not downgrade quality of evidence for imprecision 9 Calcolated
throught number of events and totals 10 Low questionnaire compliance due to failure by study site to administer
questionnaire. 11 95% confidence interval includes no effect and the upper and lower confidence limit crosses the
minimal important difference (MID= 0.08 U.K population-based index sco 12 Assuming a SD= 1.5 for both arm (data not
provided by authors) 13 95% confidence interval includes no effect and the lower confidence limit crosses the minimal
important difference (MID= 7 VAS) 14 Assuming a SD= 7.24 for both arm (Sds are not reported in the primary article) and
a p-value > 0.05 (the authors reported "Not-Ssignificant" only) 15 we added a further event both in the intervention and
in the control group to permit the calculation of relative and absolute effect IDA ore); both f for benefit and harm
Dovrebbe maintenance therapy with pemetrexed vs placebo essere utiliz POPOLAZIONE: Advanced NSCLC INTERVENTO:
Maintenance therapy with pemetrexed CONFRONTO: Placebo ESITI PRINCIPALI: Overall Survival; Progression free survival;
Objective responce rate; Quality of life -EQ-5D; Qual grade 3-4; Neutropenia grade 3-4 SETTING: PROSPETTIVA: BACKGROUND:
CONFLITTI DI INTERESSE Il problema è una priorità? GIUDIZI RICERCA DELLE PROVE DI EVIDENZA ○ No ○ Probabilmente no ○
Probabilmente si ● Si ○ Varia ○ Non so zzato per adva lity of life -VAS; Sever anced NSCLC re Toxicity (Non labor
CONSIDE ratory); Fatigue grade 3-4; trans ERAZIONI AGGIUNTIVE sfusion; G-CSF ; Anemia Effetti de Quanto consid GIUDIZI ○
Irrilevanti ○ Piccoli ○ Moderati ● Grandi ○ Variano ○ Non so esider derevoli s rabili sono gli e effetti des siderabili
attesi? RICERCA DELLE PROVE DI EVIDENZA CONS È stata eseguita una ricerca sistematica della letteratura sulle banche
dati PubMed/Medline, Embase e Central (Cochrane Library). La strategia di ricerca ha identificato 1478 documenti dopo la
rimozione dei duplicati. È stato valutato un record in full-text e incluso. Lo studio PARAMOUNT, è un trial di fase 3
randomizzato in doppio cieco, multicentrico, su pazienti affetti da NSCLC in fase avanzata (stadio IIIB/IV). Lo studio
prevedeva due fasi: una fase non randomizzata (fase di induzione) in cui 939 pazienti non pre-trattati per malattia
avanzata sono stati sottoposti a terapia di prima linea con cisplatino/pemetrexed (cisplatino 75 mg/mq e.v. g.1 e
pemetrexed 500 mg/mq

59. [outcome] score 11 ✅ BINGO (PIO)
ost of patients (80.7%) were stage IV and only one patient did not received a previous chemotherapy line QUESITO 22: Nei
pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con riarrangiamenti di ROS1, un trattamento di
prima linea con crizotinib è raccomandato (rispetto alla chemioterapia)? POPOLAZIONE: Pazienti affetti da NSCLC in
stadio localmente avanzato o metastatico con riarrangiamenti di ROS1 INTERVENTO: Inibitore tirosino-chinasico di ROS1
crizotinib CONFRONTO: Chemioterapia ESITI PRINCIPALI: Sopravvivenza libera da progressione; sopravvivenza globale; tasso
di risposte obiettive; qualità di vita; diarrea/nausea di grado superiore o uguale a 3; neutropenia di grado superiore o
uguale a 3; edema periferico di grado superiore o uguale a 3; tossicità di grado superiore o uguale a 3 SETTING:
Ambulatoriale BACKGROUND: Studi prospettici di fase 2 non randomizzati hanno valutato il profilo di attività e di
tollerabilità dell’inibitore tirosino-chinasico di ROS1 Crizotinib nei pazienti affetti da NSCLC localmente avanzato o
metastatico con riarrangiamenti del gene ROS1. VALUTAZIO Il problema è una priorità GIUDIZI ○ No ○ Probabilmente no ○
Probabilmente si ○ Varia ○ Non so Effetti desider Quanto considerevoli son GIUDIZI ○ Irrilevanti ○ Piccoli ○ Moderati X
Grandi ○ Variano ○ Non so ONE rabili no gli effet NEOPLASIE DE RICERCA DELLE PROVE tti desiderabili attesi? RICERCA
DELLE PROVE Outcomes Anticipated (95% CI) Risk with chemothera Progression free survival - Study popul Landi L. et al
(METROS) 0 per 1.000 Progression-free survival - - Shaw A.T. et al - not reported EL POLMONE d absolute effects* Relat
effect Risk with CI) apy (Q6)a first li e therapy with crizotinib lation not estima 0 per 1.000 (0 to 0) tive № of
Certain t participants the evid % (studies) (GRAD able (1 VERY observational study) nty of dence DE) LOWa,b LI Commen
INEE G CON CON nts GUIDA NSIDERAZI NSIDERAZI IONI AGGIUNTIVE IONI AGGIUNTIVE NEOP Progression-free survival - Mazières
J. et al. Overall survival - Landi L et al (METROS) Overall survival - Shaw A.T. et al 2019 Overall survival - Mazières
J. et al. - not reported Objective response rate - Shaw A.T. et al 2019 (ORR) assessed with: RECIST Objective response
rate - Landi L et al (METROS) Objective response rate - Mazières J. et al Quality of life - Landi L. et al. (METROS) -
not reported PLASIE D Study po 0 per 1.00 Study pop 0 per 1.00 S tudy pop 0 per 1.00 Study pop 0 per 1.00 Study pop 0
per 1.00 Study pop 0 per 1.00 DEL POLMON opulation 00 0 per 1.00 (0 to 0) pulation 00 0 per 1.00 (0 to 0) pulation 00 0
per 1.00 (0 to 0) pulation 00 0 per 1.00 ( 0 to 0) pulation 00 0 per 1.000 (0 to 0) pulation 00 0 per 1.00 (0 to 0) NE
not estimab not estimab not estimab not estimab not estimab not estimab ble (1 observat study) ble ( observat study) ble
(1 observat study) ble (1 observat study) ble (1 observat study) ble (1 observat study) VERY tional VERY tional VERY
tional LOW tional LOW tional MOD tional Y LOW Y LOW Y LOW Wa,c Wa,b DERAT Wa,c Wa,b Wa,c TEa,c L LINE EE GUIDA NEOPLASIE
D Quality of life - Shaw A.T. et - al - not reported Quality of life - Mazières J. et - al. - not reported
Diarrhea/Nausea/Constipation Study pop grade >=3 - Landi L. et al (METROS) 0 per 1.00 Diarrhea/Nausea/Constipation Study
po

60. [outcome] score 11
l Lung Cancer ≤ 1 cm or &gt; 1 to 2 cm Among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based Study. J
Clin Oncol; Sep 10 2016. 7.Roman, M., Labbouz, S., Valtzoglou, V., Ciesla, A., Hawari, M., Addae-Boateng, E., Thorpe, J.
A., Duffy, J. P., Majewski, A.. Lobectomy vs. segmentectomy. A propensity score matched comparison of outcomes. Eur J
Surg Oncol; May 2019. 8.Okada, M., Nishio, W., Sakamoto, T., Uchino, K., Yuki, T., Nakagawa, A., Tsubota, N.. Effect of
tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser
resection. J Thorac Cardiovasc Surg; Jan 2005. 9.Okada, M., Koike, T., Higashiyama, M., Yamato, Y., Kodama, K., Tsubota,
N.. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc
Surg; Oct 2006. 10.Nakamura, H., Taniguchi, Y., Miwa, K., Adachi, Y., Fujioka, S., Haruki, T., Takagi, Y., Yurugi, Y..
Comparison of the surgical outcomes of thoracoscopic lobectomy, segmentectomy, and wedge resection for clinical stage I
non-small cell lung cancer. Thorac Cardiovasc Surg; Apr 11.Landreneau, R. J., Normolle, D. P., Christie, N. A., Awais,
O., Wizorek, J. J., Abbas, G., Pennathur, A., Shende, M., Weksler, B., Luketich, J. D., Schuchert, M. J.. Recurrence and
survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small- cell lung cancer: a
propensity-matched analysis. J Clin Oncol; Aug 10 2014. 12.Hwang, Y., Kang, C. H., Kim, H. S., Jeon, J. H., Park, I. K.,
Kim, Y. T.. Comparison of thoracoscopic segmentectomy and thoracoscopic lobectomy on the patients with non-small cell
lung cancer: a propensity score matching study. Eur J Cardiothorac Surg; Aug 2015. 13.Dziedzic, R., Zurek, W.,
Marjanski, T., Rudzinski, P., Orlowski, T. M., Sawicka, W., Marczyk, M., Polanska, J., Rzyman, W.. Stage I non-small-
cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer
Registry. Eur J Cardiothorac Surg; Aug 1 2017. 14.Whitson, B. A., Groth, S. S., Andrade, R. S., Maddaus, M. A.,
Habermann, E. B., D'Cunha, J.. Survival after lobectomy versus segmentectomy for stage I non-small cell lung cancer: a
population-based analysis. Ann Thorac Surg; Dec 2011. 15.Zhong, C., Fang, W., Mao, T., Yao, F., Chen, W., Hu, D..
Comparison of thoracoscopic segmentectomy and thoracoscopic lobectomy for small-sized stage IA lung cancer. Ann Thorac
Surg; Aug 2012. 16.Zhang, L., Ma, W., Li, Y., Jiang, Y., Ma, G., Wang, G.. Comparative study of the anatomic
segmentectomy versus lobectomy for clinical stage IA peripheral lung cancer by video assistant thoracoscopic surgery. J
Cancer Res Ther; Sep 2013. 17.Yamashita, S., Tokuishi, K., Anami, K., Moroga, T., Miyawaki, M., Chujo, M., Yamamoto, S.,
Kawahara, K.. Thoracoscopic segmentectomy for T1 classification of non-small cell lung cancer: a single center
experience. Eur J Cardiothorac Surg; Jul 2012. 18.Yamato, Y., Koike, T., Yoshiya, K., Shinohara, H., Toyabe, S.. Results
of surgical treatment for small (2 cm or under) adenocarcinomas of the lung. Surg Today; 2008. 19.Tsubokawa, N.,
Tsutani, Y., Miyata, Y., Handa, Y., Misumi, K., Hanaki, H., Hida, E., Okada, M.. Segmentectomy Versus Lobectomy for
Radiologically Pure Solid Clinical T1a-bN0M0 L

61. [outcome] score 11
ectomy vs segmentectomy. Am J Surg; Dec 2016. 29.Schuchert, M.J., Pettiford, B.L., Keeley, S., D'Amato, T.A., Kilic, A.,
Close, J., Pennathur, A., Santos, R., Fernando, H.C., Landreneau, J.R., Luketich, J.D., Landreneau, R.J.. Anatomic
segmentectomy in the treatment of stage I non-small cell lung cancer. Ann Thorac Surg 2007. 30.Sienel, W., Stremmel, C.,
Kirschbaum, A., Hinterberger, L., Stoelben, E., Hasse, J., Passlick, B.. Frequency of local recurrence following
segmentectomy of stage IA non-small cell lung cancer is influenced by segment localisation and width of resection
margins--implications for patient selection for segmentectomy. Eur J Cardiothorac Surg; Mar 2007. 31.Okada, M., Mimae,
T., Tsutani, Y., Nakayama, H., Okumura, S., Yoshimura, M., Miyata, Y.. Segmentectomy versus lobectomy for clinical stage
IA lung adenocarcinoma. Ann Cardiothorac Surg; Mar 2014. 32.Read, R. C., Yoder, G., Schaeffer, R. C.. Survival after
conservative resection for T1 N0 M0 non-small cell lung cancer. Ann Thorac Surg; Mar 1990. 33.Martin-Ucar, A. E., Nakas,
A., Pilling, J. E., West, K. J., Waller, D. A.. A case-matched study of anatomical segmentectomy versus lobectomy for
stage I lung cancer in high-risk patients. Eur J Cardiothorac Surg; Apr 2005. 34.Nishio, W., Yoshimura, M., Maniwa, Y.,
Kitamura, Y., Tane, K., Takenaka, D., Adachi, S.. Re-Assessment of Intentional Extended Segmentectomy for Clinical T1aN0
Non-Small Cell Lung Cancer. Ann Thorac Surg; Nov 2016. 35.Kilic, A., Schuchert, M. J., Pettiford, B. L., Pennathur, A.,
Landreneau, J. R., Landreneau, J. P., Luketich, J. D., Landreneau, R. J.. Anatomic segmentectomy for stage I non-small
cell lung cancer in the elderly. Ann Thorac Surg; Jun 2009. 36.Koike, T., Yamato, Y., Yoshiya, K., Shimoyama, T.,
Suzuki, R.. Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. J Thorac Cardiovasc
Surg; Apr 2003. 37.Landreneau, R. J., Sugarbaker, D. J., Mack, M. J., Hazelrigg, S. R., Luketich, J. D., Fetterman, L.,
Liptay, M. J., Bartley, S., Boley, T. M., Keenan, R. J., Ferson, P. F., Weyant, R. J., Naunheim, K. S.. Wedge resection
versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg; Apr 1997. 38.Keenan, R.
J., Landreneau, R. J., Maley, R. H.,Jr., Singh, D., Macherey, R., Bartley, S., Santucci, T.. Segmental resection spares
pulmonary function in patients with stage I lung cancer. Ann Thorac Surg; Jul 2004. 39.Hattori, A., Matsunaga, T.,
Takamochi, K., Oh, S., Suzuki, K.. Locoregional recurrence after segmentectomy for clinical-T1aN0M0 radiologically solid
non-small-cell lung carcinoma. Eur J Cardiothorac Surg; Mar 1 2017. 40.Fiorelli, A., Caronia, F. P., Daddi, N., Loizzi,
D., Ampollini, L., Ardò, N., Ventura, L., Carbognani, P., Potenza, R., Ardissone, F., Sollitto, F., Mattioli, S., Puma,
F., Santini, M., Ragusa, M.. Sublobar resection versus lobectomy for stage I non-small cell lung cancer: an appropriate
choice in elderly patients?. Surg Today; Dec 2016. 41.Carr, S. R., Schuchert, M. J., Pennathur, A., Wilson, D. O.,
Siegfried, J. M., Luketich, J. D., Landreneau, R. J.. Impact of tumor size on outcomes after anatomic lung resection for
stage 1A non-small cell lung cancer based on the current staging system. J Thorac Cardiovasc Surg; Feb 2012. 42.Altorki,

62. [outcome] score 11
himura, M., Maniwa, Y., Kitamura, Y., Tane, K., Takenaka, D., Adachi, S.. Re-Assessment of Intentional Extended
Segmentectomy for Clinical T1aN0 Non-Small Cell Lung Cancer. Ann Thorac Surg; Nov 2016. 35.Kilic, A., Schuchert, M. J.,
Pettiford, B. L., Pennathur, A., Landreneau, J. R., Landreneau, J. P., Luketich, J. D., Landreneau, R. J.. Anatomic
segmentectomy for stage I non-small cell lung cancer in the elderly. Ann Thorac Surg; Jun 2009. 36.Koike, T., Yamato,
Y., Yoshiya, K., Shimoyama, T., Suzuki, R.. Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized
lung cancer. J Thorac Cardiovasc Surg; Apr 2003. 37.Landreneau, R. J., Sugarbaker, D. J., Mack, M. J., Hazelrigg, S. R.,
Luketich, J. D., Fetterman, L., Liptay, M. J., Bartley, S., Boley, T. M., Keenan, R. J., Ferson, P. F., Weyant, R. J.,
Naunheim, K. S.. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc
Surg; Apr 1997. 38.Keenan, R. J., Landreneau, R. J., Maley, R. H.,Jr., Singh, D., Macherey, R., Bartley, S., Santucci,
T.. Segmental resection spares pulmonary function in patients with stage I lung cancer. Ann Thorac Surg; Jul 2004.
39.Hattori, A., Matsunaga, T., Takamochi, K., Oh, S., Suzuki, K.. Locoregional recurrence after segmentectomy for
clinical-T1aN0M0 radiologically solid non-small-cell lung carcinoma. Eur J Cardiothorac Surg; Mar 1 2017. 40.Fiorelli,
A., Caronia, F. P., Daddi, N., Loizzi, D., Ampollini, L., Ardò, N., Ventura, L., Carbognani, P., Potenza, R., Ardissone,
F., Sollitto, F., Mattioli, S., Puma, F., Santini, M., Ragusa, M.. Sublobar resection versus lobectomy for stage I non-
small cell lung cancer: an appropriate choice in elderly patients?. Surg Today; Dec 2016. 41.Carr, S. R., Schuchert, M.
J., Pennathur, A., Wilson, D. O., Siegfried, J. M., Luketich, J. D., Landreneau, R. J.. Impact of tumor size on outcomes
after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system. J Thorac
Cardiovasc Surg; Feb 2012. 42.Altorki, N. K., Kamel, M. K., Narula, N., Ghaly, G., Nasar, A., Rahouma, M., Lee, P. C.,
Port, J. L., Stiles, B. M.. Anatomical Segmentectomy and Wedge Resections Are Associated with Comparable Outcomes for
Patients with Small cT1N0 Non-Small Cell Lung Cancer. J Thorac Oncol; Nov 2016. 43.Deng, B., Cassivi, S. D., de Andrade,
M., Nichols, F. C., Trastek, V. F., Wang, Y., Wampfler, J. A., Stoddard, S. M., Wigle, D. A., Shen, R. K., Allen, M. S.,
Deschamps, C., Yang, P.. Clinical outcomes and changes in lung function after segmentectomy versus lobectomy for lung
cancer cases. J Thorac Cardiovasc Surg; Oct 2014. 44.Suzuki, K., Saji, H., Aokage, K., Watanabe, S. I., Okada, M.,
Mizusawa, J., Nakajima, R., Tsuboi, M., Nakamura, S., Nakamura, K., Mitsudomi, T., Asamura, H.. Comparison of pulmonary
segmentectomy and lobectomy: Safety results of a randomized trial. J Thorac Cardiovasc Surg; Sep 2019. Dovrebbe la
segmentectomia vs lobectomia essere utilizzata per pazienti affetti da NSCLC in stadio iniziale POPULATION: Pazienti
affetti da NSCLC in stadio iniziale INTERVENTION: La segmentectomia COMPARISON: Lobectomia MAIN OUTCOMES: Overall
survival RCT; Overall Survival; Disease free survival RCT; Disease free Survival; Quality of life; Number of harvested
lymphonodes; Lengh

63. [outcome] score 11
oplasia polmonare NSCLC T1-2N0 inoperab mediche il trattamento stereotassico è raccomandato rispetto alla radio MEDLINE
(PubMed) (2019 ad Agosto 2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung Neoplasm (("lung
cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung t "Non-small-cell lung cancer"[Title/Abstract] OR
"Non small cell lung cancer"[T NSCLC[Title/Abstract]))))))) AND (("stage T1-2N0"[Title/Abstract] OR "T1-2N0
((("Radiosurgery"[Mesh])) OR ("stereotactic radiotherapy"[Title/Abstract])) Records: 8 Embase (Embase.com) (2019 ad
Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung
tumor' OR 'non-small-cell lung cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 ‘stage T1-2N0’ #5 #3 AND #4 #6
radiosurgery'/exp/mj OR 'stereotactic radiotherapy':ti,ab #7 #5 AND #6 UIDA o-assi mentec entec ng"[M "[Title R "N cance
bile pe oterap ms/sur tumor Title/A 0"[Titl g canc isted thoracic ctomy' OR ctomia anatomica è Mesh]) OR "Lung
e/Abstract] OR "lung Non small cell lung er' OR 'non small cell er controindicazioni pia convenzionale? rgery"[Mesh]) OR
"[Title/Abstract] OR Abstract])) OR le/Abstract]))))) AND cer' OR 'non small NE EOPLASIE DEL POLMONE Q5: Nei pazienti
con NSCLC radicalmente operato una chemioterapia adiuvante con combinazioni a base di cisplatino è raccomandata? MEDLINE
(PubMed) (2019 ad Agosto 2023) (((("Carcinoma, Non-Small-Cell Lung"[Majr]) OR (((((((((lung cancer*[Title/Abstract]) OR
lung tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung neoplasm*[Title/Abstract]) OR lung
carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non small cell lung
cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]) AND radical surgery AND ("Cisplatin"[Mesh] OR
cisplatin[Title/Abstract] Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung
cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'adjuvant chemotherapy'/exp/mj #5 #3 AND #4 Q6: Nei pazienti con NSCLC
radicalmente operato in stadio IB-IIIA e mutazioni attivanti classiche del gene EGFR, una terapia adiuvante con
osimertinib è raccomandata? MEDLINE (PubMed) (1946 ad Agosto 2023) (((((((( "Carcinoma, Non-Small-Cell Lung/drug
therapy"[Mesh] OR "Carcinoma, Non-Small-Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung
tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract]
OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "Non small cell lung carcinoma"[Title/Abstract)) OR
NSCLC[Title/Abstract]))))))))))))))) AND ((((((((((("grade III" OR "stage III" OR advanced OR "advanced disease")))))))
OR (metastas*[Title/Abstract]))) AND (("osimertinib" [Supplementary Concept]) OR (Tagrisso[Title/Abstract] OR
AZD9291[Title/Abstract])))) AND (((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-Analysis" [Publication Type]) OR
("meta- analysis[Title] OR systematic review"[Title] OR "meta analy*"[Title] OR "metaanaly*"[Title] OR "Meta-
Analysis"[Title])) OR ("systema

64. [outcome] score 11
sto 2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung Neoplasms/surgery"[Mesh]) OR (("lung
cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract])) OR NSCLC[Title/Abstract]))))))) AND (("grade
IA"[Title/Abstract] OR "stage IA"[Title/Abstract])))) AND (((("Thoracic Surgery, Video-Assisted"[Mesh]) OR ("VATS
Lobectomy"[Title/Abstract] OR VATS[Title/Abstract] OR "Thoracic Surgeries, Video-Assisted"[Title/Abstract] OR "Video-
assisted Thoracic Surgery (VATS) Lobectomy"[Title/Abstract] OR "Video-assisted Thoracic Surgery"[Title/Abstract]))) OR
("VATS segmentectomy"[Title/Abstract] OR segmentectomy[Title/Abstract])))) AND (((((((((("Randomized Controlled
Trial"[Publication Type]) OR "Clinical Trial"[Publication Type]) OR "drug therapy"[Subheading])) OR
((randomized[Title/Abstract] OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] OR
trial[Title/Abstract] OR groups)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND "Humans"[Mesh]))))) AND
("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) Embase (Embase.com) (2019 ad
Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung
tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'grade ia' OR
'stage ia':de,ti,ab #5 #3 AND #4 NE LINEE GU EOPLASIE DEL POLMONE #6 'vats lobectomy' OR vats OR 'thoracic surgeries,
video-assisted' OR 'video surgery (vats) lobectomy' OR 'video-assisted thoracic surgery' OR 'vats segm
segmentectomy:de,ti,ab #7 #5 AND #6 Q3 GRADE: Nei pazienti affetti da NSCLC in stadio iniziale (IA), la segme
raccomandata (rispetto alla lobectomia)? MEDLINE (PubMed) (2019 a Agosto 2023) (("Lung Neoplasms"[Mesh]) OR "Carcinoma,
Non-Small-Cell Lun Neoplasms"[Mesh]) OR "lung cancer"[Title/Abstract] OR "lung neoplasms" tumor"[Title/Abstract] OR
"Non-small-cell lung cancer"[Title/Abstract] OR cancer"[Title/Abstract] OR NSCLC[Title/Abstract]) Embase (Embase.com)
(2019 a Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR
'lung tumor' OR 'non-small-cell lung lung cancer' OR nsclc:ti,ab Q4: Nei pazienti affetti da neoplasia polmonare NSCLC
T1-2N0 inoperab mediche il trattamento stereotassico è raccomandato rispetto alla radio MEDLINE (PubMed) (2019 ad Agosto
2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung Neoplasm (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung t "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[T
NSCLC[Title/Abstract]))))))) AND (("stage T1-2N0"[Title/Abstract] OR "T1-2N0 ((("Radiosurgery"[Mesh])) OR ("stereotactic
radiotherapy"[Title/Abstract])) Records: 8 Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small
cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cell lung cancer' OR
nsclc:ti,ab #3 #1 OR #2 #4 ‘stage T1-2N0’ #5 #3 AND #4 #6 radiosurgery'/exp/mj OR 'stereotactic radiotherapy':ti,ab #7
#5 AND #6 UIDA o-assi mentec entec ng"[M "[Title R "N cance bile pe oterap ms/sur tu

65. [outcome] score 11
sto 2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung Neoplasms/surgery"[Mesh]) OR (("lung
cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract])) OR NSCLC[Title/Abstract]))))))) AND (("grade
IA"[Title/Abstract] OR "stage IA"[Title/Abstract])))) AND (((("Thoracic Surgery, Video-Assisted"[Mesh]) OR ("VATS
Lobectomy"[Title/Abstract] OR VATS[Title/Abstract] OR "Thoracic Surgeries, Video-Assisted"[Title/Abstract] OR "Video-
assisted Thoracic Surgery (VATS) Lobectomy"[Title/Abstract] OR "Video-assisted Thoracic Surgery"[Title/Abstract]))) OR
("VATS segmentectomy"[Title/Abstract] OR segmentectomy[Title/Abstract])))) AND (((((((((("Randomized Controlled
Trial"[Publication Type]) OR "Clinical Trial"[Publication Type]) OR "drug therapy"[Subheading])) OR
((randomized[Title/Abstract] OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] OR
trial[Title/Abstract] OR groups)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND "Humans"[Mesh]))))) AND
("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) Embase (Embase.com) (2019 ad
Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung
tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'grade ia' OR
'stage ia':de,ti,ab #5 #3 AND #4 NE LINEE GU EOPLASIE DEL POLMONE #6 'vats lobectomy' OR vats OR 'thoracic surgeries,
video-assisted' OR 'video surgery (vats) lobectomy' OR 'video-assisted thoracic surgery' OR 'vats segm
segmentectomy:de,ti,ab #7 #5 AND #6 Q3 GRADE: Nei pazienti affetti da NSCLC in stadio iniziale (IA), la segme
raccomandata (rispetto alla lobectomia)? MEDLINE (PubMed) (2019 a Agosto 2023) (("Lung Neoplasms"[Mesh]) OR "Carcinoma,
Non-Small-Cell Lun Neoplasms"[Mesh]) OR "lung cancer"[Title/Abstract] OR "lung neoplasms" tumor"[Title/Abstract] OR
"Non-small-cell lung cancer"[Title/Abstract] OR cancer"[Title/Abstract] OR NSCLC[Title/Abstract]) Embase (Embase.com)
(2019 a Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR
'lung tumor' OR 'non-small-cell lung lung cancer' OR nsclc:ti,ab Q4: Nei pazienti affetti da neoplasia polmonare NSCLC
T1-2N0 inoperab mediche il trattamento stereotassico è raccomandato rispetto alla radio MEDLINE (PubMed) (2019 ad Agosto
2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung Neoplasm (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung t "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[T
NSCLC[Title/Abstract]))))))) AND (("stage T1-2N0"[Title/Abstract] OR "T1-2N0 ((("Radiosurgery"[Mesh])) OR ("stereotactic
radiotherapy"[Title/Abstract])) Records: 8 Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small
cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cell lung cancer' OR
nsclc:ti,ab #3 #1 OR #2 #4 ‘stage T1-2N0’ #5 #3 AND #4 #6 radiosurgery'/exp/mj OR 'stereotactic radiotherapy':ti,ab #7
#5 AND #6 UIDA o-assi mentec entec ng"[M "[Title R "N cance bile pe oterap ms/sur tu

66. [outcome] score 11
Humans"[Mesh]))))) AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) Embase
(Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung
neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4
'grade ia' OR 'stage ia':de,ti,ab #5 #3 AND #4 NE LINEE GU EOPLASIE DEL POLMONE #6 'vats lobectomy' OR vats OR 'thoracic
surgeries, video-assisted' OR 'video surgery (vats) lobectomy' OR 'video-assisted thoracic surgery' OR 'vats segm
segmentectomy:de,ti,ab #7 #5 AND #6 Q3 GRADE: Nei pazienti affetti da NSCLC in stadio iniziale (IA), la segme
raccomandata (rispetto alla lobectomia)? MEDLINE (PubMed) (2019 a Agosto 2023) (("Lung Neoplasms"[Mesh]) OR "Carcinoma,
Non-Small-Cell Lun Neoplasms"[Mesh]) OR "lung cancer"[Title/Abstract] OR "lung neoplasms" tumor"[Title/Abstract] OR
"Non-small-cell lung cancer"[Title/Abstract] OR cancer"[Title/Abstract] OR NSCLC[Title/Abstract]) Embase (Embase.com)
(2019 a Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR
'lung tumor' OR 'non-small-cell lung lung cancer' OR nsclc:ti,ab Q4: Nei pazienti affetti da neoplasia polmonare NSCLC
T1-2N0 inoperab mediche il trattamento stereotassico è raccomandato rispetto alla radio MEDLINE (PubMed) (2019 ad Agosto
2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung Neoplasm (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung t "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[T
NSCLC[Title/Abstract]))))))) AND (("stage T1-2N0"[Title/Abstract] OR "T1-2N0 ((("Radiosurgery"[Mesh])) OR ("stereotactic
radiotherapy"[Title/Abstract])) Records: 8 Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small
cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cell lung cancer' OR
nsclc:ti,ab #3 #1 OR #2 #4 ‘stage T1-2N0’ #5 #3 AND #4 #6 radiosurgery'/exp/mj OR 'stereotactic radiotherapy':ti,ab #7
#5 AND #6 UIDA o-assi mentec entec ng"[M "[Title R "N cance bile pe oterap ms/sur tumor Title/A 0"[Titl g canc isted
thoracic ctomy' OR ctomia anatomica è Mesh]) OR "Lung e/Abstract] OR "lung Non small cell lung er' OR 'non small cell er
controindicazioni pia convenzionale? rgery"[Mesh]) OR "[Title/Abstract] OR Abstract])) OR le/Abstract]))))) AND cer' OR
'non small NE EOPLASIE DEL POLMONE Q5: Nei pazienti con NSCLC radicalmente operato una chemioterapia adiuvante con
combinazioni a base di cisplatino è raccomandata? MEDLINE (PubMed) (2019 ad Agosto 2023) (((("Carcinoma, Non-Small-Cell
Lung"[Majr]) OR (((((((((lung cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract])
OR lung neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract])
OR non small cell lung cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]) AND radical surgery AND ("Cisplatin"[Mesh] OR
cisplatin[Title/Abstract] Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small

67. [outcome] score 11
)) AND (("stage T1-2N0"[Title/Abstract] OR "T1-2N0 ((("Radiosurgery"[Mesh])) OR ("stereotactic
radiotherapy"[Title/Abstract])) Records: 8 Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small
cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cell lung cancer' OR
nsclc:ti,ab #3 #1 OR #2 #4 ‘stage T1-2N0’ #5 #3 AND #4 #6 radiosurgery'/exp/mj OR 'stereotactic radiotherapy':ti,ab #7
#5 AND #6 UIDA o-assi mentec entec ng"[M "[Title R "N cance bile pe oterap ms/sur tumor Title/A 0"[Titl g canc isted
thoracic ctomy' OR ctomia anatomica è Mesh]) OR "Lung e/Abstract] OR "lung Non small cell lung er' OR 'non small cell er
controindicazioni pia convenzionale? rgery"[Mesh]) OR "[Title/Abstract] OR Abstract])) OR le/Abstract]))))) AND cer' OR
'non small NE EOPLASIE DEL POLMONE Q5: Nei pazienti con NSCLC radicalmente operato una chemioterapia adiuvante con
combinazioni a base di cisplatino è raccomandata? MEDLINE (PubMed) (2019 ad Agosto 2023) (((("Carcinoma, Non-Small-Cell
Lung"[Majr]) OR (((((((((lung cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract])
OR lung neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract])
OR non small cell lung cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]) AND radical surgery AND ("Cisplatin"[Mesh] OR
cisplatin[Title/Abstract] Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung
cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'adjuvant chemotherapy'/exp/mj #5 #3 AND #4 Q6: Nei pazienti con NSCLC
radicalmente operato in stadio IB-IIIA e mutazioni attivanti classiche del gene EGFR, una terapia adiuvante con
osimertinib è raccomandata? MEDLINE (PubMed) (1946 ad Agosto 2023) (((((((( "Carcinoma, Non-Small-Cell Lung/drug
therapy"[Mesh] OR "Carcinoma, Non-Small-Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung
tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract]
OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "Non small cell lung carcinoma"[Title/Abstract)) OR
NSCLC[Title/Abstract]))))))))))))))) AND ((((((((((("grade III" OR "stage III" OR advanced OR "advanced disease")))))))
OR (metastas*[Title/Abstract]))) AND (("osimertinib" [Supplementary Concept]) OR (Tagrisso[Title/Abstract] OR
AZD9291[Title/Abstract])))) AND (((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-Analysis" [Publication Type]) OR
("meta- analysis[Title] OR systematic review"[Title] OR "meta analy*"[Title] OR "metaanaly*"[Title] OR "Meta-
Analysis"[Title])) OR ("systematic literature review"[Title])) OR ("systematic review"[Title/Abstract])) OR
(((("Randomized Controlled Trial" [Publication Type]) OR "Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical
Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
randomly[Title/Abstract])))))) Embase (Embase.com) (1974 ad Agosto 2023) #1 'lung tumor'/exp OR 'non s

68. [outcome] score 11
"systematic literature review"[Title])) OR ("systematic review"[Title/Abstract])) OR (((("Randomized Controlled
Trial"[Publication Type]) OR "Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical Trial" [Publication Type])) OR
(randomized[Title/Abstract] OR randomised[Title/Abstract] OR randomly[Title/Abstract]))))))) Embase (Embase.com) (2018
ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung
tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #31 OR #32 #4 durvalumab #5 #3
AND #4 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim
OR 'controlled clinical trial'/de) Q13 GRADE: Nei pazienti affetti da NSCLC in stadio avanzato oligometastatico, un
trattamento locoregionale in associazione alla terapia sistemica è raccomandato (rispetto alla sola terapia sistemica)?
MEDLINE (PubMed) (2019 a marzo 2021) (("Lung Neoplasms"[Mesh]) OR "Carcinoma, Non-Small-Cell Lung"[Mesh]) OR "Lung
Neoplasms"[Mesh]) OR "lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract]
OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR
NSCLC[Title/Abstract]) AND oligometastatic[Title/Abstract])) AND (therapy[Title/Abstract] AND (systemic[Title/Abstract]
OR locoregional[Title/Abstract])) Embase (Embase.com) (2019 a marzo 2021) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung
cancer' OR nsclc:ti,ab Q14: Nei pazienti affetti da NSCLC in stadio localmente avanzato o metastatico, con mutazioni
attivanti classiche del gene EGFR (Ex19dels e L858R), il trattamento di prima linea con inibitore tirosino-chinasico di
EGFR osimertinib è raccomandato (rispetto agli inibitori tirosino-chinasici gefitinib e/o erlotinib)? MEDLINE (PubMed)
(2021 ad Agosto 2023) ((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung Neoplasms/pathology"[Mesh] ))) OR (("lung
cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung
carcinoma"[Title/Abstract] OR "Non small cell lung NE EOPLASIE DEL POLMONE carcinoma"[Title/Abstract)) OR
NSCLC[Title/Abstract]))))))))))))))) AND (((((((((((("grade III" OR "stage III" OR advanced OR "advanced disease")))))))
OR (metastas*[Title/Abstract]))))) AND (("osimertinib" [Supplementary Concept]) OR (osimertinib[Title/Abstract]))) AND
(((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic
review"[Title] OR "meta analy*"[Title] OR "metaanaly*"[Title] OR "Meta-Analysis"[Title])) OR ("systematic literature
review"[Title])) OR ("systematic review"[Title/Abstract])) OR (((("Randomized Controlled Trial"[Publication Type]) OR
"Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical Trial" [Publication Type])) OR (randomized[Title/Abstract]
OR randomised[Title/Abstract] OR randomly[Ti

69. [outcome] score 11
non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #38 #35 OR #36 OR #37 #39 'metastasis'/exp/mj
#40 'neoplasm metastasis' OR metasta* OR 'stage 4' OR 'stage iv' OR advanced OR recurrence* OR relapse*:ti,ab #41 #39 OR
#40 #42 #38 AND #41 #43 'entrectinib'/exp/mj OR 'larotrectinib'/exp/mj OR ('entrectinib' OR 'larotrectinib' OR vitrakv
OR rozlytrek:ti,ab) Records: 157 Selezionati 4 records Q26: Nei pazienti affetti da NSCLC in stadio avanzato con
riarrangiamenti di RET, in progressione dopo precedente trattamento con chemioterapia a base di platino, un trattamento
con selpercatinib è raccomandato (rispetto alla chemioterapia)? MEDLINE (PubMed) (1976 ad Agosto 2023) ((((((((((((((((
"Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell Lung/pathology"[Mesh] )) OR ( "Lung
Neoplasms/drug therapy"[Mesh] OR "Lung Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small
cell lung cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "Non small cell lung
carcinoma"[Title/Abstract)) OR NSCLC[Title/Abstract]))))))))))))))))) ) AND (("RET"[Title/Abstract]) AND
("selpercatinib" [Supplementary Concept]) OR "pralsetinib" [Supplementary Concept] OR ((selpercatinib[Title/Abstract] OR
pralsetinib[Title/Abstract])) Embase (Embase.com) (1974 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung
cancer' OR nsclc:ti,ab #3 'grade iii' OR 'stage iii' OR advanced OR 'advanced disease' NEAR/7 (RET) #4 (#1 OR #2) AND #3
#5 'selpercatinib'/exp/mj OR 'pralsetinib'/exp/mj #6 selpercatinib OR pralsetinib:ti,ab #7 #4 AND (#5 OR #6) Records:
220 Selezionati 3 records Q27: Nei pazienti affetti da NSCLC in stadio avanzato con skipping esone 14 di MET, in
progressione dopo precedente trattamento con immunoterapia e/o chemioterapia a base di platino, un trattamento con
capmatinib è raccomandato (rispetto alla chemioterapia)? NE EOPLASIE DEL POLMONE Q28: Nei pazienti affetti da NSCLC in
stadio avanzato con skipping esone 14 di MET, in progressione dopo precedente trattamento con immunoterapia e/o
chemioterapia a base di platino, un trattamento con tepotinib è raccomandato (rispetto alla chemioterapia)? Q29: Nei
pazienti affetti da NSCLC metastatico, con mutazione p.G12C del gene KRAS, in progressione dopo precedente trattamento
chemioterapico a base di platino, un trattamento con sotorasib è raccomandato (rispetto alla chemioterapia)? MEDLINE
(PubMed) (1946 ad Agosto 2023) (((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma,
Non-Small-Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung Neoplasms/pathology"[Mesh] )))
OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-
cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung
carcinoma"[Title/Abstract] OR "Non small cell lung carcinoma"[Title/Abstract)) OR
NSCLC[Title/Abstract])))))))))))))))))))) AND (((((((((((("grade III"

70. [outcome] score 11
t]))))))) AND (("grade IA"[Title/Abstract] OR "stage IA"[Title/Abstract])))) AND (((("Thoracic Surgery, Video-
Assisted"[Mesh]) OR ("VATS Lobectomy"[Title/Abstract] OR VATS[Title/Abstract] OR "Thoracic Surgeries, Video-
Assisted"[Title/Abstract] OR "Video-assisted Thoracic Surgery (VATS) Lobectomy"[Title/Abstract] OR "Video-assisted
Thoracic Surgery"[Title/Abstract]))) OR ("VATS segmentectomy"[Title/Abstract] OR segmentectomy[Title/Abstract])))) AND
(((((((((("Randomized Controlled Trial"[Publication Type]) OR "Clinical Trial"[Publication Type]) OR "drug
therapy"[Subheading])) OR ((randomized[Title/Abstract] OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR
randomly[Title/Abstract] OR trial[Title/Abstract] OR groups)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND
"Humans"[Mesh]))))) AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) Embase
(Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung
neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4
'grade ia' OR 'stage ia':de,ti,ab #5 #3 AND #4 NE LINEE GU EOPLASIE DEL POLMONE #6 'vats lobectomy' OR vats OR 'thoracic
surgeries, video-assisted' OR 'video surgery (vats) lobectomy' OR 'video-assisted thoracic surgery' OR 'vats segm
segmentectomy:de,ti,ab #7 #5 AND #6 Q3 GRADE: Nei pazienti affetti da NSCLC in stadio iniziale (IA), la segme
raccomandata (rispetto alla lobectomia)? MEDLINE (PubMed) (2019 a Agosto 2023) (("Lung Neoplasms"[Mesh]) OR "Carcinoma,
Non-Small-Cell Lun Neoplasms"[Mesh]) OR "lung cancer"[Title/Abstract] OR "lung neoplasms" tumor"[Title/Abstract] OR
"Non-small-cell lung cancer"[Title/Abstract] OR cancer"[Title/Abstract] OR NSCLC[Title/Abstract]) Embase (Embase.com)
(2019 a Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR
'lung tumor' OR 'non-small-cell lung lung cancer' OR nsclc:ti,ab Q4: Nei pazienti affetti da neoplasia polmonare NSCLC
T1-2N0 inoperab mediche il trattamento stereotassico è raccomandato rispetto alla radio MEDLINE (PubMed) (2019 ad Agosto
2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung Neoplasm (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung t "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[T
NSCLC[Title/Abstract]))))))) AND (("stage T1-2N0"[Title/Abstract] OR "T1-2N0 ((("Radiosurgery"[Mesh])) OR ("stereotactic
radiotherapy"[Title/Abstract])) Records: 8 Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small
cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cell lung cancer' OR
nsclc:ti,ab #3 #1 OR #2 #4 ‘stage T1-2N0’ #5 #3 AND #4 #6 radiosurgery'/exp/mj OR 'stereotactic radiotherapy':ti,ab #7
#5 AND #6 UIDA o-assi mentec entec ng"[M "[Title R "N cance bile pe oterap ms/sur tumor Title/A 0"[Titl g canc isted
thoracic ctomy' OR ctomia anatomica è Mesh]) OR "Lung e/Abstract] OR "lung Non small cell lung er' OR 'non small cell er
controindicazioni pia convenzionale? rgery"[Mesh]) OR "[Title/Abstract] OR Abstract])) OR le/Abstract]))))) AND cer' OR
'non small NE EOPLASIE DEL POLMONE Q

71. [outcome] score 11
are NSCLC T1-2N0 inoperab mediche il trattamento stereotassico è raccomandato rispetto alla radio MEDLINE (PubMed) (2019
ad Agosto 2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung Neoplasm (("lung
cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung t "Non-small-cell lung cancer"[Title/Abstract] OR
"Non small cell lung cancer"[T NSCLC[Title/Abstract]))))))) AND (("stage T1-2N0"[Title/Abstract] OR "T1-2N0
((("Radiosurgery"[Mesh])) OR ("stereotactic radiotherapy"[Title/Abstract])) Records: 8 Embase (Embase.com) (2019 ad
Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung
tumor' OR 'non-small-cell lung cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 ‘stage T1-2N0’ #5 #3 AND #4 #6
radiosurgery'/exp/mj OR 'stereotactic radiotherapy':ti,ab #7 #5 AND #6 UIDA o-assi mentec entec ng"[M "[Title R "N cance
bile pe oterap ms/sur tumor Title/A 0"[Titl g canc isted thoracic ctomy' OR ctomia anatomica è Mesh]) OR "Lung
e/Abstract] OR "lung Non small cell lung er' OR 'non small cell er controindicazioni pia convenzionale? rgery"[Mesh]) OR
"[Title/Abstract] OR Abstract])) OR le/Abstract]))))) AND cer' OR 'non small NE EOPLASIE DEL POLMONE Q5: Nei pazienti
con NSCLC radicalmente operato una chemioterapia adiuvante con combinazioni a base di cisplatino è raccomandata? MEDLINE
(PubMed) (2019 ad Agosto 2023) (((("Carcinoma, Non-Small-Cell Lung"[Majr]) OR (((((((((lung cancer*[Title/Abstract]) OR
lung tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung neoplasm*[Title/Abstract]) OR lung
carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non small cell lung
cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]) AND radical surgery AND ("Cisplatin"[Mesh] OR
cisplatin[Title/Abstract] Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung
cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'adjuvant chemotherapy'/exp/mj #5 #3 AND #4 Q6: Nei pazienti con NSCLC
radicalmente operato in stadio IB-IIIA e mutazioni attivanti classiche del gene EGFR, una terapia adiuvante con
osimertinib è raccomandata? MEDLINE (PubMed) (1946 ad Agosto 2023) (((((((( "Carcinoma, Non-Small-Cell Lung/drug
therapy"[Mesh] OR "Carcinoma, Non-Small-Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung
tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract]
OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "Non small cell lung carcinoma"[Title/Abstract)) OR
NSCLC[Title/Abstract]))))))))))))))) AND ((((((((((("grade III" OR "stage III" OR advanced OR "advanced disease")))))))
OR (metastas*[Title/Abstract]))) AND (("osimertinib" [Supplementary Concept]) OR (Tagrisso[Title/Abstract] OR
AZD9291[Title/Abstract])))) AND (((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-Analysis" [Publication Type]) OR
("meta- analysis[Title] OR systematic review"[Title] OR "meta analy*"[Title] OR "metaanaly*"[Title] OR "Meta-
Analysis"[Title])) OR ("systema

72. [outcome] score 11
All Fields] OR "resectates"[All Fields] OR "resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields]
OR "resectional"[All Fields] OR "resectioned"[All Fields] OR "resectioning"[All Fields] OR "resections"[All Fields] OR
"resective"[All Fields] OR "resects"[All Fields]) AND ("lung"[MeSH Terms] OR "lung"[All Fields]) AND ("cancer s"[All
Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR "cancerized"[All
Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR
"cancers"[All Fields])) AND (meta-analysis[Filter] OR randomizedcontrolledtrial[Filter] OR systematicreview[Filter])
Q10: Nei pazienti con NSCLC in stadio IIIA/IIIB non resecabile, o IIIC un trattamento di chemio- radioterapia a dosi
radicali concomitante è raccomandato (rispetto alla sequenziale)? MEDLINE (PubMed) (2019 ad Agosto 2023)
((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp]) OR ((((((((((lung cancer*[Title/Abstract]) OR lung
tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung neoplasm*[Title/Abstract]) OR lung
carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non small cell lung
cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))))))) AND (((grade iii OR stage iii OR advance OR locally advanced
disease)) AND (inoperable OR surgically unresectable)))) AND (("Chemoradiotherapy"[Mesh]) OR
(("Chemoradiotherapy"[Mesh]) OR ("chemoradiotherapy"[Title/Abstract] OR "radiochemotherapy"[Title/Abstract] OR
"concomitant radiochemotherapy"[Title/Abstract]))) Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non
small cell lung cancer'/exp NE EOPLASIE DEL POLMONE #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-
cell lung cancer' OR 'non sma cell lung cancer' OR nsclc:ti,ab #3 #31 OR #32 #4 ('grade iii' OR 'stage iii' OR advance
OR 'locally-advanced disease') NEAR/5 ('inoperable' OR 'surgically unresectable') #5 #33 AND #34 #6
'radiotherapy'/exp/mj OR 'chemotherapy'/exp/mj #7 'radiotherapy' OR 'chemotherapy':de,ti,ab #8 #6 OR #7 #9 #5 AND #8
Q11: Nei pazienti con NSCLC in stadio IIIA/IIIB non resecabile, o IIIC, esiste un regi chemioterapico raccomandato da
eseguire in associazione alla radioterapia? MEDLINE (PubMed) (1966 ad Agosto 2023) ((((((((("Carcinoma, Non-Small-Cell
Lung/radiotherapy"[Majr:noexp]) OR ((((((((((lung cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung
tumour*[Title/Abstract]) OR lung neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lung
cancer*[Title/Abstract]) OR non small cell lung cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract])) AND (((grade iii OR
stage iii OR advance OR locally advanced disease)) AND (inoperable OR surgically unresectable)))))) AND "Antineoplastic
Combined Chemotherapy Protocols"[Mesh] Embase (Embase.com) (1974 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell
lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non sma cell
lung cancer' OR nsclc:ti,ab #3 #31 OR #32 #4 ('grade iii' OR 'stage iii' OR advance OR 'locally-advanced disease')
NEAR/5 ('inoperable' OR 'surgically unresectable') #5 #3 AND #4 #6 Antineoplastic Combined Chemotherapy

73. [outcome] score 11
OR systematic review"[Title] OR "meta analy*"[Title] OR "metaanaly*"[Title] OR "Meta-Analysis"[Title])) OR ("systematic
literature review"[Title])) OR ("systematic review"[Title/Abstract])) OR (((("Randomized Controlled Trial"[Publication
Type]) OR "Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical Trial" [Publication Type])) OR
(randomized[Title/Abstract] OR randomised[Title/Abstract] OR randomly[Title/Abstract])))))))) Embase (Embase.com) (2021
ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung
tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 'grade iii' OR 'stage iii' OR
advanced OR 'advanced disease' NEAR/7 (egfr OR 'egfr mutated') #4 (#1 OR #2) AND #3 #5 'osimertinib'/exp #6
'osimertinib':ti,ab #7 #5 OR #6 #8 #4 AND #7 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta
analysis]/lim OR [randomized controlled trial]/lim OR 'controlled clinical trial'/de) Q15: Nei pazienti affetti da NSCLC
in stadio localmente avanzato o metastatico, con mutazioni non comuni di EGFR (eccetto le inserzioni dell’esone 20), un
trattamento di prima linea con inibitore tirosino-chinasico di EGFR afatinib o osimertinib è raccomandato (rispetto alla
chemioterapia)? MEDLINE (PubMed) (1966 a dicembre 2023) (((("Carcinoma, Non-Small-Cell Lung"[Majr]) AND "EGFR,
uncommon"[Majr])) OR (((((((((lung cancer*[Title/Abstract]) OR lung tumor*[Title/Abstract]) OR lung
tumour*[Title/Abstract]) OR lung neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR non-small cell lung
cancer*[Title/Abstract]) OR non small cell lung cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]) AND EGFR,
uncommon*[Title/Abstract])) Embase (Embase.com) (1974 a dicembre 2023) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung
cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'egfr uncommon':ti,ab #5 #3 AND #4 NE EOPLASIE DEL POLMONE Q16: Nei pazienti
affetti da NSCLC metastatico, con inserzioni dell’esone 20 del gene EGFR, in progressione dopo precedente trattamento
chemioterapico a base di platino, un trattamento con amivantamab è raccomandato (rispetto alla chemioterapia)? MEDLINE
(PubMed) (2021 ad Agosto 2023) ((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung Neoplasms/pathology"[Mesh] ))) OR
(("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell
lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung
carcinoma"[Title/Abstract] OR "Non small cell lung carcinoma"[Title/Abstract)) OR NSCLC[Title/Abstract])))))))))))))))
AND (((((((((((("grade III" OR "stage III" OR advanced OR "advanced disease"))))))) OR (metastas*[Title/Abstract])))))
AND AND (("amivantamab " [Supplementary Concept]) OR amivantamab [Title/Abstract])))) AND (((((((((((("Meta- Analysis as
Topic"[Mesh]) OR "Meta-Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta
analy*"[Title] OR "metaanaly*"[Title] OR "Meta-Analysis"[Title])) OR ("systemat

74. [outcome] score 11
stasis'/exp/mj #40 'neoplasm metastasis' OR metasta* OR 'stage 4' OR 'stage iv' OR advanced OR recurrence* OR
relapse*:ti,ab #41 #39 OR #40 #42 #39 OR #40 OR #41 #43 #38 AND #42 #44 'braf v600 mutation*' OR 'braf- mutation*' OR
'val600 braf-mutation*':ti,ab #45 #43 AND #44 #46 'dabrafenib'/exp/mj #47 'trametinib'/exp/mj #48 dabrafenib OR
tafinlar:ti,ab #49 #46 OR #48 #50 trametinib OR mekinist:ti,ab #51 #47 OR #50 #52 #49 AND #51 #53 #45 AND #52 #54 #53
AND #54 Records: 0 Selezionati 2 records Q25: Nei pazienti affetti da NSCLC in stadio localmente avanzato o metastatico,
con fusione di NTRK, un trattamento di prima linea con inibitore tirosino-chinasico di NTRK entrectinib o larotrectinib
è raccomandato? MEDLINE (PubMed) (1966 ad Agosto 2023) (((((((((((((((((((((((((((((((("Lung Neoplasms"[Mesh]) OR
"Carcinoma, Non-Small-Cell Lung"[Mesh]) OR ("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung
tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract]))
OR NSCLC[Title/Abstract])))))))) AND (((((("Neoplasm Metastasis"[Mesh]) OR "Recurrence"[Mesh])) OR ("neoplasm
metastasis"[Title/Abstract] OR metasta*[Title/Abstract] OR "stage 4"[Title/Abstract] OR "stage IV"[Title/Abstract] OR
advanced[Title/Abstract] OR Recurrence*[Title/Abstract] OR relapse*[Title/Abstract])))))))))))) AND ((("larotrectinib"
[Supplementary Concept]) OR NE EOPLASIE DEL POLMONE (Vitrakvi[Title/Abstract])) OR (("entrectinib" [Supplementary
Concept]) OR (entrectinib[Title/Abstract] OR Rozlytrek[Title/Abstract]))) Embase (Embase.com) (1974 ad Agosto 2023) #35
'non small cell lung cancer'/exp/mj #36 'lung cancer'/exp/mj #37 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR
'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #38 #35 OR #36 OR #37 #39
'metastasis'/exp/mj #40 'neoplasm metastasis' OR metasta* OR 'stage 4' OR 'stage iv' OR advanced OR recurrence* OR
relapse*:ti,ab #41 #39 OR #40 #42 #38 AND #41 #43 'entrectinib'/exp/mj OR 'larotrectinib'/exp/mj OR ('entrectinib' OR
'larotrectinib' OR vitrakv OR rozlytrek:ti,ab) Records: 157 Selezionati 4 records Q26: Nei pazienti affetti da NSCLC in
stadio avanzato con riarrangiamenti di RET, in progressione dopo precedente trattamento con chemioterapia a base di
platino, un trattamento con selpercatinib è raccomandato (rispetto alla chemioterapia)? MEDLINE (PubMed) (1976 ad Agosto
2023) (((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung Neoplasms/pathology"[Mesh] ))) OR (("lung
cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung
carcinoma"[Title/Abstract] OR "Non small cell lung carcinoma"[Title/Abstract)) OR NSCLC[Title/Abstract])))))))))))))))))
) AND (("RET"[Title/Abstract]) AND ("selpercatinib" [Supplementary Concept]) OR "pralsetinib" [Supplementary Concept] OR
((selpercatinib[Title/Abstract] OR pralsetinib[Title/Abstract])) Embase (Embase.com) (1974 ad Agosto 2023) #1 'lung
tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung ne

75. [outcome] score 11
((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung Neoplasms/surgery"[Mesh]) OR (("lung cancer"[Title/Abstract]
OR "lung neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR
"Non small cell lung cancer"[Title/Abstract])) OR NSCLC[Title/Abstract]))))))) AND (("grade IA"[Title/Abstract] OR
"stage IA"[Title/Abstract])))) AND (((("Thoracic Surgery, Video-Assisted"[Mesh]) OR ("VATS Lobectomy"[Title/Abstract] OR
VATS[Title/Abstract] OR "Thoracic Surgeries, Video-Assisted"[Title/Abstract] OR "Video-assisted Thoracic Surgery (VATS)
Lobectomy"[Title/Abstract] OR "Video-assisted Thoracic Surgery"[Title/Abstract]))) OR ("VATS
segmentectomy"[Title/Abstract] OR segmentectomy[Title/Abstract])))) AND (((((((((("Randomized Controlled
Trial"[Publication Type]) OR "Clinical Trial"[Publication Type]) OR "drug therapy"[Subheading])) OR
((randomized[Title/Abstract] OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] OR
trial[Title/Abstract] OR groups)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND "Humans"[Mesh]))))) AND
("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) Embase (Embase.com) (2019 ad
Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung
tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'grade ia' OR
'stage ia':de,ti,ab #5 #3 AND #4 NE LINEE GU EOPLASIE DEL POLMONE #6 'vats lobectomy' OR vats OR 'thoracic surgeries,
video-assisted' OR 'video surgery (vats) lobectomy' OR 'video-assisted thoracic surgery' OR 'vats segm
segmentectomy:de,ti,ab #7 #5 AND #6 Q3 GRADE: Nei pazienti affetti da NSCLC in stadio iniziale (IA), la segme
raccomandata (rispetto alla lobectomia)? MEDLINE (PubMed) (2019 a Agosto 2023) (("Lung Neoplasms"[Mesh]) OR "Carcinoma,
Non-Small-Cell Lun Neoplasms"[Mesh]) OR "lung cancer"[Title/Abstract] OR "lung neoplasms" tumor"[Title/Abstract] OR
"Non-small-cell lung cancer"[Title/Abstract] OR cancer"[Title/Abstract] OR NSCLC[Title/Abstract]) Embase (Embase.com)
(2019 a Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR
'lung tumor' OR 'non-small-cell lung lung cancer' OR nsclc:ti,ab Q4: Nei pazienti affetti da neoplasia polmonare NSCLC
T1-2N0 inoperab mediche il trattamento stereotassico è raccomandato rispetto alla radio MEDLINE (PubMed) (2019 ad Agosto
2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung Neoplasm (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung t "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[T
NSCLC[Title/Abstract]))))))) AND (("stage T1-2N0"[Title/Abstract] OR "T1-2N0 ((("Radiosurgery"[Mesh])) OR ("stereotactic
radiotherapy"[Title/Abstract])) Records: 8 Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small
cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cell lung cancer' OR
nsclc:ti,ab #3 #1 OR #2 #4 ‘stage T1-2N0’ #5 #3 AND #4 #6 radiosurgery'/exp/mj OR 'stereotactic radiotherapy':ti,ab #7
#5 AND #6 UIDA o-assi mentec entec ng"[M "[Title R "N cance bile pe oterap ms/sur tu

76. [outcome] score 11
((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung Neoplasms/surgery"[Mesh]) OR (("lung cancer"[Title/Abstract]
OR "lung neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR
"Non small cell lung cancer"[Title/Abstract])) OR NSCLC[Title/Abstract]))))))) AND (("grade IA"[Title/Abstract] OR
"stage IA"[Title/Abstract])))) AND (((("Thoracic Surgery, Video-Assisted"[Mesh]) OR ("VATS Lobectomy"[Title/Abstract] OR
VATS[Title/Abstract] OR "Thoracic Surgeries, Video-Assisted"[Title/Abstract] OR "Video-assisted Thoracic Surgery (VATS)
Lobectomy"[Title/Abstract] OR "Video-assisted Thoracic Surgery"[Title/Abstract]))) OR ("VATS
segmentectomy"[Title/Abstract] OR segmentectomy[Title/Abstract])))) AND (((((((((("Randomized Controlled
Trial"[Publication Type]) OR "Clinical Trial"[Publication Type]) OR "drug therapy"[Subheading])) OR
((randomized[Title/Abstract] OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] OR
trial[Title/Abstract] OR groups)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND "Humans"[Mesh]))))) AND
("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) Embase (Embase.com) (2019 ad
Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung
tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'grade ia' OR
'stage ia':de,ti,ab #5 #3 AND #4 NE LINEE GU EOPLASIE DEL POLMONE #6 'vats lobectomy' OR vats OR 'thoracic surgeries,
video-assisted' OR 'video surgery (vats) lobectomy' OR 'video-assisted thoracic surgery' OR 'vats segm
segmentectomy:de,ti,ab #7 #5 AND #6 Q3 GRADE: Nei pazienti affetti da NSCLC in stadio iniziale (IA), la segme
raccomandata (rispetto alla lobectomia)? MEDLINE (PubMed) (2019 a Agosto 2023) (("Lung Neoplasms"[Mesh]) OR "Carcinoma,
Non-Small-Cell Lun Neoplasms"[Mesh]) OR "lung cancer"[Title/Abstract] OR "lung neoplasms" tumor"[Title/Abstract] OR
"Non-small-cell lung cancer"[Title/Abstract] OR cancer"[Title/Abstract] OR NSCLC[Title/Abstract]) Embase (Embase.com)
(2019 a Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR
'lung tumor' OR 'non-small-cell lung lung cancer' OR nsclc:ti,ab Q4: Nei pazienti affetti da neoplasia polmonare NSCLC
T1-2N0 inoperab mediche il trattamento stereotassico è raccomandato rispetto alla radio MEDLINE (PubMed) (2019 ad Agosto
2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung Neoplasm (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung t "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[T
NSCLC[Title/Abstract]))))))) AND (("stage T1-2N0"[Title/Abstract] OR "T1-2N0 ((("Radiosurgery"[Mesh])) OR ("stereotactic
radiotherapy"[Title/Abstract])) Records: 8 Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small
cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cell lung cancer' OR
nsclc:ti,ab #3 #1 OR #2 #4 ‘stage T1-2N0’ #5 #3 AND #4 #6 radiosurgery'/exp/mj OR 'stereotactic radiotherapy':ti,ab #7
#5 AND #6 UIDA o-assi mentec entec ng"[M "[Title R "N cance bile pe oterap ms/sur tu

77. [population] score 10
anemia (follow up: median 14.5 months; assessed with: NCI-CTCAE 4.03) 1 randomised not serious a not serious serious b
serious f trials IE DEL POLMONE none 133/443 (30.0%) 38/213 (17.8%) RR 1.68 12 more ⨁⨁⨁◯ IMPORTANT (1.22 to 2.32) per
100 MODERATE (from 4 more to 24 more) none 27/126 (21.4%) c 12/34 (35.3%) c HR 0.43 18 fewer ⨁⨁⨁◯ IMPORTANT (0.22 to
0.84) per 100 MODERATE (from 26 fewer to 5 fewer) - - - - - - CRITICAL none 21/475 (4.4%) 9/234 (3.8%) RR 1.15 1 more
⨁⨁◯◯ CRITICAL (0.53 to 2.47) per 100 LOW (from 2 fewer to 6 more) sessed with: NCI-CTCAE 4.03)g none 16/475 (3.4%) 6/234
(2.6%) RR 1.31 1 more ⨁⨁◯◯ CRITICAL (0.52 to 3.31) per 100 LOW (from 1 fewer to 6 more) none 14/475 (2.9%) 8/234 (3.4%)
RR 0.86 0 fewer ⨁⨁◯◯ CRITICAL (0.37 to 2.03) per 100 LOW (from 2 fewer to 4 more) Grade 3-4 adverse events (follow up:
median 14.5 months; assessed with: NCI-CTCAE 4.03) 1 randomised not serious a not serious serious b serious f none
145/475 (30.5%) 61/234 (26.1%) RR 1.17 4 more ⨁⨁◯◯ CRITICAL trials (0.90 to 1.51) per 100 LOW (from 3 fewer to 13 more)
1 randomised not serious not serious serious b serious f none 7/475 (1.5%) 3/234 (1.3%) RR 1.15 0 fewer ⨁⨁◯◯ CRITICAL
trials (0.30 to 4.41) per 100 LOW (from 1 fewer to 4 more) CI: Confidence interval; HR: Hazard Ratio; RR: Risk ratio;
MD: Mean difference Explanations a. We cannot exclude the risk of selection bias due to the lack of information.
Progression free survival/Objective response and duraion of response were assessed by means of blinded independent
central review; patients-reported outcome had an high risk of performance bias b. Outcome data reported in the overall
population c. Number of patients with a tumor response. The tumor response was assessed by an independent centralized
review d. More than the 80% of patients in both arms completed the questionnaire. Data extracted from a ESMO 2017
communication (.ppt) e. A deterioration or an improvement is defined, according to the QLQ-LC13 questionnaire, a score
variation >= +-10 from baseline f. The 95% CI includes both negligible effect and appreciable benefit or appreciable
harm. For all these reasons we decided to downgrade the quality of the evidence by two levels for this outcome g .
“pneumonitis” term included “acute interstitial pneumonitis, interstitial lung disease, pneumonitis and pulmonary
fibrosis”. QUESITO 12: N chemio-radioter consolidamento POPOLAZIONE: INTERVENTO: CONFRONTO: ESITI PRINCIPALI: SETTING:
BACKGROUND: Il problema è una priorità? GIUDIZI ○ No ○ Probabilmente no Nei pazienti affetti da NSCLC in stadio III non
resecabile, in risposta o stabilità di malattia dopo trattamento rapico a dosi radicali e con espressione di PD-L1 sulle
cellule tumorali superiore o uguale a 1%, una terapia di o con durvalumab è raccomandata rispetto all’osservazione?
Pazienti affetti da NSCLC in stadio III non resecabile, in risposta o stabilità di malattia dopo trattamento chemio-
radioterapico a dosi radicali e con espressione del PD-L1 sulle cellule tumorali superiore o uguale a 1% Durvalumab
Osservazione Sopravvivenza globale; sopravvivenza libera da malattia; metastasi a distanza; controllo locale di
malattia; tasso di risposte obiettive; durata delle risposte; qualità di vita; eventi avversi di grado 3-4; polmoniti di
grado 3-4; morti corr

78. [population] score 10 ✅ BINGO (PIO)
to 11 more) 9 RR 0.80 16 fewer ⨁◯◯◯ CRITICAL ) (0.73 to per 100 VERY LOW 0.88) (from 21 fewer to 9 fewer) a. Unclear
risk of attrition bias in both studies due to the lack of information b. We decided to downgrade the quality of the
evidence by one level for the risk of bias dimension because in both study crossover to pembrolizumab monotherapy was
permitted among the patients in the chemotherapy combination group who had verified disease progression c. In
Keynote-021 trial, the maintenance treatment consisted of pembrolizumab and optional indefinite pemetrexed d. In
KEYNOTE-21 study, subgroups analysis according to tumour proportion score for PD-L1 were not designed and performed. For
this reason we decided to downgrade the quality of the evidence by one level for indirectness e. KEYNOTE-021 trial was
an open-label trial but efficacy was based on masked, independent, central radiology review f. High risk of performance
and detection bias because KEYNOTE-021 was an open-label trial g. I2=53% h. In KEYNOTE 189 study safety results were
showed in the overall population and not according to PD-L1 tumour proportion score i. We decided to downgrade the
quality of the evidence by one level for imprecision because the 95% CI includes both negligible effect and appreciable
benefit or appreciable harm j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination
treatment for the following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded
medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients
withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment
in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients
withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued
treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab
combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician
decision, 2 new anticancer therapy and 13 clinical progression; k. in KEYNOTE-189 study information for this outcome
were showed in the overall population and not according to PD-L1 tumour proportion score Dovrebbe un trattamento di
prima linea a base di platino, pemetrexed e pembrolizumab, seguito da mantenimento con pemetrexed e pembrolizumab in
caso di risposta o stabilità di malattia dopo 4 cicli di trattamento vs. la chemioterapia essere usato per pazienti
affetti da NSCLC a istologia non-squamosa con espressione di PD-L1 <50% in stadio metastatico senza mutazione attivante
l’EGFR o riarrangiamento di ALK e con buon performance status (0-1)? POPULATION: Pazienti affetti da NSCLC a istologia
non-squamosa con espressione di PD-L1 <50% in stadio metastatico senza mutazione attivante l’EGFR o riarrangiamento di
ALK e con buon performance status (0-1) INTERVENTION: Un trattamento di prima linea a base di platino, pemetrexed e
pembrolizumab, seguito da mantenimento con pemetrexed e pembrolizumab in caso di risposta o stabilità di malattia dopo 4
cicli di trattamento COMPARISON: Alla

79. [population] score 10
zumab and optional indefinite pemetrexed d. In KEYNOTE-21 study, subgroups analysis according to tumour proportion score
for PD-L1 were not designed and performed. For this reason we decided to downgrade the quality of the evidence by one
level for indirectness e. KEYNOTE-021 trial was an open-label trial but efficacy was based on masked, independent,
central radiology review f. High risk of performance and detection bias because KEYNOTE-021 was an open-label trial g.
I2=53% h. In KEYNOTE 189 study safety results were showed in the overall population and not according to PD-L1 tumour
proportion score i. We decided to downgrade the quality of the evidence by one level for imprecision because the 95% CI
includes both negligible effect and appreciable benefit or appreciable harm j. KEYNOTE-021 study: 31 patients
discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 17 PD, 6 AEs, 4 patients
withdrawal, 3 physician decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm
for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician decision, 1 use of excluded medication.
KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following
reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11
clinical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268 patients
discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21
AEs, 8 patients withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression; k. in
KEYNOTE-189 study information for this outcome were showed in the overall population and not according to PD-L1 tumour
proportion score Dovrebbe un trattamento di prima linea a base di platino, pemetrexed e pembrolizumab, seguito da
mantenimento con pemetrexed e pembrolizumab in caso di risposta o stabilità di malattia dopo 4 cicli di trattamento vs.
la chemioterapia essere usato per pazienti affetti da NSCLC a istologia non-squamosa con espressione di PD-L1 <50% in
stadio metastatico senza mutazione attivante l’EGFR o riarrangiamento di ALK e con buon performance status (0-1)?
POPULATION: Pazienti affetti da NSCLC a istologia non-squamosa con espressione di PD-L1 <50% in stadio metastatico senza
mutazione attivante l’EGFR o riarrangiamento di ALK e con buon performance status (0-1) INTERVENTION: Un trattamento di
prima linea a base di platino, pemetrexed e pembrolizumab, seguito da mantenimento con pemetrexed e pembrolizumab in
caso di risposta o stabilità di malattia dopo 4 cicli di trattamento COMPARISON: Alla chemioterapia MAIN OUTCOMES:
Overall survival; Progression free survival; Objective response rate; Grade 3-5 any AEs; Discontinuation rate of any
treatment component SETTING: PERSPECTIVE: BACKGROUND: CONFLICT OF INTERESTS: Assenti alla votazione: Dr. Novello, Dr.
Facchinetti, Dr. Passaro, Dr. Rossi, Dr. Trisolini, Dr. Ferrara, Dr. Menis Is the problem a priority? ○ No Inhibitors of
programmed death 1 (PD-1) and its ligand PD-L1 are effective therapies for metastatic non–small-cell ○ Probably no lung
cancer (NSCLC) lackin

80. [intervention] score 10
n't know What would be the impact on health equity? GIUDIZI RICERCA DELLE PROVE DI EVIDENZA ○ Reduced Nessuna evidenza
trovata. ○ Probably reduced ● Probably no impact ○ Probably increased ○ Increased ○ Varies ○ Don't know NEO e effects
OPLASI favor the IE DEL e interve L POLM ention or MONE r the com mparison n? LINEE E GUID CON CON DA NSIDERAZI
NSIDERAZI IONI AGGIUNTIVE IONI AGGIUNTIVE Is the intervention acceptable to key stakeholders? ○ No Nessuna evidenza
trovata. ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know Is the intervention feasible to implement? ○ No
Nessuna evidenza trovata. ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know PROBLEM No Trivial NEO Probab Sma
OPLASI bly no all IE DEL L POLM Probab Mode MONE bly yes erate GIUDIZ ZI Yes Large e CON CON Varies Varies A
NSIDERAZIONI AGGIUNTIVE NSIDERAZIONI AGGIUNTIVE Don't know Don't know CERTAINTY OF EVIDENCE VALUES BALANCE OF EQUITY
ACCEPTABILITY FEASIBILITY Large Moderate Small Trivial Very Low Moderate High low Probably no No important Possibly
important Important uncertainty important uncertainty uncertainty or or variability uncertainty or or variability
variability variability Does not favor either Favors the Probably favors the Probably favors the intervention or
comparison comparison interventio the comparison Probably Reduced Probably reduced Probably no impact increased Probably
Probably No Yes no yes Probably Probably No Yes no yes Varies the Favors the Varies on intervention Increased Varies
Varies Varies Don't know No included studies Don't know Don't know Don't know Don't know Strong recommendation
Conditional Conditional against the intervention recommendation against recommendation for the the intervention
intervention Un trattamento loco-regionale + terapia sistemica vs. sola terapia sistemica in pazienti affetti da NSCL
considerazione. La forza della raccomandazione è forte nonostante la certezza nelle prove è stata giudicata complessiv
l’intervento può rappresentare un trattamento salvavita. Strong recommendation for the intervention LC in stadio
avanzato oligometastatico dovrebbe essere preso in vamente bassa, poiché a fronte di un potenziale danno insignificante,
LINEE GUID Author(s): MC Date: September 2019 Question: Osimertinib compared to standard EGFR-TKI in untreated EGFR-
Mutated advanced non-small-cell lung cancer Setting: inpatients Bibliography: Ramalingam oral presentation ESMO 2019;
Soria J.C. "Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer", N Engl J Med 2018; 378:113-25;
Planchard 2019, Clin Cancer Res. 2019 Apr 1;25(7):2058-2063; Reungwetwattana 2018, J Clin Oncol 36:3290-3297 Certainty
assessment № of patients Effect Certain № of Study Other standard Relative Absolute Risk of bias Inconsistency
Indirectness Imprecision Osimertinib studies design considerations EGFR-TKI (95% CI) (95% CI) Progression free survival
(follow up: median 15.0 months)a 1 randomised not serious not serious serious b not serious none 136/279 206/277 HR 0.46
28 fewer ⨁⨁⨁ trials (48.7%) (74.4%) (0.37 to 0.57) per 100 MODER (from 35 fewer to 20 fewer) 1 randomised not serious
not serious serious b not serious none 128/279 155/277 HR 0.799 8 fewer ⨁⨁⨁ trials (45.9%) (56.0%) (0.641 to per 100
MODER 0.997) (from 15 fewer to 0 fewer) 1 randomised not

81. [intervention] score 10 ✅ BINGO (PIO)
1 trial was an open-label trial but efficacy was based on masked, independent, central radiology review f. We decided to
downgrade the quality of the evidence by one level for imprecision because the 95% CI includes both negligible effect
and appreciable benefit or appreciable harm g. I2=53% h. In KEYNOTE 189 study safety results were showed in the overall
population and not according to PD-L1 tumour proportion score i. High risk of performance and detection bias because
KEYNOTE-021 was an open-label trial j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab
combination treatment for the following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of
excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3
patients withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued
treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients
withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued
treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab
combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician
decision, 2 new anticancer therapy and 13 clinical progression;| Row 1: Grade 3-5 any AEs||||||RR 1.06 (0.94 to
1.19)|728 (2 RCTs)|⨁◯◯◯ VERY LOWa,c,d,f,g,h,i| Row 2: ||Study population||||||| Row 3: ||||||||| Row 4: ||||||||| Row 5:
|56 per 100|||60 per 100||||| Row 6: ||||(53 to 67)||||| Row 7: ||||||||| Row 8: Discontinuation rate of any treatment
componentj||||||RR 0.80 (0.73 to 0.88)|739 (2 RCTs)|⨁◯◯◯ VERY LOWa,c,d,i,k| Row 9: ||Study population||||||| Row 10:
||||||||| Row 11: ||||||||| Row 12: |78 per 100|||62 per 100||||| Row 13: ||||(57 to 68)||||| Row 14: ||||||||| Row 1:
|k. in KEYNOTE-189 study information for this outcome were showed in the overall population and not according to PD-L1
tumour proportion score Forest Plot OS: PFS: Objective response rate:| Row 1: |Any AEs grade 3-5: Discontinuation rate:|
Row 1: |||| Row 2: |Undesirable effects||| Row 3: |How substantial are the undesirable anticipated effects?||| Row 4:
|||| Row 5: JUDGEMENT||RESEARCH EVIDENCE|ADDITIONAL CONSIDERATIONS| Row 6: ○ Large ○ Moderate X Small ○ Trivial ○ Varies
○ Don't know||Outcomes Anticipated absolute effects* (95% CI) Relative № of Certainty of the Comments effect
participants evidence Risk with alla Risk with un trattamento di prima linea a (95% (studies) (GRADE) chemioterapia base
di platino, pemetrexed e CI) pembrolizumab, seguito da mantenimento con pemetrexed e pembrolizumab in caso di risposta o
stabilità di malattia dopo 4 cicli di trattamento Overall survival Study population HR 0.61 499 ⨁⨁◯◯ (0.45 to (2 RCTs)
LOWa,b,c,d 61 per 100 44 per 100 0.83) (35 to 55) Progression free Study population HR 0.63 499 ⨁⨁⨁◯ survival (0.50 to
(2 RCTs) MODERATEa,c,d,e 81 per 100 65 per 100 0.80) (56 to 73) Objective response Study population RR 2.16 499 ⨁⨁⨁◯
rate (1.58 to (2 RCTs) MODERATEa,c,d,e 21 per 100 46 per 100 2.95) (33 to 63) Grade 3-5 any AEs Study population RR 1.06
728 ⨁◯◯

82. [intervention] score 10
ed Trial" [Publication Type]) OR "Clinic Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR
randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] trial[Title/Abstract] OR groups OR))))
NOT ((("Animals"[Mesh]) NOT "Animals"[Mes "Humans"[Mesh]))) espressione del zolizumab dopo oma, Non-Small- g mall-cell
lung pt]) OR cer' OR 'non sma apia postoperat (((((lung ract]) OR lung ung C*[Title/Abstract]) Title/Abstract] OR )))
AND "radical cal Trial" [Publica OR sh]) AND l PD- o la -Cell all toria R ation NE EOPLASIE DEL POLMONE Embase
(Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung
neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4
'grade ia' OR 'stage ia':de,ti,ab #5 #3 AND #4 #6 "radical surgery:de,ti,ab #7 #5 AND #6 AND ([cochrane review]/lim OR
[systematic review]/lim OR [meta analysis]/lim OR [controlled clinical trial]/lim OR [randomized controlled trial]/lim)
AND [embase]/lim Q9: Nei pazienti con NSCLC in stadio II-III resecabile una chemioterapia neoadiuvante seguita da
chirurgia è raccomandata (rispetto a sola chirurgia)? (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields]
AND "therapy"[All Fields]) OR "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All
Fields] OR "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR ("drug"[All
Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All Fields] OR "drug therapy"[MeSH
Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All Fields] OR "resectability"[All Fields] OR "resectable"[All
Fields] OR "resectates"[All Fields] OR "resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields] OR
"resectional"[All Fields] OR "resectioned"[All Fields] OR "resectioning"[All Fields] OR "resections"[All Fields] OR
"resective"[All Fields] OR "resects"[All Fields]) AND ("lung"[MeSH Terms] OR "lung"[All Fields]) AND ("cancer s"[All
Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR "cancerized"[All
Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR
"cancers"[All Fields])) AND (meta-analysis[Filter] OR randomizedcontrolledtrial[Filter] OR systematicreview[Filter])
Q10: Nei pazienti con NSCLC in stadio IIIA/IIIB non resecabile, o IIIC un trattamento di chemio- radioterapia a dosi
radicali concomitante è raccomandato (rispetto alla sequenziale)? MEDLINE (PubMed) (2019 ad Agosto 2023)
((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp]) OR ((((((((((lung cancer*[Title/Abstract]) OR lung
tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung neoplasm*[Title/Abstract]) OR lung
carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non small cell lung
cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))))))) AND (((grade iii OR stage iii OR advance OR locally advanced
disease)) AND (inoperable OR surgically unresectable)))) AND (("Chemoradiotherapy"[Mesh]) OR
(("Chemoradiotherapy"[Mesh]) OR ("chemoradiotherapy"[Title/Abstract] OR "radiochemoth

83. [intervention] score 10 ✅ BINGO (PIO)
ING:||Ambulatoriale Row 11: ||| Row 12: |PROSPETTIVA:|| Row 13: ||| Row 14: BACKGROUND:|||Studi prospettici di fase 2
non randomizzati hanno valutato il profilo di attività e di tollerabilità dell’inibitore tirosino-chinasico di ROS1
Crizotinib nei pazienti affetti da NSCLC localmente avanzato o metastatico con riarrangiamenti del gene ROS1. Row 15:
||| Row 16: |CONFLITTI DI INTERESSE|| Row 17: ||| Row 1: |||| Row 2: |Problema||| Row 3: |Il problema è una priorità?|||
Row 4: |||| Row 5: GIUDIZI||RICERCA DELLE PROVE|CONSIDERAZIONI AGGIUNTIVE| Row 6: ○ No ○ Probabilmente no ○
Probabilmente si X Si ○ Varia ○ Non so|||| Row 7: |||| Row 8: |Effetti desiderabili||| Row 9: |Quanto considerevoli sono
gli effetti desiderabili attesi?||| Row 10: |||| Row 11: GIUDIZI||RICERCA DELLE PROVE|CONSIDERAZIONI AGGIUNTIVE| Row 12:
○ Irrilevanti ○ Piccoli ○ Moderati X Grandi ○ Variano ○ Non so||Outcomes Anticipated absolute effects* Relative № of
Certainty of Comments (95% CI) effect participants the evidence (95% (studies) (GRADE) Risk with Risk with CI)
chemotherapy (Q6)a first li e therapy with crizotinib Progression free survival - Study population not 26 ⨁◯◯◯ Landi L.
et al (METROS) estimable (1 VERY LOWa,b 0 per 1.000 0 per 1.000 observational (0 to 0) study) Progression-free survival
- - - - - - Shaw A.T. et al - not reported|| Row 1: ||||||||| Row 2: Outcomes||Anticipated absolute effects*||||Relative
effect (95% CI)|№ of participants (studies)|Certainty of the evidence (GRADE)|Comments Row 3: ||(95% CI)||||||| Row 4:
||||||||| Row 5: ||||||||| Row 6: |Risk with chemotherapy|||Risk with||||| Row 7: ||||(Q6)a first||||| Row 8: ||||li e
therapy||||| Row 9: ||||with||||| Row 10: ||||crizotinib||||| Row 11: ||||||||| Row 12: Progression free survival -
Landi L. et al (METROS)||||||not estimable|26 (1 observational study)|⨁◯◯◯ VERY LOWa,b| Row 13: ||Study
population||||||| Row 14: ||||||||| Row 15: ||||||||| Row 16: |0 per 1.000|||0 per 1.000||||| Row 17: ||||(0 to 0)|||||
Row 18: ||||||||| Row 19: Progression-free survival - Shaw A.T. et al - not reported||||||-|-|-| Row 20: |-||-|||||| Row
21: ||||||||| Row 1: Relative Row 2: effect Row 3: (95% Row 4: CI) Row 1: № of Row 2: participants Row 3: (studies) Row
1: Certainty of Row 2: the evidence Row 3: (GRADE) Row 1: Risk with Row 2: chemotherapy Row 1: | Row 2: |Problema Row 3:
|Il problema è una priorità Row 4: | Row 1: | Row 2: |Effetti desider Row 3: |Quanto considerevoli son Row 4: | Row 1:
Row 2:  Row 3: à? Row 4:  Row 1:  Row 2: rabili Row 3: no gli effet Row 4:  Row 1:  Row 2:  Row 3:  Row 4:  Row 1: | Row
2: | Row 3: tti desiderabili attesi?| Row 4: | Row 1: || Row 2: Outcomes||Anticipated Row 3: ||(95% CI) Row 4: || Row 5:
|| Row 6: |Risk with chemothera|Risk with Row 7: ||chemothera Row 8: || Row 9: Progression free survival - Landi L. et
al (METROS)|| Row 10: ||Study popul Row 11: || Row 12: || Row 13: |0 per 1.000|0 per 1.000 Row 14: || Row 15:
Progression-free survival - Shaw A.T. et al - not reported|| Row 16: |-|- Row 17: || Row 1: ||||| Row 2: d absolute
effects*||||Relat effect (95% CI)|Relat Row 3: |||||effect Row 4: |||||(95% Row 5: ||||| Row 6: ||Risk with|||CI) Row 7:
apy||(Q6)a first||| Row 8: ||li e therapy||| Row 9: ||with||| Row 10: ||crizotinib||| Row 11: ||||| Row 12: ||||| Row
13: latio

84. [intervention] score 10
ial" [Publication Type]) OR "Clinic Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR
randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] trial[Title/Abstract] OR groups OR))))
NOT ((("Animals"[Mesh]) NOT "Animals"[Mes "Humans"[Mesh]))) espressione del zolizumab dopo oma, Non-Small- g mall-cell
lung pt]) OR cer' OR 'non sma apia postoperat (((((lung ract]) OR lung ung C*[Title/Abstract]) Title/Abstract] OR )))
AND "radical cal Trial" [Publica OR sh]) AND l PD- o la -Cell all toria R ation NE EOPLASIE DEL POLMONE Embase
(Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung
neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4
'grade ia' OR 'stage ia':de,ti,ab #5 #3 AND #4 #6 "radical surgery:de,ti,ab #7 #5 AND #6 AND ([cochrane review]/lim OR
[systematic review]/lim OR [meta analysis]/lim OR [controlled clinical trial]/lim OR [randomized controlled trial]/lim)
AND [embase]/lim Q9: Nei pazienti con NSCLC in stadio II-III resecabile una chemioterapia neoadiuvante seguita da
chirurgia è raccomandata (rispetto a sola chirurgia)? (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields]
AND "therapy"[All Fields]) OR "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All
Fields] OR "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR ("drug"[All
Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All Fields] OR "drug therapy"[MeSH
Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All Fields] OR "resectability"[All Fields] OR "resectable"[All
Fields] OR "resectates"[All Fields] OR "resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields] OR
"resectional"[All Fields] OR "resectioned"[All Fields] OR "resectioning"[All Fields] OR "resections"[All Fields] OR
"resective"[All Fields] OR "resects"[All Fields]) AND ("lung"[MeSH Terms] OR "lung"[All Fields]) AND ("cancer s"[All
Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR "cancerized"[All
Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR
"cancers"[All Fields])) AND (meta-analysis[Filter] OR randomizedcontrolledtrial[Filter] OR systematicreview[Filter])
Q10: Nei pazienti con NSCLC in stadio IIIA/IIIB non resecabile, o IIIC un trattamento di chemio- radioterapia a dosi
radicali concomitante è raccomandato (rispetto alla sequenziale)? MEDLINE (PubMed) (2019 ad Agosto 2023)
((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp]) OR ((((((((((lung cancer*[Title/Abstract]) OR lung
tumor*[Title/Abstract]) OR lung tumour*[Title/Abstract]) OR lung neoplasm*[Title/Abstract]) OR lung
carcinoma*[Title/Abstract]) OR non-small cell lung cancer*[Title/Abstract]) OR non small cell lung
cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))))))) AND (((grade iii OR stage iii OR advance OR locally advanced
disease)) AND (inoperable OR surgically unresectable)))) AND (("Chemoradiotherapy"[Mesh]) OR
(("Chemoradiotherapy"[Mesh]) OR ("chemoradiotherapy"[Title/Abstract] OR "radiochemotherapy"[T

85. [intervention] score 10 ✅ BINGO (ICO)
etti da NSCLC in stadio IIIA/IIIB non resecabile o IIIC. Qualità globale Forza della Raccomandazione clinica delle prove
raccomandazione Nei pazienti con NSCLC in stadio IIIA/IIIB non resecabile, o IIIC, una chemioterapia a base di platino
dovrebbe essere presa Moderata Forte a favore in considerazione come opzione terapeutica di prima scelta in associazione
al trattamento radioterapico (229-234) Quesito 12 GRADE. Nei pazienti affetti da NSCLC in stadio III non resecabile, in
risposta o stabilità di malattia dopo trattamento chemio-radioterapico a dosi radicali e con espressione di PD-L1 sulle
cellule tumorali superiore o uguale a 1%, una terapia di consolidamento con durvalumab è raccomandata rispetto
all’osservazione? RACCOMANDAZIONE: Nei pazienti affetti da NSCLC in stadio III non resecabile, in risposta o stabilità
di malattia dopo trattamento chemio-radioterapico a dosi radicali, e con espressione di PD-L1 sulle cellule tumorali
superiore o uguale a 1%, una terapia di consolidamento con durvalumab della durata di 12 mesi dovrebbe essere presa in
considerazione come opzione terapeutica di prima scelta. Forza della raccomandazione: FORTE A FAVORE
Motivazioni/commenti al bilancio beneficio/danno: Lo studio di fase III “PACIFIC” è un trial randomizzato in doppio
cieco, multicentrico, che ha incluso 713 pazienti con performance status 0-1, affetti da NSCLC localmente avanzato
(stadio III non resecabile secondo TNM VII edizione), in risposta o stabilità di malattia dopo un trattamento di chemio-
radioterapia concomitante (almeno 2 cicli di chemioterapia a base di platino concomitanti alla radioterapia) ad intento
radicale (dose totale di radioterapia compresa tra 54 Gy e 66 Gy). I pazienti venivano randomizzati, in un intervallo
temporale compreso tra 1 e 42 giorni dall’ultima dose di radioterapia, a ricevere un trattamento immunoterapico con
durvalumab o placebo (2:1) 10 mg/kg e.v. ogni 2 settimane sino a un massimo di 12 mesi di trattamento. I due endpoint
primari erano PFS e OS. Il tempo alla progressione è stato valutato da un comitato di revisione centrale indipendente in
cieco, secondo i criteri RECIST v1.1. Alla prima analisi ad interim pianificata, la PFS è risultata significativamente
superiore nei pazienti trattati con durvalumab rispetto al placebo (PFS mediana 16,8 mesi vs 5,6 mesi; HR 0,52; IC95%
0,42-0,65; p=0,001). Gli eventi avversi di grado 3 e 4 sono stati solo lievemente più frequenti nel braccio durvalumab
(29,9% vs 26,1%), così come gli eventi avversi che hanno portato a una sospensione del trattamento (15,4% vs 9,8%)
(235). Dopo un follow-up mediano di 25,2 mesi, la sopravvivenza globale nella popolazione generale è risultata a favore
del braccio di immunoterapia con durvalumab (OS mediana non raggiunta vs 28,7 mesi; HR 0,68; IC95% 0,53-0,87; tasso di
sopravvivenza a 2 anni: 66,3% vs 55,6%; p=0,005), così come pure il dato aggiornato di PFS (HR 0,51; IC95% 0,41- 0,63;
p=0,001) (236). Un’analisi per sottogruppi pre-pianificata ha inizialmente dimostrato un vantaggio in sopravvivenza in
favore del durvalumab indipendentemente dai livelli espressione di PD-L1 al cut-off prestabilito del 25%, misurato su
tessuto d’archivio, disponibile nel 63% circa dei pazienti: cut-off ≥25% (HR 0,46) e cut-off <25% (HR 0,92). Sulla base
di qu

86. [comparator] score 10 ✅ BINGO (ICO)
z-Ares Lancet Oncol 2012). PFS results were not updated in the final report (Paz-Ares JCO 2013) 5 The primary outcome
declared in  is PFS detected by investigators. Taking into account the high proportion of indipendent evaluation
available 88% and the similar results LINEE GUI obtained we decided to report the investigator assessed PFS 6
Investigator -> pemetrexed median PFS 4,1 mesi (3,2-4,6), placebo 2,8 (2,6-3,1); Indipendent -> pemetrexed median PFS
3,9 mesi (3- 4,2) , placebo 2,6 ( 2.2-2.9) 7 Assessed by the indipendent review 8 Wide 95% CI due to low number of
events. For this reason we decided to not downgrade quality of evidence for imprecision 9 Calcolated throught number of
events and totals 10 Low questionnaire compliance due to failure by study site to administer questionnaire. 11 95%
confidence interval includes no effect and the upper and lower confidence limit crosses the minimal important difference
(MID= 0.08 U.K population-based index sco 12 Assuming a SD= 1.5 for both arm (data not provided by authors) 13 95%
confidence interval includes no effect and the lower confidence limit crosses the minimal important difference (MID= 7
VAS) 14 Assuming a SD= 7.24 for both arm (Sds are not reported in the primary article) and a p-value > 0.05 (the authors
reported "Not-Ssignificant" only) 15 we added a further event both in the intervention and in the control group to
permit the calculation of relative and absolute effect IDA ore); both f for benefit and harm Dovrebbe maintenance
therapy with pemetrexed vs placebo essere utiliz POPOLAZIONE: Advanced NSCLC INTERVENTO: Maintenance therapy with
pemetrexed CONFRONTO: Placebo ESITI PRINCIPALI: Overall Survival; Progression free survival; Objective responce rate;
Quality of life -EQ-5D; Qual grade 3-4; Neutropenia grade 3-4 SETTING: PROSPETTIVA: BACKGROUND: CONFLITTI DI INTERESSE
Il problema è una priorità? GIUDIZI RICERCA DELLE PROVE DI EVIDENZA ○ No ○ Probabilmente no ○ Probabilmente si ● Si ○
Varia ○ Non so zzato per adva lity of life -VAS; Sever anced NSCLC re Toxicity (Non labor CONSIDE ratory); Fatigue grade
3-4; trans ERAZIONI AGGIUNTIVE sfusion; G-CSF ; Anemia Effetti de Quanto consid GIUDIZI ○ Irrilevanti ○ Piccoli ○
Moderati ● Grandi ○ Variano ○ Non so esider derevoli s rabili sono gli e effetti des siderabili attesi? RICERCA DELLE
PROVE DI EVIDENZA CONS È stata eseguita una ricerca sistematica della letteratura sulle banche dati PubMed/Medline,
Embase e Central (Cochrane Library). La strategia di ricerca ha identificato 1478 documenti dopo la rimozione dei
duplicati. È stato valutato un record in full-text e incluso. Lo studio PARAMOUNT, è un trial di fase 3 randomizzato in
doppio cieco, multicentrico, su pazienti affetti da NSCLC in fase avanzata (stadio IIIB/IV). Lo studio prevedeva due
fasi: una fase non randomizzata (fase di induzione) in cui 939 pazienti non pre-trattati per malattia avanzata sono
stati sottoposti a terapia di prima linea con cisplatino/pemetrexed (cisplatino 75 mg/mq e.v. g.1 e pemetrexed 500 mg/mq
e.v. g.1 ogni tre settimane) per 4 cicli ed una successiva fase randomizzata (fase di mantenimento), in cui i pazienti
eleggibili che non erano in progressione di malattia dopo l’induzione (n = 539) venivano randomizzati (2:1) a ricevere
pemetrexed (500 mg/mq e.v. g

87. [outcome] score 10 ✅ BINGO (PIO)
ies design dell’encefalo irradiazione (95% CI) (95% CI) (PCI) Brain metastases free survival - not reported - - - - - -
- - - - - - CRITICAL 21 observational serious b,c very serious d serious e not serious none 748/1859 644/5536 HR 0.62 4
fewer ⨁◯◯◯ CRITICAL studies a (40.2%) f (11.6%) f (0.59 to 0.66) per 100 VERY LOW (from 5 fewer to 4 fewer) 5
observational serious h serious i serious e not serious none 0/261 (0.0%) 0/406 (0.0%) HR 0.76 -- per 100 ⨁◯◯◯ CRITICAL
studies g (0.65 to 0.89) (from -- to VERY LOW 1 randomised not serious k not serious not serious not serious none
Authors stated that "The rate of compliance with the quality-of-life ⨁⨁⨁⨁ CRITICAL trials j assessment was 93.7% at
baseline but decreased to 46.3% at 9 HIGH months. From baseline to month 9, there was no statistically or clinically
significant difference in global health status between the study groups (P = 0.10)" Impared Cognitive Function
(neurologica damage) - not reported - - - - - - - - - - - - CRITICAL Any grade 3-5 AEs - not reported - - - - - - - - -
- - - CRITICAL 2 observational not serious not serious not serious serious m none 52/386 (13.5%) 16/570 (2.8%) RR 4.92
110 more ⨁◯◯◯ IMPORTANT studies l (2.86 to 8.44) per 1.000 VERY LOW (from 52 more to 209 more) CI: Confidence interval;
HR: Hazard Ratio; RR: Risk ratio a. There was 9 RCT and 12 observational studies b. In 13 out of 21 studies, the number
of events were not showed c. The quality of the observational included studies was assessed according to the Newcastle-
Ottawa scale. Studies was considerate as moderate or high quality, the reasons for downgrade the quality were selection
and outcome bias. The quality of the included RCTs was assessed according to the Cochrane Handbook 5.1. Studies had, in
general, a low risk of bias d. I2=84% e. Patients included in the Prophylactic Cranial irradiation overview
collaborative group had achieved a complete response after induction treatment. In Rule at al. all patients were 70
years or older. Salama et al presented a secondary analysis of the CALGB 30504 study, included patients received placebo
or sunitinib f. This is not the total number of events, Ge 2018 et al. did not show the number of events but only the
overall number of patients g. There was 2 RCT and 3 observational studies h. The number of events were not showed in all
included studies i. I2=64% j. Slotman et al 2007 k. Unclear risk of bias due to the lack of information l. There were 1
RCT and 1 observational study m. Low number of events QUESITO 45: Nei pazienti affetti da SCLC con malattia estesa e in
risposta dopo chemioterapia, l’irradiazione profilattica dell’encefalo (PCI) è raccomandata? POPOLAZIONE: INTERVENTO:
CONFRONTO: ESITI PRINCIPALI: SETTING: BACKGROUND: VALUTA Il problema è una priorità GIUDIZI ○ No ○ Probabilmente no ○
Probabilmente si X Si ○ Varia ○ Non so Pazienti affetti da SCLC con malattia estesa e in risposta dopo chemioterapia
Irradiazione profilattica dell’encefalo (PCI) Osservazione Sopravvivenza libera da progressione; sopravvivenza globale;
sopravvivenza libera da progres tossicità di grado superiore o uguale a 3; Fatigue e Letargia di ogni grado.
Ambulatoriale Molteplici studi hanno valutato efficacia e tollerabilità dell’irradiazione profilattica dell’encefa
chemioterapico. AZI

88. [outcome] score 10 ✅ BINGO (PIO)
-L1 tumour proportion score i. High risk of performance and detection bias because KEYNOTE-021 was an open-label trial
j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the following
reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43 patients
discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician
decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab
combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician
decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone arm
for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the
following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician decision, 2 new anticancer therapy
and 13 clinical progression;| Row 1: Grade 3-5 any AEs||||||RR 1.06 (0.94 to 1.19)|728 (2 RCTs)|⨁◯◯◯ VERY
LOWa,c,d,f,g,h,i| Row 2: ||Study population||||||| Row 3: ||||||||| Row 4: ||||||||| Row 5: |56 per 100|||60 per
100||||| Row 6: ||||(53 to 67)||||| Row 7: ||||||||| Row 8: Discontinuation rate of any treatment componentj||||||RR
0.80 (0.73 to 0.88)|739 (2 RCTs)|⨁◯◯◯ VERY LOWa,c,d,i,k| Row 9: ||Study population||||||| Row 10: ||||||||| Row 11:
||||||||| Row 12: |78 per 100|||62 per 100||||| Row 13: ||||(57 to 68)||||| Row 14: ||||||||| Row 1: |k. in KEYNOTE-189
study information for this outcome were showed in the overall population and not according to PD-L1 tumour proportion
score Forest Plot OS: PFS: Objective response rate:| Row 1: |Any AEs grade 3-5: Discontinuation rate:| Row 1: |||| Row
2: |Undesirable effects||| Row 3: |How substantial are the undesirable anticipated effects?||| Row 4: |||| Row 5:
JUDGEMENT||RESEARCH EVIDENCE|ADDITIONAL CONSIDERATIONS| Row 6: ○ Large ○ Moderate X Small ○ Trivial ○ Varies ○ Don't
know||Outcomes Anticipated absolute effects* (95% CI) Relative № of Certainty of the Comments effect participants
evidence Risk with alla Risk with un trattamento di prima linea a (95% (studies) (GRADE) chemioterapia base di platino,
pemetrexed e CI) pembrolizumab, seguito da mantenimento con pemetrexed e pembrolizumab in caso di risposta o stabilità
di malattia dopo 4 cicli di trattamento Overall survival Study population HR 0.61 499 ⨁⨁◯◯ (0.45 to (2 RCTs) LOWa,b,c,d
61 per 100 44 per 100 0.83) (35 to 55) Progression free Study population HR 0.63 499 ⨁⨁⨁◯ survival (0.50 to (2 RCTs)
MODERATEa,c,d,e 81 per 100 65 per 100 0.80) (56 to 73) Objective response Study population RR 2.16 499 ⨁⨁⨁◯ rate (1.58
to (2 RCTs) MODERATEa,c,d,e 21 per 100 46 per 100 2.95) (33 to 63) Grade 3-5 any AEs Study population RR 1.06 728 ⨁◯◯◯
(0.94 to (2 RCTs) VERY 56 per 100 60 per 100 1.19) LOWa,c,d,f,g,h,i ( 53 to 67)|| Row 1: ||||||||| Row 2:
Outcomes||Anticipated absolute effects* (95% CI)||||Relative effect (95% CI)|№ of participants (studies)|Certainty of
the evidence (GRADE)|Comments Row 3: ||||||||| Row 4: ||||||||| Row 5: |Risk with alla chemioterapia|||Risk with un
trattamento di prima linea a||||| Row 6: ||||bas

89. [outcome] score 10 ✅ BINGO (PIO)
utropenia di grado superiore o uguale a 3; edema periferico di grado superiore o uguale a 3; tossicità di grado
superiore o uguale a 3 Row 9: ||| Row 10: |SETTING:||Ambulatoriale Row 11: ||| Row 12: |PROSPETTIVA:|| Row 13: ||| Row
14: BACKGROUND:|||Studi prospettici di fase 2 non randomizzati hanno valutato il profilo di attività e di tollerabilità
dell’inibitore tirosino-chinasico di ROS1 Crizotinib nei pazienti affetti da NSCLC localmente avanzato o metastatico con
riarrangiamenti del gene ROS1. Row 15: ||| Row 16: |CONFLITTI DI INTERESSE|| Row 17: ||| Row 1: |||| Row 2: |Problema|||
Row 3: |Il problema è una priorità?||| Row 4: |||| Row 5: GIUDIZI||RICERCA DELLE PROVE|CONSIDERAZIONI AGGIUNTIVE| Row 6:
○ No ○ Probabilmente no ○ Probabilmente si X Si ○ Varia ○ Non so|||| Row 7: |||| Row 8: |Effetti desiderabili||| Row 9:
|Quanto considerevoli sono gli effetti desiderabili attesi?||| Row 10: |||| Row 11: GIUDIZI||RICERCA DELLE
PROVE|CONSIDERAZIONI AGGIUNTIVE| Row 12: ○ Irrilevanti ○ Piccoli ○ Moderati X Grandi ○ Variano ○ Non so||Outcomes
Anticipated absolute effects* Relative № of Certainty of Comments (95% CI) effect participants the evidence (95%
(studies) (GRADE) Risk with Risk with CI) chemotherapy (Q6)a first li e therapy with crizotinib Progression free
survival - Study population not 26 ⨁◯◯◯ Landi L. et al (METROS) estimable (1 VERY LOWa,b 0 per 1.000 0 per 1.000
observational (0 to 0) study) Progression-free survival - - - - - - Shaw A.T. et al - not reported|| Row 1: |||||||||
Row 2: Outcomes||Anticipated absolute effects*||||Relative effect (95% CI)|№ of participants (studies)|Certainty of the
evidence (GRADE)|Comments Row 3: ||(95% CI)||||||| Row 4: ||||||||| Row 5: ||||||||| Row 6: |Risk with
chemotherapy|||Risk with||||| Row 7: ||||(Q6)a first||||| Row 8: ||||li e therapy||||| Row 9: ||||with||||| Row 10:
||||crizotinib||||| Row 11: ||||||||| Row 12: Progression free survival - Landi L. et al (METROS)||||||not estimable|26
(1 observational study)|⨁◯◯◯ VERY LOWa,b| Row 13: ||Study population||||||| Row 14: ||||||||| Row 15: ||||||||| Row 16:
|0 per 1.000|||0 per 1.000||||| Row 17: ||||(0 to 0)||||| Row 18: ||||||||| Row 19: Progression-free survival - Shaw
A.T. et al - not reported||||||-|-|-| Row 20: |-||-|||||| Row 21: ||||||||| Row 1: Relative Row 2: effect Row 3: (95%
Row 4: CI) Row 1: № of Row 2: participants Row 3: (studies) Row 1: Certainty of Row 2: the evidence Row 3: (GRADE) Row
1: Risk with Row 2: chemotherapy Row 1: | Row 2: |Problema Row 3: |Il problema è una priorità Row 4: | Row 1: | Row 2:
|Effetti desider Row 3: |Quanto considerevoli son Row 4: | Row 1:  Row 2:  Row 3: à? Row 4:  Row 1:  Row 2: rabili Row
3: no gli effet Row 4:  Row 1:  Row 2:  Row 3:  Row 4:  Row 1: | Row 2: | Row 3: tti desiderabili attesi?| Row 4: | Row
1: || Row 2: Outcomes||Anticipated Row 3: ||(95% CI) Row 4: || Row 5: || Row 6: |Risk with chemothera|Risk with Row 7:
||chemothera Row 8: || Row 9: Progression free survival - Landi L. et al (METROS)|| Row 10: ||Study popul Row 11: || Row
12: || Row 13: |0 per 1.000|0 per 1.000 Row 14: || Row 15: Progression-free survival - Shaw A.T. et al - not reported||
Row 16: |-|- Row 17: || Row 1: ||||| Row 2: d absolute effects*||||Relat effect (95% CI)|Relat Row 3: |||||effect Row 4:
|||||(95% Row 5: |||||

90. [outcome] score 10
hende, M., Weksler, B., Luketich, J. D., Schuchert, M. J.. Recurrence and survival outcomes after anatomic segmentectomy
versus lobectomy for clinical stage I non-small- cell lung cancer: a propensity-matched analysis. J Clin Oncol; Aug 10
2014. 12.Hwang, Y., Kang, C. H., Kim, H. S., Jeon, J. H., Park, I. K., Kim, Y. T.. Comparison of thoracoscopic
segmentectomy and thoracoscopic lobectomy on the patients with non-small cell lung cancer: a propensity score matching
study. Eur J Cardiothorac Surg; Aug 2015. 13.Dziedzic, R., Zurek, W., Marjanski, T., Rudzinski, P., Orlowski, T. M.,
Sawicka, W., Marczyk, M., Polanska, J., Rzyman, W.. Stage I non-small-cell lung cancer: long-term results of lobectomy
versus sublobar resection from the Polish National Lung Cancer Registry. Eur J Cardiothorac Surg; Aug 1 2017.
14.Whitson, B. A., Groth, S. S., Andrade, R. S., Maddaus, M. A., Habermann, E. B., D'Cunha, J.. Survival after lobectomy
versus segmentectomy for stage I non-small cell lung cancer: a population-based analysis. Ann Thorac Surg; Dec 2011.
15.Zhong, C., Fang, W., Mao, T., Yao, F., Chen, W., Hu, D.. Comparison of thoracoscopic segmentectomy and thoracoscopic
lobectomy for small-sized stage IA lung cancer. Ann Thorac Surg; Aug 2012. 16.Zhang, L., Ma, W., Li, Y., Jiang, Y., Ma,
G., Wang, G.. Comparative study of the anatomic segmentectomy versus lobectomy for clinical stage IA peripheral lung
cancer by video assistant thoracoscopic surgery. J Cancer Res Ther; Sep 2013. 17.Yamashita, S., Tokuishi, K., Anami, K.,
Moroga, T., Miyawaki, M., Chujo, M., Yamamoto, S., Kawahara, K.. Thoracoscopic segmentectomy for T1 classification of
non-small cell lung cancer: a single center experience. Eur J Cardiothorac Surg; Jul 2012. 18.Yamato, Y., Koike, T.,
Yoshiya, K., Shinohara, H., Toyabe, S.. Results of surgical treatment for small (2 cm or under) adenocarcinomas of the
lung. Surg Today; 2008. 19.Tsubokawa, N., Tsutani, Y., Miyata, Y., Handa, Y., Misumi, K., Hanaki, H., Hida, E., Okada,
M.. Segmentectomy Versus Lobectomy for Radiologically Pure Solid Clinical T1a-bN0M0 Lung Cancer. World J Surg; Aug 2018.
20.Sugi, K., Kobayashi, S., Sudou, M., Sakano, H., Matsuda, E., Okabe, K.. Long-term prognosis of video-assisted limited
surgery for early lung cancer. Eur J Cardiothorac Surg; Feb 2010. 21.Shapiro, M., Weiser, T. S., Wisnivesky, J. P.,
Chin, C., Arustamyan, M., Swanson, S. J.. Thoracoscopic segmentectomy compares favorably with thoracoscopic lobectomy
for patients with small stage I lung cancer. J Thorac Cardiovasc Surg; Jun 2009. 22.Soukiasian, H. J., Hong, E.,
McKenna, R. J.,Jr.. Video-assisted thoracoscopic trisegmentectomy and left upper lobectomy provide equivalent survivals
for stage IA and IB lung cancer. J Thorac Cardiovasc Surg; Sep 2012. 23.Song, C. Y., Sakai, T., Kimura, D., Tsushima,
T., Fukuda, I.. Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy
for patients with clinical stage IA non-small cell lung cancer: a propensity score matching study. J Thorac Dis; Aug
2018. 24.Darras, M., Ojanguren, A., Forster, C., Zellweger, M., Perentes, J. Y., Krueger, T., Gonzalez, M.. Short-term
local control after VATS segmentectomy and lobectomy for solid NSCLC of less than 2 cm. Thorac Cancer; Feb 2021. 25.De
Giacomo, T., Di St

91. [outcome] score 10
Sakai, T., Kimura, D., Tsushima, T., Fukuda, I.. Comparison of perioperative and oncological outcomes between video-
assisted segmentectomy and lobectomy for patients with clinical stage IA non-small cell lung cancer: a propensity score
matching study. J Thorac Dis; Aug 2018. 24.Darras, M., Ojanguren, A., Forster, C., Zellweger, M., Perentes, J. Y.,
Krueger, T., Gonzalez, M.. Short-term local control after VATS segmentectomy and lobectomy for solid NSCLC of less than
2 cm. Thorac Cancer; Feb 2021. 25.De Giacomo, T., Di Stasio, M., Diso, D., Anile, M., Venuta, F., Furio Coloni, G.. Sub-
lobar lung resection of peripheral T1N0M0 NSCLC does not affect local recurrence rate. Scand J Surg; 2009. 26.Zhao, X.,
Qian, L., Luo, Q., Huang, J.. Segmentectomy as a safe and equally effective surgical option under complete video-
assisted thoracic surgery for patients of stage I non-small cell lung cancer. J Cardiothorac Surg; Apr 29 2013. 27.Wang,
B. Y., Tu, C. C., Liu, C. Y., Shih, C. S., Liu, C. C.. Single-incision thoracoscopic lobectomy and segmentectomy with
radical lymph node dissection. Ann Thorac Surg; Sep 2013. 28.Echavarria, M. F., Cheng, A. M., Velez-Cubian, F. O., Ng,
E. P., Moodie, C. C., Garrett, J. R., Fontaine, J. P., Robinson, L. A., Toloza, E. M.. Comparison of pulmonary function
tests and perioperative outcomes after robotic-assisted pulmonary lobectomy vs segmentectomy. Am J Surg; Dec 2016.
29.Schuchert, M.J., Pettiford, B.L., Keeley, S., D'Amato, T.A., Kilic, A., Close, J., Pennathur, A., Santos, R.,
Fernando, H.C., Landreneau, J.R., Luketich, J.D., Landreneau, R.J.. Anatomic segmentectomy in the treatment of stage I
non-small cell lung cancer. Ann Thorac Surg 2007. 30.Sienel, W., Stremmel, C., Kirschbaum, A., Hinterberger, L.,
Stoelben, E., Hasse, J., Passlick, B.. Frequency of local recurrence following segmentectomy of stage IA non-small cell
lung cancer is influenced by segment localisation and width of resection margins--implications for patient selection for
segmentectomy. Eur J Cardiothorac Surg; Mar 2007. 31.Okada, M., Mimae, T., Tsutani, Y., Nakayama, H., Okumura, S.,
Yoshimura, M., Miyata, Y.. Segmentectomy versus lobectomy for clinical stage IA lung adenocarcinoma. Ann Cardiothorac
Surg; Mar 2014. 32.Read, R. C., Yoder, G., Schaeffer, R. C.. Survival after conservative resection for T1 N0 M0 non-
small cell lung cancer. Ann Thorac Surg; Mar 1990. 33.Martin-Ucar, A. E., Nakas, A., Pilling, J. E., West, K. J.,
Waller, D. A.. A case-matched study of anatomical segmentectomy versus lobectomy for stage I lung cancer in high-risk
patients. Eur J Cardiothorac Surg; Apr 2005. 34.Nishio, W., Yoshimura, M., Maniwa, Y., Kitamura, Y., Tane, K., Takenaka,
D., Adachi, S.. Re-Assessment of Intentional Extended Segmentectomy for Clinical T1aN0 Non-Small Cell Lung Cancer. Ann
Thorac Surg; Nov 2016. 35.Kilic, A., Schuchert, M. J., Pettiford, B. L., Pennathur, A., Landreneau, J. R., Landreneau,
J. P., Luketich, J. D., Landreneau, R. J.. Anatomic segmentectomy for stage I non-small cell lung cancer in the elderly.
Ann Thorac Surg; Jun 2009. 36.Koike, T., Yamato, Y., Yoshiya, K., Shimoyama, T., Suzuki, R.. Intentional limited
pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. J Thorac Cardiovasc Surg; Apr 2003. 37.Landreneau,
R. J., Sugarbaker, D. J., Ma

92. [outcome] score 10
26.Zhao, X., Qian, L., Luo, Q., Huang, J.. Segmentectomy as a safe and equally effective surgical option under complete
video-assisted thoracic surgery for patients of stage I non-small cell lung cancer. J Cardiothorac Surg; Apr 29 2013.
27.Wang, B. Y., Tu, C. C., Liu, C. Y., Shih, C. S., Liu, C. C.. Single-incision thoracoscopic lobectomy and
segmentectomy with radical lymph node dissection. Ann Thorac Surg; Sep 2013. 28.Echavarria, M. F., Cheng, A. M., Velez-
Cubian, F. O., Ng, E. P., Moodie, C. C., Garrett, J. R., Fontaine, J. P., Robinson, L. A., Toloza, E. M.. Comparison of
pulmonary function tests and perioperative outcomes after robotic-assisted pulmonary lobectomy vs segmentectomy. Am J
Surg; Dec 2016. 29.Schuchert, M.J., Pettiford, B.L., Keeley, S., D'Amato, T.A., Kilic, A., Close, J., Pennathur, A.,
Santos, R., Fernando, H.C., Landreneau, J.R., Luketich, J.D., Landreneau, R.J.. Anatomic segmentectomy in the treatment
of stage I non-small cell lung cancer. Ann Thorac Surg 2007. 30.Sienel, W., Stremmel, C., Kirschbaum, A., Hinterberger,
L., Stoelben, E., Hasse, J., Passlick, B.. Frequency of local recurrence following segmentectomy of stage IA non-small
cell lung cancer is influenced by segment localisation and width of resection margins--implications for patient
selection for segmentectomy. Eur J Cardiothorac Surg; Mar 2007. 31.Okada, M., Mimae, T., Tsutani, Y., Nakayama, H.,
Okumura, S., Yoshimura, M., Miyata, Y.. Segmentectomy versus lobectomy for clinical stage IA lung adenocarcinoma. Ann
Cardiothorac Surg; Mar 2014. 32.Read, R. C., Yoder, G., Schaeffer, R. C.. Survival after conservative resection for T1
N0 M0 non-small cell lung cancer. Ann Thorac Surg; Mar 1990. 33.Martin-Ucar, A. E., Nakas, A., Pilling, J. E., West, K.
J., Waller, D. A.. A case-matched study of anatomical segmentectomy versus lobectomy for stage I lung cancer in high-
risk patients. Eur J Cardiothorac Surg; Apr 2005. 34.Nishio, W., Yoshimura, M., Maniwa, Y., Kitamura, Y., Tane, K.,
Takenaka, D., Adachi, S.. Re-Assessment of Intentional Extended Segmentectomy for Clinical T1aN0 Non-Small Cell Lung
Cancer. Ann Thorac Surg; Nov 2016. 35.Kilic, A., Schuchert, M. J., Pettiford, B. L., Pennathur, A., Landreneau, J. R.,
Landreneau, J. P., Luketich, J. D., Landreneau, R. J.. Anatomic segmentectomy for stage I non-small cell lung cancer in
the elderly. Ann Thorac Surg; Jun 2009. 36.Koike, T., Yamato, Y., Yoshiya, K., Shimoyama, T., Suzuki, R.. Intentional
limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. J Thorac Cardiovasc Surg; Apr 2003.
37.Landreneau, R. J., Sugarbaker, D. J., Mack, M. J., Hazelrigg, S. R., Luketich, J. D., Fetterman, L., Liptay, M. J.,
Bartley, S., Boley, T. M., Keenan, R. J., Ferson, P. F., Weyant, R. J., Naunheim, K. S.. Wedge resection versus
lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg; Apr 1997. 38.Keenan, R. J.,
Landreneau, R. J., Maley, R. H.,Jr., Singh, D., Macherey, R., Bartley, S., Santucci, T.. Segmental resection spares
pulmonary function in patients with stage I lung cancer. Ann Thorac Surg; Jul 2004. 39.Hattori, A., Matsunaga, T.,
Takamochi, K., Oh, S., Suzuki, K.. Locoregional recurrence after segmentectomy for clinical-T1aN0M0 radiologically solid
non-small-cell lung carcinoma. Eur J Cardiot

93. [outcome] score 10
Apr 2003. 37.Landreneau, R. J., Sugarbaker, D. J., Mack, M. J., Hazelrigg, S. R., Luketich, J. D., Fetterman, L.,
Liptay, M. J., Bartley, S., Boley, T. M., Keenan, R. J., Ferson, P. F., Weyant, R. J., Naunheim, K. S.. Wedge resection
versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg; Apr 1997. 38.Keenan, R.
J., Landreneau, R. J., Maley, R. H.,Jr., Singh, D., Macherey, R., Bartley, S., Santucci, T.. Segmental resection spares
pulmonary function in patients with stage I lung cancer. Ann Thorac Surg; Jul 2004. 39.Hattori, A., Matsunaga, T.,
Takamochi, K., Oh, S., Suzuki, K.. Locoregional recurrence after segmentectomy for clinical-T1aN0M0 radiologically solid
non-small-cell lung carcinoma. Eur J Cardiothorac Surg; Mar 1 2017. 40.Fiorelli, A., Caronia, F. P., Daddi, N., Loizzi,
D., Ampollini, L., Ardò, N., Ventura, L., Carbognani, P., Potenza, R., Ardissone, F., Sollitto, F., Mattioli, S., Puma,
F., Santini, M., Ragusa, M.. Sublobar resection versus lobectomy for stage I non-small cell lung cancer: an appropriate
choice in elderly patients?. Surg Today; Dec 2016. 41.Carr, S. R., Schuchert, M. J., Pennathur, A., Wilson, D. O.,
Siegfried, J. M., Luketich, J. D., Landreneau, R. J.. Impact of tumor size on outcomes after anatomic lung resection for
stage 1A non-small cell lung cancer based on the current staging system. J Thorac Cardiovasc Surg; Feb 2012. 42.Altorki,
N. K., Kamel, M. K., Narula, N., Ghaly, G., Nasar, A., Rahouma, M., Lee, P. C., Port, J. L., Stiles, B. M.. Anatomical
Segmentectomy and Wedge Resections Are Associated with Comparable Outcomes for Patients with Small cT1N0 Non-Small Cell
Lung Cancer. J Thorac Oncol; Nov 2016. 43.Deng, B., Cassivi, S. D., de Andrade, M., Nichols, F. C., Trastek, V. F.,
Wang, Y., Wampfler, J. A., Stoddard, S. M., Wigle, D. A., Shen, R. K., Allen, M. S., Deschamps, C., Yang, P.. Clinical
outcomes and changes in lung function after segmentectomy versus lobectomy for lung cancer cases. J Thorac Cardiovasc
Surg; Oct 2014. 44.Suzuki, K., Saji, H., Aokage, K., Watanabe, S. I., Okada, M., Mizusawa, J., Nakajima, R., Tsuboi, M.,
Nakamura, S., Nakamura, K., Mitsudomi, T., Asamura, H.. Comparison of pulmonary segmentectomy and lobectomy: Safety
results of a randomized trial. J Thorac Cardiovasc Surg; Sep 2019. Dovrebbe la segmentectomia vs lobectomia essere
utilizzata per pazienti affetti da NSCLC in stadio iniziale POPULATION: Pazienti affetti da NSCLC in stadio iniziale
INTERVENTION: La segmentectomia COMPARISON: Lobectomia MAIN OUTCOMES: Overall survival RCT; Overall Survival; Disease
free survival RCT; Disease free Survival; Quality of life; Number of harvested lymphonodes; Lenght hospital stay; Local
recurrence RCT; Local recurrence; Postoperative air leaks; Postoperative air leaks (RCT); Recidiva linfonodale;
Postoperative complications RCT); Postoperative complications; Rehospitalization SETTING: Inpatients Is the problem a
priority? GIUDIZI RICERCA DELLE PROVE DI EVIDENZA CO ○ No ○ Probably no ○ Probably yes ● Yes ○ Varies ○ Don't know How
substantial are the desirable anticipated effects? GIUDIZI RICERCA DELLE PROVE DI EVIDENZA CO ○ Trivial E' stata
eseguita una ricerca bibliografica sulle banche dati Medline ed Embase fino a ottobre 2023. Dopo la rimozione dei
duplicati sono stati repe

94. [outcome] score 10
hy (CT)"[Title/Abstract]))))))) Q2: Nei pazienti con NSCLC in stadio clinico I la lobectomia dovrebbe essere eseguita
con approccio mini-invasivo (VATS o robotico) o toracotomico? MEDLINE (PubMed) (2019 ad Agosto 2023) (((((((("Carcinoma,
Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung Neoplasms/surgery"[Mesh]) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small
cell lung cancer"[Title/Abstract])) OR NSCLC[Title/Abstract]))))))) AND (("grade IA"[Title/Abstract] OR "stage
IA"[Title/Abstract])))) AND (((("Thoracic Surgery, Video-Assisted"[Mesh]) OR ("VATS Lobectomy"[Title/Abstract] OR
VATS[Title/Abstract] OR "Thoracic Surgeries, Video-Assisted"[Title/Abstract] OR "Video-assisted Thoracic Surgery (VATS)
Lobectomy"[Title/Abstract] OR "Video-assisted Thoracic Surgery"[Title/Abstract]))) OR ("VATS
segmentectomy"[Title/Abstract] OR segmentectomy[Title/Abstract])))) AND (((((((((("Randomized Controlled
Trial"[Publication Type]) OR "Clinical Trial"[Publication Type]) OR "drug therapy"[Subheading])) OR
((randomized[Title/Abstract] OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] OR
trial[Title/Abstract] OR groups)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND "Humans"[Mesh]))))) AND
("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) Embase (Embase.com) (2019 ad
Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung
tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 #1 OR #2 #4 'grade ia' OR
'stage ia':de,ti,ab #5 #3 AND #4 NE LINEE GU EOPLASIE DEL POLMONE #6 'vats lobectomy' OR vats OR 'thoracic surgeries,
video-assisted' OR 'video surgery (vats) lobectomy' OR 'video-assisted thoracic surgery' OR 'vats segm
segmentectomy:de,ti,ab #7 #5 AND #6 Q3 GRADE: Nei pazienti affetti da NSCLC in stadio iniziale (IA), la segme
raccomandata (rispetto alla lobectomia)? MEDLINE (PubMed) (2019 a Agosto 2023) (("Lung Neoplasms"[Mesh]) OR "Carcinoma,
Non-Small-Cell Lun Neoplasms"[Mesh]) OR "lung cancer"[Title/Abstract] OR "lung neoplasms" tumor"[Title/Abstract] OR
"Non-small-cell lung cancer"[Title/Abstract] OR cancer"[Title/Abstract] OR NSCLC[Title/Abstract]) Embase (Embase.com)
(2019 a Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR
'lung tumor' OR 'non-small-cell lung lung cancer' OR nsclc:ti,ab Q4: Nei pazienti affetti da neoplasia polmonare NSCLC
T1-2N0 inoperab mediche il trattamento stereotassico è raccomandato rispetto alla radio MEDLINE (PubMed) (2019 ad Agosto
2023) (((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh]) OR "Lung Neoplasm (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung t "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[T
NSCLC[Title/Abstract]))))))) AND (("stage T1-2N0"[Title/Abstract] OR "T1-2N0 ((("Radiosurgery"[Mesh])) OR ("stereotactic
radiotherapy"[Title/Abstract])) Records: 8 Embase (Embase.com) (2019 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small
cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell

95. [outcome] score 10
a-Analysis" [Publication Type]) OR ("meta- analysis[Title] OR systematic review"[Title] OR "meta analy*"[Title] OR
"metaanaly*"[Title] OR "Meta- Analysis"[Title])) OR ("systematic literature review"[Title])) OR ("systematic
review"[Title/Abstract])) OR (((("Randomized Controlled Trial" [Publication Type]) OR "Randomized Controlled Trials as
Topic"[Mesh]) OR ("Clinical Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
randomly[Title/Abstract])))))) Embase (Embase.com) (1974 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung
cancer' OR nsclc:ti,ab #3 'grade iii' OR 'stage iii' OR advanced OR 'advanced disease' NEAR/7 (egfr OR 'egfr mutated')
#4 (#1 OR #2) AND #3 #5 'osimertinib'/exp #6 osimertinib:ti,ab NE EOPLASIE DEL POLMONE #8 #4 AND #5 OR #6 Q7: Nei
pazienti con NSCLC radicalmente operato in stadio II-IIIA e livelli di e L1 ≥50% un trattamento immunoterapico di
consolidamento con atez chemioterapia adiuvante a base di platino è raccomandato? MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcino Lung/pathology"[Mesh] )) OR ( "Lung
Neoplasms/drug therapy"[Mesh] OR "Lung Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small
cell lung cancer"[Title/Abstract] OR "Non-sm carcinoma"[Title/Abstract] OR "Non small cell lung
carcinoma"[Title/Abstract)) OR NSCLC[Title/Abstract])))))))))))))))))) AND ("atezolizumab" [Supplementary Concep
((atezolizumab[Title/Abstract] Embase (Embase.com) (1974 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung canc cell lung cancer' OR
nsclc:ti,ab #3 'grade iii' OR 'stage iii' OR advanced OR 'advanced disease' NEAR/7 (RET) #4 (#1 OR #2) AND #3 #5
'atezolizumab'/exp/mj #6 atezolizumab:ti,ab #7 #4 AND (#5 OR #6) Q8: Nei pazienti con NSCLC in stadio I-II radicalmente
operato una radiotera è raccomandata rispetto alla semplice osservazione? MEDLINE (PubMed) (2019 ad Agosto 2023)
(((((((((((((((("Carcinoma, Non-Small-Cell Lung/radiotherapy"[Majr:noexp]) OR (((((( cancer*[Title/Abstract]) OR lung
tumor*[Title/Abstract]) OR lung tumour*[Title/Abstr neoplasm*[Title/Abstract]) OR lung carcinoma*[Title/Abstract]) OR
non-small cell lu cancer*[Title/Abstract]) OR non small cell lung cancer*[Title/Abstract]) OR NSCLC AND ((("grade
IA"[Title/Abstract] OR "stage IA"[Title/Abstract])))))) OR ("grade I"[T "grade II"[Title/Abstract] OR "stage
I"[Title/Abstract] OR "stage II"[Title/Abstract])))) surgery")) AND (((((((("Randomized Controlled Trial" [Publication
Type]) OR "Clinic Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR randomised[Title/Abstract]
OR placebo[Title/Abstract] OR randomly[Title/Abstract] trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh])
NOT "Animals"[Mes "Humans"[Mesh]))) espressione del zolizumab dopo oma, Non-Small- g mall-cell lung pt]) OR cer' OR 'non
sma apia postoperat (((((lung ract]) OR lung ung C*[Title/

96. [outcome] score 10
tle/Abstract])))))))))))))))) AND "durvalumab" [Supplemen all ime all attia llule b è -Cell Lung ract] lung lung ntary
NE EOPLASIE DEL POLMONE Concept] AND ((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-Analysis"[Publication Type]) OR
"meta-analysis[Title] OR systematic review"[Title] OR "meta analy*"[Title] OR "metaanaly*"[Title] OR "Meta-
Analysis"[Title])) OR ("systematic literature review"[Title])) OR ("systematic review"[Title/Abstract])) OR
(((("Randomized Controlled Trial"[Publication Type]) OR "Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical
Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
randomly[Title/Abstract]))))))) Embase (Embase.com) (2018 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung
cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung
cancer' OR nsclc:ti,ab #3 #31 OR #32 #4 durvalumab #5 #3 AND #4 AND ([cochrane review]/lim OR [systematic review]/lim OR
[meta analysis]/lim OR [randomized controlled trial]/lim OR 'controlled clinical trial'/de) Q13 GRADE: Nei pazienti
affetti da NSCLC in stadio avanzato oligometastatico, un trattamento locoregionale in associazione alla terapia
sistemica è raccomandato (rispetto alla sola terapia sistemica)? MEDLINE (PubMed) (2019 a marzo 2021) (("Lung
Neoplasms"[Mesh]) OR "Carcinoma, Non-Small-Cell Lung"[Mesh]) OR "Lung Neoplasms"[Mesh]) OR "lung cancer"[Title/Abstract]
OR "lung neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR
"Non small cell lung cancer"[Title/Abstract] OR NSCLC[Title/Abstract]) AND oligometastatic[Title/Abstract])) AND
(therapy[Title/Abstract] AND (systemic[Title/Abstract] OR locoregional[Title/Abstract])) Embase (Embase.com) (2019 a
marzo 2021) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor'
OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab Q14: Nei pazienti affetti da NSCLC in
stadio localmente avanzato o metastatico, con mutazioni attivanti classiche del gene EGFR (Ex19dels e L858R), il
trattamento di prima linea con inibitore tirosino-chinasico di EGFR osimertinib è raccomandato (rispetto agli inibitori
tirosino-chinasici gefitinib e/o erlotinib)? MEDLINE (PubMed) (2021 ad Agosto 2023) ((((((((( "Carcinoma, Non-Small-Cell
Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh]
OR "Lung Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung
tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract]
OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "Non small cell lung NE EOPLASIE DEL POLMONE
carcinoma"[Title/Abstract)) OR NSCLC[Title/Abstract]))))))))))))))) AND (((((((((((("grade III" OR "stage III" OR
advanced OR "advanced disease"))))))) OR (metastas*[Title/Abstract]))))) AND (("osimertinib" [Supplementary Concept]) OR
(osimertinib[Title/Abstract]))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-Analysis"[Publication Type]) OR
"meta-analysis[Title] OR systematic review"[Title] OR "meta analy

97. [outcome] score 10
ab #5 (#1 OR #2) AND (#4 OR #5) #6 ('brigatinib'/exp/mj OR ('brigatinib' OR alunbrig:ti,ab)) #7 #5 AND #6 AND ([cochrane
review]/lim OR [systematic review]/lim OR [meta analysis]/lim OR [controlled clinical trial]/lim OR [randomized
controlled trial]/lim) Records: 27 Selezionati 1 record all ent' con to al ] OR g eta- all NE EOPLASIE DEL POLMONE Q20:
Nei pazienti affetti da NSCLC metastatico, con riarrangiamenti del gene ALK, un trattam di I linea con lorlatinib è
raccomandato (rispetto al crizotinib)? (((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR
"Carcinoma, Non-Sm Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung
tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract]
OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "Non small cell lung carcinoma"[Title/Abstract)) OR
NSCLC[Title/Abstract])))))))))))))))))))) AND (((((((((((("grade III" OR "stage III" OR advanced OR "advanced
disease"))))))) OR (metastas*[Title/Abstract]))))) AND ((((("capmatinib" [Supplementar Concept]) OR "tepotinib"
[Supplementary Concept]) OR "amivantamab-vmjw" [Supplementary Concept]) OR "lorlatinib" [Supplementary Concept]) OR
(capmatinib[Title/Abstract] OR tepotinib[Title/Abstract] OR amivantamab[Title/Abstract] OR lorlatinib[Title/Abstract]))
#1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-
small-cell lung cancer' OR 'non sm cell lung cancer' OR nsclc:ti,ab #3 'grade iii' OR 'stage iii' OR advanced OR
'advanced disease' NEAR/7 (RET) #4 (#1 OR #2) AND #3 #5 'capmatinib'/exp/mj OR 'tepotinib'/exp/mj OR
'amivantamab'/exp/mj OR 'lorlatinib'/exp/mj #6 capmatinib OR tepotinib OR amivantamab OR lorlatinib:ti,ab #7 #4 AND (#5
OR #6) Q21 GRADE: Nei pazienti affetti da NSCLC in stadio localmente avanzato o metastatico riarrangiamento di ALK in
progressione a una terapia con alectinib o ceritinib, un trattam con lorlatinib è raccomandato (rispetto alla
chemioterapia)? MEDLINE (PubMed) (2021 ad Agosto 2023) (((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR
"Carcinoma, Non-Small-Cell Lung/pathology"[Mesh] OR "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] OR "lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstrac "lung
tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lun cancer"[Title/Abstract] OR
"Non-small-cell lung carcinoma"[Title/Abstract] OR "Non small cell lung carcinoma"[Title/Abstract])) OR
NSCLC[Title/Abstract) AND ("Gene Rearrangement"[Mesh]) OR (alk[Title/Abstract] OR "alk rearrangement"[Title/Abstract])))
AND (progression[Title/Abstract] OR "disease progression"[Title/Abstract])) AND ((("lorlatinib" [Supplementary Concept])
OR lorlatinib[Title/Abstract])) AND ((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-Analysis"[Public Type]) OR "meta-
analysis[Title] OR systematic review"[Title] OR "meta analy*"[Title] OR "metaanaly*"[Title] OR "Meta-Analysis"[Title]))
OR ("systematic literature review"[Title])) OR ("systematic review"[Title/Abstract])) OR (((("Randomized Controlled
Trial"[Publica

98. [outcome] score 10
di MET, in progressione dopo precedente trattamento con immunoterapia e/o chemioterapia a base di platino, un
trattamento con tepotinib è raccomandato (rispetto alla chemioterapia)? Q29: Nei pazienti affetti da NSCLC metastatico,
con mutazione p.G12C del gene KRAS, in progressione dopo precedente trattamento chemioterapico a base di platino, un
trattamento con sotorasib è raccomandato (rispetto alla chemioterapia)? MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung Neoplasms/pathology"[Mesh] ))) OR (("lung
cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung
carcinoma"[Title/Abstract] OR "Non small cell lung carcinoma"[Title/Abstract)) OR
NSCLC[Title/Abstract])))))))))))))))))))) AND (((((((((((("grade III" OR "stage III" OR advanced OR "advanced
disease"))))))) OR (metastas*[Title/Abstract]))))) AND ((((("capmatinib" [Supplementary Concept]) OR "tepotinib"
[Supplementary Concept]) OR "amivantamab-vmjw" [Supplementary Concept]) OR "lorlatinib" [Supplementary Concept]) OR
(capmatinib[Title/Abstract] OR tepotinib[Title/Abstract] OR amivantamab[Title/Abstract] OR lorlatinib[Title/Abstract]))
Embase (Embase.com) (1974 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR
'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3
'grade iii' OR 'stage iii' OR advanced OR 'advanced disease' NEAR/7 (RET) #4 (#1 OR #2) AND #3 #5 'capmatinib'/exp/mj OR
'tepotinib'/exp/mj OR 'amivantamab'/exp/mj OR 'lorlatinib'/exp/mj #6 capmatinib OR tepotinib OR amivantamab OR
lorlatinib:ti,ab #7 #4 AND (#5 OR #6) GRADE Q30: Nei pazienti affetti da NSCLC metastatico, con espressione di PDL1 ≥
50%, senza mutazioni attivanti il gene di EGFR o riarrangiamenti di ALK, e con buon performance status (0- 1), un
trattamento di prima linea con pembrolizumab è raccomandato (rispetto alla chemioterapia)? MEDLINE (PubMed) (2018 ad
Agosto 2023) ((((((((((((((((((("Lung Neoplasms"[Mesh]) OR "Carcinoma, Non-Small-Cell Lung"[Mesh]) OR ("lung
cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non- small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract])) OR NSCLC[Title/Abstract])))))))) AND
(((((("Neoplasm Metastasis"[Mesh]) OR "Recurrence"[Mesh])) OR ("neoplasm metastasis"[Title/Abstract] OR
metasta*[Title/Abstract] OR "stage 4"[Title/Abstract] OR "stage IV"[Title/Abstract] OR advanced[Title/Abstract] OR
Recurrence*[Title/Abstract] OR relapse*[Title/Abstract])))))))) AND (("Biomarkers, Tumor/analysis"[Mesh]) OR (((PD-L1
[Title/Abstract] OR PD L1[Title/Abstract])) AND (expression[Title/Abstract] OR antibody[Title/Abstract] OR
diagnostic*[Title/Abstract] OR testing[Title/Abstract]))))) AND (((("pembrolizumab" [Supplementary Concept]) OR
(Ambrolizumab[Title/Abstract] OR Keytruda[Title/Abstract] OR MK- NE EOPLASIE DEL POLMONE 3475[Title/Abstract]))) OR ((((
"Drug Therapy/therapeutic use"[Mesh] OR "Drug

99. [outcome] score 10
ung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 'grade iii' OR 'stage iii' OR advanced OR 'advanced
disease' NEAR/7 (RET) #4 (#1 OR #2) AND #3 #5 'atezolizumab'/exp/mj #6 atezolizumab:ti,ab #7 #4 AND (#5 OR #6) Q32: Nei
pazienti affetti da NSCLC in stadio IIIB-C e IV, con espressione di PDL1 ≥50%, senza mutazioni attivanti il gene di EGFR
o riarrangiamenti di ALK, e con buon performance status (0- 1), un trattamento di prima linea con cemiplimab è
raccomandato (rispetto alla chemioterapia a base di platino)? MEDLINE (PubMed) (1946 ad Agosto 2023) ((((((((((((((((((
"Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell Lung/pathology"[Mesh] )) OR ( "Lung
Neoplasms/drug therapy"[Mesh] OR "Lung Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small
cell lung cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "Non small cell lung
carcinoma"[Title/Abstract)) OR NSCLC[Title/Abstract])))))))))))))))))) NOT ("EGFR-Mutated")) AND
(PD-L1[Title/Abstract])) AND ("atezolizumab" [Supplementary Concept] OR "cemiplimab" [Supplementary Concept]) OR
("Ipilimumab"[Mesh] AND 'nivolumab'/exp/mj) OR ((atezolizumab[Title/Abstract] OR cemiplimab[Title/Abstract]) OR
((ipilimumab[Title/Abstract] AND nivolumab[Title/Abstract]))) Embase (Embase.com) (1974 ad Agosto 2023) #1 'lung
tumor'/exp OR 'non small cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell
lung cancer' OR 'non small cell lung cancer' OR nsclc:ti,ab #3 'grade iii' OR 'stage iii' OR advanced OR 'advanced
disease' NEAR/7 (RET) #4 (#1 OR #2) AND #3 #5 ('atezolizumab'/exp/mj OR ‘cemiplimab’/exp/mj) OR ('ipilimumab'/exp/mj AND
'nivolumab'/exp/mj) #6 atezolizumab OR cemiplimab OR (ipilimumab AND nivolumab):ti,ab #7 #4 AND (#5 OR #6) Q33 GRADE:
Nei pazienti affetti da NSCLC a istologia non-squamosa in stadio avanzato senza mutazioni attivanti di EGFR o
riarrangiamenti di ALK, con espressione di PD-L1 <50% e con buon performance status (0-1), un trattamento di prima linea
a base di platino, pemetrexed e pembrolizumab, seguito da una terapia di mantenimento con pemetrexed e pembrolizumab in
caso di risposta o stabilità di malattia dopo 4 cicli di trattamento, è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (2018 ad Agosto 2023) (((((((((((((((((((((((((((((((((("Lung Neoplasms"[Mesh]) OR "Carcinoma, Non-
Small-Cell Lung"[Mesh]) OR ("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung
tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract]))
OR NE EOPLASIE DEL POLMONE NSCLC[Title/Abstract]))))))))))))))) AND (("non-squamous"[Title/Abstract] OR "non
squamous"[Title/Abstract] OR nonsquamous[Title/Abstract])))) AND ((((((((((("pembrolizumab"[Supplementary Concept]) OR
(Ambrolizumab[Title/Abstract] OR Keytruda[Title/Abstract] OR MK-3475[Title/Abstract]))))) AND (("Pemetrexed"[Mesh]) OR
(“Pemetrexed Disodium”[Title/Abstract] OR Alimta[Title/Abstract] OR pemetrexed[Title/Abstract])))) AND (((("Randomized
Controlled Trial"[Publication Type]) OR "Randomized Controlled Trials as To

100. [outcome] score 10
oncept]) OR (entrectinib[Title/Abstract] OR Rozlytrek[Title/Abstract]) AND (((((((((((("Meta-Analysis as Topic"[Mesh])
OR "Meta-Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta analy*"[Title] OR
"metaanaly*"[Title] OR "Meta-Analysis"[Title])) OR ("systematic literature review"[Title])) OR ("systematic
review"[Title/Abstract])) OR (((("Randomized Controlled Trial"[Publication Type]) OR "Randomized Controlled Trials as
Topic"[Mesh]) OR ("Clinical Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
randomly[Title/Abstract])))))))) Records: 42 Embase (Embase.com) (2018 ad Agosto 2023) #1 'lung tumor'/exp OR 'non small
cell lung cancer'/exp #2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small
cell lung cancer' OR nsclc:ti,ab #3 'stage 4' OR 'stage iv' OR advanced:ti,ab #4 'ros1 gene'/exp/mj OR 'ros1 gene'
NEAR/3 rearrangement #5 (#1 OR #2) AND #3 AND #4 #7 'entrectinib'/exp/mj OR entrectinib' OR rozlytrek:ti,ab #8 #6 OR #7
#9 #5 AND #8 Records: 1 Selezionati 3 records Q24 GRADE: Nei pazienti affetti da NSCLC in stadio localmente avanzato o
metastatico con mutazione BRAF-V600, un trattamento di prima linea con dabrafenib in combinazione con trametinib è
raccomandato? MEDLINE (PubMed) (2019 ad Agosto 2023) ((((((((((((((((((((((((((((((("Lung Neoplasms"[Mesh]) OR
"Carcinoma, Non-Small-Cell Lung"[Mesh]) OR ("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung
tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract]))
OR NSCLC[Title/Abstract])))))))) AND (((((("Neoplasm Metastasis"[Mesh]) OR "Recurrence"[Mesh])) OR ("neoplasm
metastasis"[Title/Abstract] OR metasta*[Title/Abstract] OR "stage 4"[Title/Abstract] OR "stage IV"[Title/Abstract] OR
advanced[Title/Abstract] OR Recurrence*[Title/Abstract] OR relapse*[Title/Abstract]))))))))))) AND (("BRAF V600
mutation*"[Text Word]))) OR ("BRAF V600 mutation*"[Title/Abstract] OR "BRAF- mutation*"[Title/Abstract] OR "Val600 BRAF-
NE EOPLASIE DEL POLMONE mutation*"[Title/Abstract])))))))))) AND (((("trametinib" [Supplementary Concept]) OR
(trametinib[Title/Abstract] OR Mekinist[Title/Abstract]))) AND (("dabrafenib" [Supplementary Concept]) OR
(Dabrafenib[Title/Abstract] OR Tafinlar[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-
Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta analy*"[Title] OR
"metaanaly*"[Title] OR "Meta-Analysis"[Title])) OR ("systematic literature review"[Title])) OR ("systematic
review"[Title/Abstract])) OR (((("Randomized Controlled Trial"[Publication Type]) OR "Randomized Controlled Trials as
Topic"[Mesh]) OR ("Clinical Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
randomly[Title/Abstract])))))))) Embase (Embase.com) (2019 ad Agosto 2023) #35 'non small cell lung cancer'/exp/mj #36
'lung cancer'/exp/mj #37 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small
cell lung cancer' OR nsclc:ti,ab #38 #35 OR #36 OR #37 #39 'metastasis'/exp/mj #40 'neoplasm metastasis' OR metasta* OR
'stage 4' OR 'stage iv' OR advanced OR recurren

